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ABSTRACT 
 
 Optimization for circulating miRNA library preparations, multiplexing capacity, 
and sequencing with the Ion Torrent System was executed in order to process patient 
samples effectively. Multiple modifications were attempted in two published protocols 
before miRNA library preparations reached adequate quality for sequencing. A cohort of 
nine psoriatic arthritis patients, recruited for a pharmacogenomics investigation of 
treatment with IL-12/23 or IL-17 inhibitors, had blood samples drawn at baseline, as well 
as one- and three-month post treatment. The pharmacogenomics samples from baseline 
were sequenced and the resultant data underwent several analyses in order to identify 
predictive miRNA markers or profiles. Differential miRNA expression analyses were 
performed both between the American College of Rheumatology response criteria 
groupings and on clinical datasets, followed by a comprehensive literature review to 
examine potential implications of identified miRNAs. Pathway analyses, network analyses, 
and an in silico functional enrichment analysis were performed on the data to identify 
associations with signalling cascades, collectively targeted genes, and biological functions, 
respectively. The results of this exploratory study demonstrate the potential of the miRNA 
sequencing framework for identifying predictive miRNA markers and profiles associated 
with response to pharmaceuticals. 
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CHAPTER 1 
1 INTRODUCTION 
 
 Psoriatic Arthritis and Clinical Features 
Psoriatic arthritis (PsA) is a disease that causes joint pain, inflammation, and 
stiffness in patients with psoriasis (PS) (Gladman & Ritchlin, 2016). PS is defined as red, 
scaly, hardened epithelial tissue that ranges from minimal patches to generalized 
involvement (National Clinical Guideline Centre UK, 2012). The notion that PS and 
arthritis were not comorbidities but rather one disease was supported by concurrent relapse 
and remission (Lane & Crawford, 1937). Dermatologists noted that the atrophic arthritis 
occurred more frequently in PS patients, while rheumatologists noted that PS occurred 
more frequently in patients with atrophic arthritis than those with osteoarthritis (Wright, 
1956).  
The prevalence of PS is approximately 1.3-2.2% globally and is on average higher 
in Caucasian populations (National Clinical Guideline Centre UK, 2012). Within PS 
populations, arthritis occurs in approximately 30% of cases, resulting in a Psoriatic Arthritis 
prevalence of 0.3-1.0% in the general population (Eder, Haddad, Rosen, Lee, Chandran, 
Cook, & Gladman, 2016; Sankowski, Lebkowska, Cwikla, Walecka, & Walecki, 2013). 
PsA occurs at equal frequency in men and women. The frequency of PsA varies depending 
on the incidence of PS and environmental factors such as the ultraviolet (UV) indexes per 
annum (Sankowski et al., 2013). 
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The incidence of PS on the island of Newfoundland (NF) is double that of any other 
Caucasian population worldwide (Gulliver et al., 2011). This is due in part to NF’s small 
founding population of 20,000-25,000 Irish and English settlers in 1760 (Zhai et al., 2016). 
The genetic isolation as well as the low UV indexes per annum contribute to the increased 
prevalence of PS in NF (Gulliver et al., 2011). Given that arthritis is developed by one third 
of PS patients it can be reasonably assumed that there is also an increased incidence of PsA 
in NF, although it has not been officially documented (Rahman & Elder, 2005). 
 
 Clinical Catergorization of Psoriasis and Psoriatic Arthritis  
There are several subcategories of PS: plaque PS, guttate PS, erythrodermic PS, 
flexural PS, seborrheic PS, and pustular PS. The most common form is chronic plaque PS 
(or PS Vulgaris) which occurs in 85-90% of patients (National Clinical Guideline Centre 
UK, 2012). Unless otherwise indicated, the term PS refers to plaque PS. Plaque PS often 
occurs in ‘difficult to treat sites’ and can impact function and mobility. Guttate PS is defined 
by small drop-shaped red spots that are acute, persist for approximately one month, and 
precede a streptococcal infection in ~60% of cases.  Erythrodermic PS is a rare and 
aggressive form of PS involving the whole body. Flexural PS, which is often less scaly, is 
located at a point of flexion. Seborrheic PS, affects the scalp, face, and torso with flaky and 
itchy skin. Pustular PS is distinctive by its “pus”-filled bumps and can be generalized or 
localized. Multiple categories of PS can occur simultaneously or subsequently within the 
same individual (National Clinical Guideline Centre UK, 2012; Weger, 2010). 
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The arthritis associated with PsA is an inflammatory arthritis, as opposed to a 
degenerative arthritis such as osteoarthritis. The inflammation leads to swelling and often 
pain in the affected joints. Due to its inflammatory nature, PsA is associated with morning 
stiffness that improves with movement. PsA patients predominantly develop peripheral 
arthritis, which affects the large joints, but can also develop peri-arthritis, which affects the 
structures surrounding the joint, and spondylitis, which affects the spine.  PsA often 
presents as oligoarthritis (less than five joints involved) and, as the disease progresses with 
time, a polyarticular subtype is more common (five or more joints involved). Spondylitis 
involves the sacroiliac joint, as well as cervical, thoracic or lumbar spine causing chronic 
pain, reduced flexibility of the spine, decreased chest expansion, and difficulty with 
cervical rotation (Gladman, 2015).  
Dactylitis, commonly known as sausage finger, refers to the inflammation of an 
entire digit. In dactylitis, the inflammation targets not only the joints of the finger but also 
the tendon sheaths and the soft tissues. Dactylitis is observed in approximately 30% of 
patients at disease presentation and approximately 48% of patients during the course of the 
disease (Gladman, 2015). Enthesitis is the inflammation of the entheseal site, the point of 
insertion of a tendon or a ligament on the bone. Enthesitis is a symptom common to all 
spondyloarthropathies but is most frequently seen in PsA. Upon diagnosis, approximately 
35% of patients present with enthesitis and approximately half the patients with PsA will 
develop it over the course of their disease. Nail involvement is a risk factor for the 
manifestation of PsA and is a good indicator that PS patients may develop PsA. The nail 
lesions present as pits, hardening and thickening of the nail (hyperkeratosis), the separation 
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of the nail from the bed (onycholysis), and the crumbling of the nail bed. There is often a 
correlation between the nail involvement and inflammation the joint of the same finger 
(Gladman, 2015). 
PsA falls within the disease category of seronegative spondyloarthropatheis (SpA). 
Other classical SpAs include Ankylosing Spondylitis (AS), arthritis that affects the spine; 
Inflammatory Bowel Disease (IBD), arthritis linked to IBD (i.e., enteropathic spondylitis); 
Reactive Arthritis, which is triggered by a bacterial infection; and Undifferentiated 
Spondyloarthropathies, arthritis that does not meet the classification criteria for the 
aforementioned conditions (Wright, 1978). 
 
 Comorbidities  
There are numerous comorbidities associated with PsA, most of which relate to 
systemic inflammation and psycho-social factors. Conditions due to systemic inflammation 
cause increased insulin resistance, endothelial cell dysfunction, and the hardening of 
arteries, which affect multiple organ systems and lead to different clinical manifestations 
(Haddad & Zisman, 2017). Metabolic syndrome and diabetes mellitus are both 
independently correlated with PsA severity. PS is associated with an increased chance of 
developing cardiovascular disease, with similar trends documented for PsA (Haddad & 
Zisman, 2017). Other extra-articular immune-mediated comorbidities include IBD, 
Crohn’s disease, and iritis. Psycho-social aspects involved with PsA such as depression, 
anxiety, and a lower quality of life. There is also a large financial burden on patients being 
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treated for their PS and PsA due to the high cost of pharamaceuticals, which can exacerbate 
psycho-social distresses (Haddad & Zisman, 2017). 
 
 Classification Criteria  
The classification criteria for PsA was originally described by Wright and Moll in 
1973 (Moll & Wright, 1973). Over the years many researchers have contributed to these 
criteria, as well as classifying subgroups (Gladman, 2015; Helliwell & Taylor, 2005; Torre 
Alonso, 2010). The criteria presently used for PsA was created by the ClASsification of 
Psoriatic Arthritis (CASPAR) study group. Upon examination by a rheumatologist, a PsA 
patient must receive ≥ 3 points in 5 classification criteria as described in Table 1.1 
(Carmona, 2012; Taylor et al., 2006). 
 
Table 1.1 - ClASsification of Psoriatic ARthritis (CASPAR)  
The CASPAR Classification Criteria for PsA 
Criterion Description Points 
Current psoriasis and/or 
a personal or family 
history of psoriasis 
Psoriasis currently present on skin or scalp as 
judged by a rheumatologist or dermatologist. 
A personal or family history of psoriasis (family 
history pertains to an affected first- or second-
degree relative) 
2 (current 
presentation) 
or 1 (personal 
or family 
history) 
Observation of current 
psoriatic nail dystrophy Onycholysis, nail pitting, or hyperkeratosis 1 
Negative for rheumatoid 
factor 
ELISA (enzyme-linked immunosorbent assay) 
or nephelometry 1 
Current or history of 
dactylitis 
Swelling of an entire digit, or a history of 
dactylitis recorded by a rheumatologist. 1 
Radiographic indication 
of new bone formation 
New bone formation near joint margins (but 
excluding osteophyte formation) on radiographic 
images of the hand or foot. 
1 
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 Monitoring Disease Progression and Response to Treatment 
 PsA disease activity, progression, and response to treatment can be monitored by 
a variety of critera. Outline below are the American College of Rheumatologist Criteria 
(ACR), the Clinical Disease Activity Index (CDAI), Health Assessment Questionnaire-
Disability Index (HAQ-DI), as well as a systemic marker of inflammation such as the 
Erythrocyte Sedimentation Rate (ESR) (Orbai & Ogdie, 2016). 
1.1.4.1 American College of Rheumatologist Criteria  
The ACR Criteria is the most well-recognized outcome measure for PsA treatment 
(Gladman et al., 2004). The ACR criteria dichotomously categorizes a patient as either a 
responder or a non-responder to treatment by the percentage of improvement between two 
time points. ACR20/50/70 is an equal to or greater than 20%/50%/70% improvement in 
disease activity, respectively. The ACR criteria, which is assessed recurrently during 
treatment, indicates improvement in swollen or tender joints. A joint count is taken based 
on at least three of the following measures: patient assessment, physician assessment, pain 
scale, disability/functional questionnaire (HAQ-DI), and/or acute phase reactant 
(erythrocyte sedimentation rate [ESR]) (PhUSE Wiki contributors, 2012). 
1.1.4.2 Clinical Disease Activity Index  
The Clinical Disease Activity Index (CDAI) is a validated score for Rheumatoid 
Arthritis (RA) that considers multiple factors including: a 28-point swollen joint count and 
a 28-point tender joint count (of the shoulders, elbows, wrists, metacarpophalangeal joints, 
proximal interphalangeal joints including thumb, and knees), a patient global disease 
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activity score (a self-assessment completed by the patient of overall disease activity on a 
scale of 1-10, 10 being the highest), and an evaluator’s global disease activity score (a score 
assigned by the clinician of overall disease activity on a scale of 1- 10, 10 being the highest). 
The CDAI score is interpreted as “remission” if CDAI ≤ 2.8, as “Low Disease Activity” if 
CDAI > 2.8 and ≤ 10, as “Moderate Disease Activity” if CDAI > 10 and ≤ 22, and as “High 
Disease Activity” if CDAI > 22 (Carmona, 2012). Given that the CDAI does not involve 
an acute phase reactant or any complex calculations, its can be measured relatively easily 
in clinic.  
1.1.4.3 Health Assessment Questionnaire-Disability Index  
The Health Assessment Questionnaire-Disability Index (HAQ-DI) is a measure of 
disease impact on quality of life, originally developed for monitoring disability of 
Rheumatoid Arthritis patients over time (Gunda, Syeda, & Jugl, 2015). The HAQ has been 
adapted for spondyloarthritis and for patients that have PS (Husted, Gladman, Long, & 
Farewell, 1995). The HAQ-DI assesses eight categories: dressing and grooming, arising, 
eating, walking, hygiene, reach, grip, and common daily activities. The patient self-reports 
the amount of difficulty they have performing the tasks in each category. Patients can rate 
their level of disease-caused disability for each category as “usual” (meaning the task is as 
easy as usual), “some” (meaning the task is performed with some difficulty), or “much” 
(meaning the task is performed with much difficulty) (Gunda et al., 2015). 
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1.1.4.4 Patient Reported Outcomes 
Patient Reported Outcomes (PROs) are self-reports of health from the patient’s own 
perspective. PROs are used to assess the patient’s experience of symptoms, function, and 
their general quality of life. PROs include measures for pain, fatigue, sleep, and mobility 
(Orbai & Ogdie, 2016). 
1.1.4.5 Minimal Disease Activity   
Minimal Disease Activity (MDA) is a composite score commonly used for 
assessing low disease activity in patients with PsA. The MDA criteria evaluates articular 
disease, peri-articular disease, PS, and PROs. These aspects are measured by a tender and 
swollen joint count, enthesitis, PS activity (measured using body surface area affected 
and/or a severity index), a visual analogue scale for pain, a global disease activity, and a 
health assessment questionnaire. Five of seven aforementioned aspects must be considered 
in order to satisfy the criteria for MDA (Coates, Fransen, & Helliwell, 2010). 
1.1.4.6 Erythrocyte Sedimentation Rate  
 Erythrocyte sediment rate (ESR) is a standard laboratory test that is used as a 
biomarker for inflammation and is the most traditional acute phase reactant. The ESR is a 
measure of red blood cell aggregation, determined by the distance travelled down a 
vibration-free, room-temperature vertical column over a one hour period and is expressed 
in mm/hr. A normal ESR for men is < 6.5 mm/hr and normal ESR for women is <16 mm/hr 
(Olshaker & Jerrard, 1997).  
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 Pathogenesis of PsA 
The pathogenesis of PsA has many contributing factors such as environmental 
influences and genetic components that prompt an immunological response. PsA can 
manifest due to environmental factors such as viral or bacterial infections and trauma. 
These triggers often precipitate PS, the effects of which can progress to include enthesial 
micro-damage leading to joint involvement (Roberts, J., O’Rielly, D.D., Rahman, P., 
2017). Extensive evidence of PsA familial aggregation indicates a clear genetic component 
in the development of disease. Genetic associations of PsA are found primarily in human 
leukocyte antigen (HLA) alleles and others within the major histocompatibility complex 
(MHC) region. These genetic associations affect gene and subsequent protein expression, 
influencing pathways implicated in both innate and adaptive immune responses – 
specifically involving Cluster of Differentiation 8 positive (CD8+) T-lymphocytes and T-
helper (Th)-17-lymphocyte signaling. Further insight has been gained in the Interleukin 
(IL)-23/Th-17 axis through gene and protein expression changes by treatment with IL-
12/23 inhibitors, or more directly through IL-17A inhibitor. This has revealed the 
significance of the Th-17 signaling pathway in the pathogenesis of PsA (Roberts, J., 
O’Rielly, D.D., Rahman, P., 2017). 
 
 Pathogenesis at the Level of the Tissue 
 PsA manifests as inflammation at multiple sites and in multiple tissues, primarily 
the skin, synovium, enthesis, and bone. 
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In the skin of PS patients, dendritic cells engulf foreign antigens and present them 
to T-cells, thereby activating them (Diani, Altomare, & Reali, 2015). It is widely 
hypothesized that infection or injury induces ‘danger signals’ triggering an autoimmune 
response, known as the Koebner phenomena (Barnas & Ritchlin, 2015). Models propose 
that dendritic cells (DC) sense stressed keratinocytes and invading microorganisms, and 
respond by excreting cytokines and chemokines (Diani et al., 2015). These signalling 
molecules bind to the antibacterial peptide LL37; that complex then binds to and activates 
the TLR-9 on plasmacytoid DC. TLR-9 activation leads the plasmacytoid DC to activate 
dermal DCs with IFN-α, which then migrates to lymph nodes. Within the lymph node, DCs 
produce IL-12 and IL-23, causing naive T-lymphocytes to differentiate into Th-1 and Th-
17 cells that migrate back to the skin. In the dermis, Th-1 cells release IFN-α and Tumor 
Necrosis Factor Alpha (TNFα) and Th-17 cells release TNFα, IL-1, IL-17, and IL-22. The 
IL-22 release causes increased keratinocyte proliferation which leads to increased IL-1, IL-
6 and TNFα release (Barnas & Ritchlin, 2015). TNFα promotes expression of adhesion 
molecules on endothelial cells and aids neutrophil migration (Diani et al., 2015). An 
abundance of neutrophils within the epidermis progress to form psoriatic plaques (Barnas 
& Ritchlin, 2015). 
 In the synovium of PsA patients, there is greater vascularity and lining-layer 
hyperplasia than other types of spondyloarthritis. Vascularization of the synovium is a 
known response to inflammation. Synovial hyperplasia can be explained by a higher 
proportion of CD8+ T-cells, which are cytotoxic, found in the tissue (Butt, 2009). In PsA 
synovial tissue, TNFα, IL-1B, IL-6, and IL-18 are found to have similar expression profiles 
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as seen in other spondyloarthropathies. Several studies have found that mast cells in the 
synovium of PsA patients express IL-17 (Barnas & Ritchlin, 2015).  
 PsA patients often have inflammation of the enthesis and the tissue structures 
surrounding it. A healthy enthesis organ dissipates mechanical stress and lacks vasculature. 
Mechanical stress or damage causes cells in the adjacent synovium to release inflammatory 
signals, which leads to the production of growth factors and cytokines. It is therefore 
thought that the inflammatory response in PsA originates in the enthesis. IL-23 receptor-
expressing cells are present in the enthesial interface of tendons or ligaments. When IL-23 
binds these cells there is increased production of IL-17A, IL-22, and Bmp7 – all of which 
are cytokines that perpetuate the inflammatory state (Barnas & Ritchlin, 2015).  
 In PsA patients, there is often a substantial amount of structural remodeling in the 
bone affecting skeletal joints. Disease-associated inflammation causes bone loss and new 
bone formation at the enthesial insertion. The altered bone remodeling can manifest: 
arthritis mutilans, eccentric bone erosions (particularly within the spine), and rapid new 
bone formation (Butt, 2009). The discovery of the IL-23/Th-17 axis provided new insight 
into the pathogenesis of bone remodeling in PsA. Inflammation causes an increase in 
circulating CD14+ cells, and a subset of these are triggered for differentiation into 
osteoclasts by M-CSF and RANKL. Osteoclastgenesis is also induced by TNFα, which 
induces upregulation of OSCAR on monocytes. Both RANKL and OSCAR activation send 
a secondary signal which leads to differentiation of monocyte to osteoclasts. Activated 
osteoclasts cause bone reabsorption and structural remodeling in the joint (Barnas & 
Ritchlin, 2015). 
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 Pathogenesis at the Molecular Level 
 The molecular pathogenesis of PsA involves many inflammatory cytokines, 
primarily TNFα, IL-12/23, and IL-17. 
 
1.2.2.1 TNFα  
TNFα, which is also known as cachexin or cachectin, is a regulatory molecule of 
immune cells. TNFα can trigger apoptotic cell death, cachexia (wasting of the tissue), and 
inflammatory pathways. TNFα can be either membrane bound or soluble trimeric, either of 
which can bind the receptors TNFR1 and TNFR2. TNFR1 is expressed in most tissues, 
whereas TNFR2 is typically found in cells of the immune system. When the TNFα ligand 
binds either of these TNFRs, the receptor undergoes a conformational change. This change 
triggers the release of the inhibitory protein SODD which permits TRADD to bind the death 
domain. This binding activates three different pathways: NF-κB, MAPK, and death 
signalling. In the nucleus, NF-κB acts as a transcription factor for many proteins involved 
in cell survival, proliferation, inflammatory response, and anti-apoptotic factors. When the 
MAPK pathways are triggered it leads to cell differentiation, proliferation, and are 
generally pro-apoptotic. Death signalling pathways lead primarily to apoptosis (Gottlieb et 
al., 2005). 
TNFα levels are increased in the synovial fluid and membranes in affected joints of 
PsA patients. Agents that target TNFα, such as etanercept, have been shown to improve the 
symptoms of PsA and TNFα levels (Mease, 2002). Both of these findings are evidence of 
the involvement of TNFα in the pathogenesis of PsA. 
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1.2.2.2 IL-12/23  
The IL-12/23 pathway is highly complex and requires further investigation to 
clarify the exact mechanism of action in inflammation. What is currently known is that the 
IL-12 and IL-23 ligand bind together and activate a heterodimer receptor complex 
containing IL-12R that is paired with either IL-12RB or IL-23R. After the ligand binds the 
receptor, Jak2 and Tyk2 are activated. This activation, in turn, phosphorylates the STAT 
protein which dimerizes and undergoes nuclear translocation. Once in the nucleus, these 
STAT proteins cause transcriptional activation of target genes, which code for IL-17, IL-
17F, and IL-23R as illustrated in Figure 1.1 (Teng et al., 2015). 
Both IL-12 and IL-23 are characterized as pro-inflammatory but they are also 
responsible for stimulating different immune responses. IL-12-induced signalling causes 
the differentiation of naive T-cells, proliferation and IFN-γ secretion by Natural Killer (NK) 
and T-cells, and increased cytotoxicity of NK cells and T-lymphocytes. IL-23-induced 
signalling stabilizes and maintains T-cells, increases memory T-cell activation and 
activates IL-17 mediated neutrophil recruitment at the site of trauma/infection (Teng et al., 
2015). The IL-23/Th-17 axis has helped better elucidate the mechanism of PsA and all other 
spondyloathropathies (Barnas & Ritchlin, 2015).  
Genetic associations have been found between variations in genes coding for 
proteins involved in the IL-12/23 signalling pathway, suggesting a connection to PsA 
pathogenesis. There is overexpression of the IL-12 and IL-23 receptor subunits in psoriatic 
plaque and overexpression of IL-23 in the synovium of PsA patients. IL-12/23 inhibitors, 
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such as ustekinumab, have proven effective in relieving symptoms of PsA – providing 
further evidence of IL-12/23 signalling pathway involvement (Johnsson & McInnes, 2015). 
 
 
Figure 1.1 – Schematic of IL-12/23 and IL-17 signalling pathways, which are implicated 
in the pathogenesis of PsA. This figure was adapted with permission by Elsevier 
Publishing Company from (E. Suzuki, Mellins, Gershwin, Nestle, & Adamopoulos, 
2014). Appendix D contains copyright permissions to use this figure.  
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1.2.2.3 IL-17  
IL-17 is a pro-inflammatory cytokine produced by T-helper cells when induced by 
IL-23 (Figure 1.1). IL-17 acts synergistically with TNFα and IL-1 in promoting 
inflammation. When IL-17 signalling is redirected towards the host, autoimmune disorders 
develop. Signalling from IL-17 recruits monocytes and neutrophils to the site of 
inflammation (Miossec, 2017). 
One of the six members of the IL-17 cytokine family binds an oligo-complex 
composed of various forms of the cell surface receptor IL-17R. Binding of these receptors 
leads to activation of the IL-17 cascade (Miossec, 2017). This cascade begins with the 
recruitment of ACT1 adaptor proteins. When ACT1 binds IL-17R, the recruitment of 
TRAF-6 and TRAF-3 occurs. ACT1 binding also activates intracellular kinases that interact 
and promote NF-κB-dependent, AP-1-dependant, and C/EBP-dependent expression of 
cytokine and chemokines. Triggering the IL-17 cascade increases the production 
inflammatory proteins, such as TNFα, in cell types such as fibroblasts, endothelial cells, 
keratinocytes, and macrophages (Gaffen, Jain, Garg, & Cua, 2014).  
Evidence that the IL-17 pathway contributes to the pathogenesis of PsA includes: 
IL-17 knockout animal models developing PsA, the increased expression of IL-17 positive 
T-cells in synovial fluid of PsA patients, the increased expression of IL-17R in synovial 
fibroblasts of PsA patients, and a decrease in disease activity in skin and joints seen with 
treatment IL-17 inhibitors (Raychaudhuri, Saxena, & Raychaudhuri, 2015). 
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When the TNFα, IL-12/23, and IL-17 signalling pathways are triggered 
concurrently with other pathways in the innate autoimmune response, an over production 
of inflammatory cytokines occurs. These cytokines promote an adaptive immune response, 
leading to the differentiation of T-lymphocytes. T-lymphocytes can differentiate into either 
CD4+ or CD8+ cells. When triggered by cytokines/chemokines, CD4+ cells differentiate 
into many types of Th-cells, but those that pertain to PsA are Th-1, Th-17, and Th-22 cells. 
Th-1 cells increase the cellular response of the immune system by aiding in the activation 
of CD8+ and NK cells. Th-17 cells play a large role in the pro-inflammatory arm of the 
immune system and are often associated with the pathogenesis of autoimmunity. These 
differentiated Th-cells release additional cytokines and chemokines triggering positive 
feedback in the signalling pathway of destructive autoimmunity in the skin, synovium, 
entheses, bones, digits, and nails (Barnas & Ritchlin, 2015). 
 
 Genetics of PsA  
 Heritability of PS and PsA 
PsA is a complex disease that manifests due to genetic and environmental 
contributing factors. Heritability is often estimated through recurrence rate within family 
members of affected individuals and the rate of concordance in twins.  
Both PsA and PS are highly heritable diseases and therefore there is an increased 
prevalence within families. The prevalence of PsA in first-degree relatives of PsA patients 
is 5.5%.  First-degree relatives of PsA patients were found to have a 19-fold increase in 
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prevalence of PS (Rahman & Elder, 2005). Familial aggregations indicate heritability in 
both PsA and PS, classifying them as genetic disorders. 
Strong heritability in PS and PsA is evident, with a recurrence risk ratio in first-
degree relatives (λ1) of ~8 (Pedersen, Svendsen, Ejstrup, Skytthe, & Junker, 2008). As well, 
there is a more than a 30-fold increase in the risk of developing PsA among the first-degree 
relatives of PS probands (Chandran, 2013). Familial aggregation of different types of SpAs 
present in individuals of the same kinship (Dougados & Baeten, 2011). 
 The rate of concordance amongst monozygotic and dizygotic twins can indicate 
the genetic and environmental contributions to disease.  The rate of concordance of PsA in 
monozygotic twins is between 35-72% and between 12-23% for dizygotic twins. The 
incidence of PsA is approximately three-times higher in identical twins, indicating a strong 
genetic contribution in the development of the disease (Chandran et al., 2009). Because 
PsA is a multifactorial disease, there are also known environmental factors involving gut 
flora, infection, and smoking that impact the manifestation of PsA (Dougados & Baeten, 
2011). 
 
 Genetic Contributions to PsA within the MHC locus 
 Linkage and associations studies on the genetics of PsA have been performed less 
frequently than with PS due to the decreased prevalence of PsA. In linkage studies, the 
most consistently observed genetic contribution to the development of PsA is located on 
chromosome 6p21.3, the MHC. Genetic variants in this region are, for the most part, class 
1 HLA alleles and some are non-HLA MHC genes. (O'Rielly & Rahman, 2014) Nair et al. 
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determined that the PSORS1 gene is actually the HLA-Cw*0602 allele which has a strong 
association to PsA. (Nair et al., 2006)  
 Linkage studies have found that HLA-B27 is associated with all 
spondyloarthropathies. With regard to PsA, HLA-B27 is particularly associated with 
spondylitis and dactylitis (Gladman, Anhorn, Schachter, & Mervart, 1986; Gladman, 
Ziouzina, Thavaneswaran, & Chandran, 2013). HLA-antigens such as B38 and B39 are 
associated with peripheral polyarthritis (Gladman et al., 1986). Chandran et al. (2013) 
found that HLA-C12/B38, HLA-B27, and HLA-C06/B57 haplotypes and alleles show the 
strongest association with PsA in a case-control and family-based study (Chandran et al., 
2013). Disease progression has also been found to be associated with HLA-B39, with the 
presence of both HLA-B27 and HLA-DR7, and with HLA-DQw3 in the absence of HLA-
DR7 and HLA Cw0602 (Ellinghaus et al., 2012). 
 There is mounting evidence for two associations between PsA and non-HLA 
genes within the MHC region (Al-Heresh et al., 2002; S. Gonzalez et al., 2002; Hohler et 
al., 2002). Polymorphisms in the promoter region of the TNFα gene, single nucleotide 
polymorphisms (SNPs) at position -238, and a SNP at position -308 each have associations 
to PsA in several Caucasian populations (Al-Heresh et al., 2002; S. Gonzalez et al., 2002; 
Hohler et al., 2002). The SNP at -308 has been found to be specifically associated with 
erosive changes in the PsA of affected individuals (Balding et al., 2003). Also within the 
TNFα gene, an association has been found between a SNP located at -857 and PsA; 
however, no association with PS has been found (Reich et al., 2007). 
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 The second non-HLA association within the MHC is to MICA. An association has 
been found between a triple microsatellite repeat in exon 5 of the MICA gene and various 
immunological disorders such as RA, AS, and Bechet’s Disease. The MICA gene is in 
extensive linkage disequilibrium with PsA-associated HLA alleles, establishing a weak 
association (Gao et al., 2006; Lucas et al., 2008; Ribas, Oliveira, Petzl-Erler, & Bicalho, 
2008). 
 
 Genetic Contributions to PsA outside the MHC locus 
Only a few studies have identified genetic contributions from outside the MHC to 
the development of PsA.  KIR genes have been investigated given that MHC class 1 
molecules interact with this receptor and perpetuate PsA-associated inflammatory 
pathways (K. C. Hsu, Chida, Geraghty, & Dupont, 2002). Associations have been observed 
between the development of PsA with polymorphisms in KIR2DS1 and KIR2DS2 so long 
as the corresponding HLA ligand for the inhibitory receptors were not present; there have 
been similar findings in PS (Nelson et al., 2004; Y. Suzuki et al., 2004; Williams et al., 
2005). An association with PsA was found to the IL-1α 889C polymorphism, however this 
finding has not been successfully replicated (Peddle, Butt, Snelgrove, & Rahman, 2005). 
There is also evidence for an association with a variant in PTPN22 and PsA; however, this 
association was not seen in PS (Bowes et al., 2015). 
One linkage study, conditioned on paternal inheritance of PsA, identified a locus 
proximal to PSORS8 (16q) (Karason et al., 2003). Within the same study, CARD15 was 
identified as a contributor to the disease. This finding was then replicated in a NF cohort 
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but has not been replicated in other cohorts (Karason et al., 2003; Rahman et al., 2003). An 
association was identified between the ERAP1/2 genes. The association between a SNP in 
the ERAP 2 gene was strongest in individuals who were HLA-B27 negative. Contrarily, an 
association was also found between PsA patients who are HLA-B27 positive and possess a 
SNP in ERAP1 (Popa et al., 2016). Two polymorphisms in the promoter regions of IL-6 
and IL1B were found to be associated with the peripheral pattern of PsA and higher disease 
activity in the peripheral joints, respectively (Cubino et al., 2016). Most recently, an 
association was found with a rare coding allele in the IFIH1 gene (Budu-Aggrey et al., 
2017). 
An association between IL-2 and IL-21 and PsA has been shown in a Genome Wide 
Association Study (GWAS) (Liu et al., 2008). GWASs that investigated PsA found some 
associations with genes outside of the MHC region. The strongest of these associations is 
with IL-12B, IL-23R, TNIP1, TRAF3IP2, FBXL19, and REL (Huffmeier et al., 2010; Liu et 
al., 2008; Stuart et al., 2010). A GWAS identified a strong association between PS and a 
haplotype in the IL-23R gene (Nair et al., 2008). This finding was also replicated in two 
studies defining the same association with PsA (Filer et al., 2008; Rahman et al., 2009).   
 
 Treatment of PS and PsA 
The treatment regime for the management of PS symptoms includes topical 
treatments, traditional systemic agents, small molecule inhibitors, and biologic agents. 
Therapeutics are prescribed based on the severity and location of disease as well as relevant 
comorbidities. For mild PS affecting a small region, topical steroids are most commonly 
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recommended (Sutherland, Power, Rahman, & O'Rielly, 2016). Other topical management 
options include vitamin D analogs, tar, and retinoids (American Academy of Dermatology 
Work Group, 2011). PS that is moderate to severe is often treated with topical therapies in 
conjunction with phototherapy or oral systemic agents. Patients with severe PS are typically 
prescribed traditional oral systemic therapies such as retinoids, methotrexate (MTX), and 
cyclosporine. Should the patient’s PS persist after these treatments, biologic agents are then 
considered (Sutherland et al., 2016). Generally biologics have better treatment efficacy than 
oral systemic agents. The three most commonly prescribed types of biologics for PS include 
anti-TNFα agents (i.e., adalimumab, etanercept, and infliximab), anti-IL-17 agents (i.e., 
secukinumab), and anti-IL-12/23 agents (i.e., ustekinumab) (American Academy of 
Dermatology Work Group, 2011). 
PsA is treated by a regime of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), 
traditional systemic agents, Disease Modifying Anti-Rheumatic Drugs (DMARDs), and 
biologic agents (Table 1.2). The aim of treatment is to reduce stiffness, limit pain, and 
increase mobility and function. First-line treatment for PsA is the use of NSAIDs. If 
symptoms persist, systemic agents such as MTX and leflunomide are then considered. 
Sulfasalazine, another systemic agent, is less frequently prescribed due to its inefficacy 
relative to other treatment options. An orally administered phosphodiesterase-4 inhibitor, 
Apremilast, has recently been approved in North America. As with PS, biologic agents are 
more effective than oral systemic agents in the management of PsA (Sutherland et al., 
2016). Three types of biologic agents have been deemed appropriate for the management 
of PsA: anti-TNFα agents (i.e., adalimumab, certolizumab, etanercept, golimumab, and 
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infliximab), anti-interleukin-12/23 agents (i.e., ustekinumab), and anti-IL-17 agents 
(secukinumab) (McInnes et al., 2017). 
 
Table 1.2 – Typical regime for treatment of PsA. 
Treatment Regime for PsA Patients 
Topical Agents Corticosteriods 
Vitamin D3 Analogues 
Topical Retinoids 
Anthralin and Tars 
Phototherapy 
Traditional Oral Agents Oral Retinoids 
Non-Steroidal Anti-inflammatory Agents 
Methotrexate  
Cyclosporine 
Leflunomide 
Sulphasalazine 
Small Molecule Inhibitor Agents Apremilast 
Biologic Agents TNFα inhibitors 
IL-12/IL-23 inhibitors 
IL-17 inhibitors 
 
Despite a range of options, there is great variability in patient response to the 
treatment regime for PS and PsA, with a high percentage of patients experiencing non-
response and adverse events while undergoing therapy (Sutherland et al., 2016). 
 
 Topical Agents for the Treatment of PS 
Topical agents prescribed for PS are corticosteroids, vitamin D3 analogues, topical 
retinoids, anthralin and tars, as well as phototherapy. The most commonly used topical 
23 
 
treatment of PS symptoms for the past 50 years has been corticosteroids. These high-
potency topical steroid treatments, are considered to be most efficacious, followed by 
vitamin D3 analogues. The most commonly prescribed vitamin D3 analogues is calcipotriol. 
Calcipotriol simulates calcitriol, the active form of vitamin D3 that is naturally produced 
by the body, which decreases redness, scaling, itchiness, and plaque elevation in psoriatic 
skin. Tazarotene is a commonly prescribed topical retinoid to treat PS. The proposed 
mechanism of tazarotene is through modulating the proliferation and differentiation of 
keratinocytes. Anthralin is another topical treatment for PS that has anti-[roliferative and 
anti-inflammatory effects. Tar therapy is one of the original methods of PS treatment; 
however, currently it is less commonly prescribed (Canadian Psoriasis Guidelines 
Addendum Committee, 2016). Controlled exposure to UV light is a widely utilized and 
well-established PS therapy (Menter et al., 2008). UV light is administered based on the 
complexion of the patient as well as the location and intensity of symptoms (Canadian 
Psoriasis Guidelines Addendum Committee, 2016). 
 
 Oral Agents for the Treatment of PS and PsA  
 Oral agents prescribed to treat PS and/or PsA include oral retinoids, NSAIDs, and 
DMARDs – such as methotrexate, cyclosporine, leflunomide, and sulphasalazine.  
Acitretin is the only oral retinoid that is currently prescribed in Canada to treat PS. 
There are severe restrictions on the use of this pharmaceutical because of its teratogenic 
potential, and is therefore contraindicated for women of childbearing age. The therapeutic 
capability of acitretin is realized in combination with topical calcipotriol (Canadian 
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Psoriasis Guidelines Addendum Committee, 2016). NSAIDs are a first-line treatment for a 
wide range of symptoms in PsA patients. NSAIDs are proven effective in treating 
peripheral arthritis, axial involvement, enthesitis, and dactylitis (Ritchlin et al., 2009).  
Pharmaceutical agents that act systemically by modifying immune response are 
referred to as traditional systemic agents (Sutherland et al., 2016). These systemic agents, 
otherwise known as DMARDs, include MTX and cyclosporine for PS treatment and 
include MTX, leflunomide, and sulphasalazine for PsA treatment (Canadian Psoriasis 
Guidelines Addendum Committee, 2016). 
MTX is a first-line systemic agent prescribed to treat moderate to severe PS and 
PsA (Sutherland et al., 2016). MTX promotes the release of adenosine which subsequently 
suppresses inflammation (Puig, 2014). MTX has proven to be effective in suppressing the 
cutaneous and articular manifestations of the disease. There are some adverse events 
associated with MTX, mainly hepatotoxicity, leading to one third of patients discontinuing 
the therapy (Sutherland et al., 2016).  
Cyclosporine is a DMARD that suppresses the immune system by inhibiting 
calcineurin. Calcineurin inhibition impedes B-cell activation and T-cell proliferation by 
blocking the inflammatory signalling cascade. Cyclosporine has proven effective in 
treating PS and marginally effective in treating PsA, therefore it is rarely prescribed by 
rheumatologists. Patient response to cyclosporine varies significantly due to differential 
intestinal absorption rates (Sutherland et al., 2016). Leflunomide is an immunosuppressant 
that inhibits the activation and proliferation of T-cells by inhibiting pyrimidine synthesis 
(Kaltwasser, 2007). Leflunomide has proven to be effective in suppressing the cutaneous 
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and articular manifestations of the disease (Ritchlin et al., 2009). Leflunomide has a high 
response rate and a favourable safety profile (Kaltwasser, 2007). Sulphasalazine is 
moderately effective in improving the symptoms of peripheral synovitis in PsA, and to a 
greater extent improving cutaneous and peripheral articular features (Ritchlin et al., 2009; 
Sutherland et al., 2016).  
 Small Molecule Inhibitors  
Cells that regulate immune response highly express small molecules, such as 
phosphodiesterare 4. Apremilast is an orally administered small molecule inhibitor that is 
approved for treatment of PS and PsA. Inhibiting phosphodiesterare 4 can suppress immune 
response and regulate autoimmunity. Apremilast has proven to be efficient in treating both 
PsA and moderate-to-severe PS (Deeks, 2015).  
 
 Biologic agents 
Biologics are a relatively new class of pharmaceuticals which are manufactured 
from biological sources or processes. Because biologics are not synthesized, like in the 
manufacturing processes of other pharmaceuticals, they are much more costly to produce 
(Rader, 2008). The high cost associated with production and inflation on pharmaceuticals 
have resulted in biologics costing between $380 and $4500 per treatment resulting in an 
annual cost of between $17,000 and $31,200 (Ustekinumab Injection, 2016). Biologics 
target different inflammatory pathways involved in autoimmune reaction and have proven 
to be efficacious in the treatment of PS and PsA (Rader, 2008). Biologic agents such as 
TNFα, IL-12/23, and IL-17 inhibitors are increasingly being prescribed to treat moderate-
26 
 
to-severe PS or PsA in patients who do not respond to traditional systemic therapies 
(Sutherland et al., 2016). 
 
1.4.4.1 TNFα Inhibitors 
There are five anti-TNFα agents prescribed for the treatment of PsA: etanercept, a 
recombinant human TNFα receptor protein; infliximab, a human-mouse chimeric anti-
TNFαmonoclonal antibody; adalimumab, a fully human anti-TNFαmonoclonal antibody; 
certoluzimab, a (mouse-human) chimeric monoclonal antibody; and golimumab, a human 
monoclonal antibody (Canadian Psoriasis Guidelines Addendum Committee, 2016). It is 
common for PsA patients to be prescribed biologics as monotherapies, or in combination 
with traditional systemic agents (Sutherland et al., 2016).  
TNFα inhibitors act by binding either free-floating TNFα cytokines or by binding 
the TNFα cell surface receptors thereby inhibiting the inflammatory signalling cascades 
that cause autoimmunity. With regards to cutaneous symptoms, TNFα binds to the surface 
of pro-inflammatory leukocytes, including neutrophils, monocytes, and activated T-cells, 
triggering the production of inflammatory chemokines which in turn perpetuates 
inflammation in that region (Koch, 2005).  Arthritic symptoms are improved with TNFα 
inhibitors by decreasing bone loss and by improving osteoblast function and differentiation 
(Gilbert et al., 2000). In both serum and lesioned skin, TNFα levels return to normal in 
patients who respond to TNFα inhibitor treatment. The decrease in TNFα levels is 
proportional to the decrease in cutaneous and articular symptoms (Mizutani, Ohmoto, 
Mizutani, Murata, & Shimizu, 1997). Consistent with these clinical findings are patient-
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reported outcomes indicating significant improvement in function and quality of life after 
treatment with TNFα inhibitors (Carron et al., 2017). 
 
1.4.4.2 IL-12/IL-23 Inhibitors 
The inflammatory cytokines IL-12 and IL-23 are known to play a role in the 
pathogenesis of PS and PsA (Lopez-Ferrer, Laiz, & Puig, 2017). Ustekinumab is a human 
monoclonal antibody that has demonstrated high efficacy in targeting IL-12/IL-23 
inflammatory pathways by binding the IL-12/23 cell surface receptor (Krueger et al., 2007). 
Ustekinumab has proven efficacious in treating moderate-to-severe PS and is regarded as 
efficacious for treating PsA. Similar response profiles were observed in PS and PsA 
patients taking ustekinumab, with a patient response rate of approximately 50% (Lopez-
Ferrer et al., 2017). There are minimal adverse events associated with ustekinumab 
treatment, though side effects include headache, abdominal pain, and infection (Chien, 
Elder, & Ellis, 2009).  
Although proven effective in treating PsA, ustekinumab has shown to be effective 
in treating cutaneous symptoms more so than in articular disease (Johnsson & McInnes, 
2015). Symptoms of PsA, such as enthesitis, dactylitis, spondylitis, and nail involvement 
have shown to improve with IL-12/23 treatment (Johnsson & McInnes, 2015; Pasch, 2016). 
Similarly, significant improvements have been documented through patient-reported 
outcomes by those undergoing treatment with ustekinumab (Rahman et al., 2016). 
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1.4.4.3 IL-17 Inhibitors 
 The inflammatory cytokine IL-17 has a known association with the pathogenesis 
of PS and PsA through the IL-23/Th-17 axis. Secukinumab and ixekizumab are both 
biologic agents that target the IL-17 signalling pathways by binding the IL-17 cell surface 
receptor (McInnes et al., 2015; Leonardi et al., 2012). 
Secukinumab is an anti-IL-17A human monoclonal antibody that functions by 
inhibiting the IL-17 inflammatory pathway. Secukinumab is approved worldwide for 
treating PS and has recently been approved for the treating PsA. The IL-17A and the IL-
17A receptors, which are expressed in the synovium and mediate enthesial inflammation, 
are inhibited by secukinumab; this results in a decrease in both joint damage and tissue 
remodeling (McInnes et al., 2015). An overall reduction of periarticular features, such as 
enthesitis and dactylitis, has been frequently seen with secukinumab treatment (Gladman 
& Ritchlin, 2016). Secukinumab has also proven efficacious in treating nail and skin 
features associated with PsA (Mease & McInnes, 2016). Consistent with these clinical 
findings are patient-reported outcomes indicating significant improvement in function and 
quality of life after secukinumab treatment (Mease et al., 2015). Adverse events associated 
with secukinumab treatment include upper-respiratory infections and nasopharyngitis. 
Response rates to secukinumab are similar to those of other biologics prescribed for PS and 
PsA treatment. Response rates were higher in patients who were naive to anti-TNFα and 
not being treated concomitantly with MTX (McInnes et al., 2015). 
Ixekizumab is a humanized monoclonal antibody used to treat PS and PsA by 
inhibiting IL-17A (Leonardi et al., 2012).  Ixekizumab is prescribed to patients with PsA 
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and moderate-to-severe PS. Cutaneous and articular features have shown improvement 
with Ixekizumab treatment (Gladman & Ritchlin, 2016). Consistent with these clinical 
findings are patient-reported outcomes indicating significant improvement in function and 
quality of life after ixekizumab treatment (Edson-Heredia et al., 2016). Up to 40% of 
patients treated with ixekizumab show partial or complete disease remission of their skin 
disease. As with other biologics, some patients treated with ixekizumab experienced 
increased rate of infection, reaction at the site of infection, upper-respiratory tract infection, 
as well as pain and inflammation of the oropharyngeal region (Nash et al., 2017). 
 
 Prediction of Treatment Response  
There are many biological traits that are associated with predicting response to 
treatment. Prediction of treatment response is typically examined through four main 
approaches: pharmacokinetics, pharmacodynamics, pharmacogenetics, and 
pharmacogenomics. The known associations between these fields and PsA are outlined 
below.  
 
 Pharmacokinetics 
Pharmacokinetics is the impact that the body has on an administered pharmaceutical. 
There are four main mechanisms involved in the study of pharmacokinetics: absorption, 
distribution, metabolism, and excretion (ADME). Relating to all of these variables is the 
concept of drug clearance, which is the elimination of a pharmaceutical from the body. 
Clearance estimates over time produce either a linear or nonlinear pharmacokinetic model. 
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A linear pharmacokinetic model is limited by the half-life of the pharmaceutical assuming 
it will remain consistent regardless of its concentration with one bolus administration 
distributed instantaneously. A nonlinear pharmacokinetic model is limited by the saturation 
of one pharmacokinetic aspect, such as a major metabolic pathway (Ratain & Plunkett, 
2003). 
Interpatient pharmacokinetic variability is dependent on differential ADME rates. 
Absorption of pharmaceuticals is dependent of factors such as gastrointestinal and renal 
tubular function. The drug absorption percentage can be discussed in the context of 
bioavailability. Bioavailability is determined in part by liver function and in part by drug 
metabolism rates in the gastrointestinal tract. Pharmaceutical distribution rates vary based 
on body size and fat percentage, while irregular drug distribution will decrease clearance 
rates. Excretion rates, which are highly variable between patients and difficult to predict, 
are impacted by liver function (metabolism) and renal function (clearance) (Ratain & 
Plunkett, 2003). 
When determining dosage levels in clinic, multiple patient characteristics must be 
considered. Age, sex, body fat, blood flow, and organ function are key traits in 
pharmacokinetics. With advanced age there is a decrease in many regulatory and functional 
processes within the cell (Ratain & Plunkett, 2003). The decrease in general cellular activity 
results in a reduction in metabolic rate/gastrointestinal absorption as well as in hepatic and 
renal clearance potential (Mangoni & Jackson, 2004). Sex has a social and biological 
influence on pharmacokinetics. In general, there has been fewer investigations into 
pharmacokinetics in females. These discrepancies should be addressed as studies have 
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indicated that women have worse safety profiles, with increased incidence and severity of 
adverse events (Franconi & Campesi, 2014). Body fat percentage plays a large role in 
pharmacokinetics due to its contribution to total mass and influence on the metabolism of 
lipophilic drugs. Each of the aforementioned characteristics affect organ function and 
subsequent pharmacokinetics, especially within the gastrointestinal tract, the liver, and the 
kidneys (Ratain & Plunkett, 2003). 
 When treating PsA with biologics (TNFα, IL-12/23, or IL-17 inhibitors) the 
pharmacokinetic properties that contribute to inter-patient variability include: slow 
clearance, long half-lives, and limited tissue distribution. The intramuscular injections of 
biologics involve slow absorption, with maximal plasma concentrations recorded for 
approximately 1-8 days post treatment. The distribution of biologic agents is limited by 
fluid circulation from blood into interstitial spaces, diffusion of the drug across a tissue, 
pinocytosis (invagination of extra-cellular fluid into a cell), and receptor-mediated 
endocytosis. Excretion of biologics is challenging because they are too large to undergo 
glomerular filtration. Biologics are therefore metabolized and primarily eliminated by 
catabolism of the protein into its amino acid subunits, which are then reused for the 
synthesis of new proteins (Kamath, 2016). 
 
 Pharmacodynamics 
 Pharmacodynamics relates to the impact that an administered pharmaceutical has 
on the body. In clinical trials pharmacodynamic investigations examine the relationship 
between dose and response to determine the maximally tolerated dosage and dose-limiting 
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toxicities in patients. Interpatient variation in dosage-to-toxicity can be attributed to two 
factors: differential pharmacokinetic characteristics and/or heightened sensitivity to certain 
pharmaceuticals. Establishing which pharmacodynamic factor is contributing to excessive 
toxicity must be determined before dosage is adjusted (Ratain & Plunkett, 2003). 
 To quantify a drug’s pharmacodynamics properties, the maximal effect and the 
median dose (dosage necessary for 50% of the maximal effect) must be established. When 
establishing these pharmacodynamic quantifications, it is important to consider that the 
impact of a pharmaceutical is dependent on its interaction with a cell-surface receptor. 
Based on this, pharmaceutical exposure can be saturable or nonsaturable, producing either 
a sigmoidal or linear pharmacodynamic plot, respectively (Ratain & Plunkett, 2003). 
 When treating PsA with biologics the pharmacodynamics properties of TNFα, IL-
12/23, and IL-17 inhibitors that contribute to inter-patient variability include: the ligand-
receptor interaction after binding of drug, the reduction of target cells by the down-
regulation of target antigens, and the consequences on signalling pathways after blocking 
initiation receptors. Numerous factors can influence the pharmacodynamics of biologics, 
such as antigen expression levels, the affinity of the target antigen, the distribution of an 
antigen within a tissue and which tissues it is expressed. Other characteristics of biologics 
that contribute to inter-patient variability include their charge, hydrophobicity, and 
glycosylation (Kamath, 2016). 
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 Pharmacogenetics and Pharmacogenomics 
Pharmacogenetics is the study of how genetic variation affects differential response 
to pharmaceuticals. Pharmacogenetic investigations are undertaken with a hypothesis and 
use a targeted approach that examines regions of the genome associated with the 
pathogenesis of a disease or pharmaceutical metabolism. Pharmacogenomics, takes a 
broader approach, evaluating genome-wide variations that contribute to differential 
treatment response. Pharmacogenomic investigations are comprehensive evaluations that 
are “hypothesis-free” or “hypothesis generating”, which identify regions of the genome 
associated with pharmaceutical response. Those associations are then scrutinized by 
various “-omic” approaches to establish the impact of biological functions on response to 
treatment and determine possible causation (Sutherland et al., 2016).  
Together, pharmacokinetic, pharmacodynamic, pharmacogenetic, and 
pharmacogenomic factors should be taken into consideration before a patient begins 
treatment with biologics. Studies investigating these factors in PsA treatments differ in 
number, scale, and statistical power. Often, associations found have not reached 
significance levels appropriate for clinical utility. Genetic variations involved in differential 
drug response can occur in the deoxyribonucleic acid (DNA), ribonucleic acid (RNA), and 
can be affected by epigenetic modifications that impact the regulation of gene expression. 
 
1.5.3.1 DNA Variations in Precision Medicine 
There are many types of DNA variations that affect gene expression and gene 
function, including single nucleotide variations (SNVs) and copy number variations 
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(CNVs). The most common DNA variations are SNVs, in which one nucleotide differs 
from the reference genome on one or both strands of DNA. SNVs differ from SNPs in that 
they have a minor allele frequency of >1%. CNVs are variations in the number of copies 
of a certain sequence that possess 95% homology in the repeated units and are less than 
1000kb in length (Feuk, Carson, & Scherer, 2006).  
The aforementioned DNA variations can be investigated for associations to 
interpatient variability to drug response within the disciplines of pharmacogenetics and 
pharmacogenomics. There are a number of methods used to investigate pharmacogenetic 
DNA variants. Genotyping assays and next-generation sequencing (NGS) technologies are 
the two main approaches to targeted pharmacogenetic studies. Genotyping assays such as 
polymerase chain reaction (PCR), Sanger Sequencing, and restriction fragment length 
polymorphism are simple and cost-efficient procedures.  NGS technologies such as 
Illumina or Ion Torrent platforms are more complex and costly procedures for sequencing 
panels of targeted variants. Similarly, NGS technologies, which sequence whole-exome, 
transcriptome, and methylome, are used to comprehensively investigate 
pharmacogenomics to identify genetic variants. These approaches involve sequencing a 
patient’s whole genome or whole exome (the coding regions of the genome) to identify 
associations with treatment response. Those associations are then investigated for 
causation.  
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1.5.3.2 DNA Variations Causing Differential Drug Response in Psoriatic Disease 
 Pharmacogenetic profiles of efficacy and toxicity have been compiled for patients 
undergoing treatment for PS and PsA. Genetic variations are primarily associated with 
pharmacokinetic and pharmacodynamic pathways. The DNA variations associated with 
response to topical treatments are found primarily within genes coding for vitamin D 
absorption. Variations that impact response to oral agent treatment are generally found in 
genes that code for drug-metabolizing enzymes, drug-transportation proteins, and cell-
surface receptors. Variant associations to response to biologics have predominantly been 
found in the signalling pathways that these pharmaceuticals act on, such as TNFα, IL-12/23, 
and IL-17 (Sutherland et al., 2016).  
 
1.5.3.2.1 Differential Response to Topical Agents in PS Patients 
1.5.3.2.1.1 Vitamin D3 Analogues  
 Pharmacogenetic variants associated with topical agents for the treatment of PS 
have been found primarily in genes involved in Vitamin D absorption. The Taq1 
polymorphic site in the vitamin D receptor (VDR) correlates with a decreased calcipotriol 
response in PS patients (Dayangac-Erden, Karaduman, & Erdem-Yurter, 2007). 
Contravening this finding, Hasall et al. demonstrated that the VDR polymorphism Taq1, A-
1012G, and Fok1 are associated with an efficacious calcipotriol response (Halsall, Osborne, 
Pringle, & Hutchinson, 2005). 
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1.5.3.2.1.2 Phototherapy  
The pharmacogenetics of phototherapy has yet to be systematically evaluated, 
although some studies have been completed. One study of PS patients found that the 
presence of an indel in the GSTM1 was associated with an increased probability of 
achieving clearance of PS symptoms (Smith, Weidlich, Dawe, & Ibbotson, 2011).  Ryan et 
al. determined that patients treated with narrow-band UVB therapy who possessed a certain 
genotype in Taq1 VDR had a significantly reduced time to remission (Ryan, Renfro, 
Collins, Kirby, & Rogers, 2010).  
 
1.5.3.2.2 Differential Response to Oral Agents in PS Patients 
1.5.3.2.2.1 Non-Steroidal Anti-Inflammatory Drugs  
It is known that NSAIDs are metabolized by cytochrome P450 enzymes, yet 
establishing pharmacogenetic profiles of response remains challenging (Jani, Barton, & 
Ho, 2015). When compared with PS patients possessing the CYP2C9*1 allele (wildtype), 
those who have the CYP2C9*2 and CYP2C9*3 alleles were found to have reduced 
metabolic clearance of NSAIDs. Reduced clearance of these pharmaceuticals can lead to 
toxicity and must be considered when determining dosage (Martinez et al., 2004).  
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1.5.3.2.3 Differential Response to Traditional Systemic Agents in PS and PsA 
Patients 
1.5.3.2.3.1 Methotrexate 
Ample research has been done into polymorphisms associated with response to 
MTX treatment in PS patients.  Polymorphisms associated with differential response can 
be categorized as effectors of MTX transport across the cell membrane (ABCC1, ABCG2 
and SLC19A1) and as effectors of enzymes involved signalling pathways and metabolism 
of MTX (MTHFR, DHFR, TYMS, ATIC and ADORA2A) (Ranganathan & McLeod, 2006).  
Three variants in the ABCC1 gene and two variants in the ABCG2 gene are 
associated with PS patients who responded to MTX treatment (Warren et al., 2008). The 
presence of a, 28 base-pair, triplet tandem repeat in the 5’ untranslated region (UTR) of 
TYMS was correlated with patients who failed to respond to MTX (Campalani et al., 2007). 
Six variants in the ABCC1 gene were found to be associated with PS patients who 
experienced at least one adverse event during MTX treatment. Additionally, a minor 
increase in the occurrence of MTX toxicity was observed in patients with a SNP in either 
ADORA2A or in SLC19A1 (Warren et al., 2008). A deletion in the TYMS gene was also 
found to be associated with the occurrence of hepatotoxicity. Similarly, a variant in ATIC 
was found to be associated with a greater risk of side effects including nausea, elevated 
alanine, and aminotransferase (Campalani et al., 2007). 
Research into the pharmacogenetics of MTX in PsA patients is not as extensive as 
those done for PS patients.  Chandran et al. examined polymorphisms in genes in the folate 
pathway in relation to efficacy and toxicity of MTX in PsA patients (Chandran et al., 2010). 
They found variant in DHFR was associated with a significant increase in response to 
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MTX. Some evidence was found for a genotype in MTHFR that correlates to an increased 
incidence of hepatotoxicity (Chandran et al., 2010).  
 
1.5.3.2.3.2 Cyclosporine  
There is high inter-individual variability in PS patient response when treated with 
cyclosporine. This variable response is attributed hepatic levels of metabolizing 
cytochrome P450 (CYP)-3A isozymes (i.e., CYP3A4) and MDR1-ABCB1 (Naesens, 
Kuypers, & Sarwal, 2009). The CYP3 enzyme is known to influence oral bioavailability 
and systemic clearance of cyclosporine (O'Rielly & Rahman, 2011). One study showed a 
genotype in ABCB1 was more common in non-responders when compared to responders 
(Vasilopoulos et al., 2014).  
 
1.5.3.2.3.3 Sulphasalazine  
There has been some studies done on the pharmacogenetics of sulphasalazine, the 
efficacy and toxicity of which is monitored by sulphapyridine serum levels. To be secreted 
via the kidneys, an acetate group is bound to sulphasalazine by NAT2 to form N-acetyl 
sulphasalazine (Das & Dubin, 1976). Inter-individual variability in the acetylation of 
sulphasalazine is correlated with differential plasma concentrations: patients who are rapid 
acetylators (i.e., efficient secretors) are less prone to adverse events and may require 
increased dosage to maintain efficacy (Wiese et al., 2014). NAT2 has seven variants which 
have been positively correlated to sulphasalazine acetylation rates (Hein & Doll, 2012). 
Patients who are heterozygous for these variants are known to be either slow or 
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intermediate acetylators, while those who are homozygous for these variants are known to 
be either rapid or intermediate acetylators) (Davila & Ranganathan, 2015; Hein & Doll, 
2012).  
1.5.3.2.4 Differential Response to Biologic Agents in PS and PsA Patients 
Research has been done in the pharmacogenetics of biologics therapy in PsA 
patients because this pharmaceutical class has a low response rate (~50%) and very high 
financial costs associated with treatment (between $380 and $4500 per treatment) 
(Ustekinumab Injection, 2016). 
 
1.5.3.2.4.1 TNFα inhibitors 
Two types of TNFα inhibitors are currently used to treat PsA: fusion-chimeric 
proteins (etanercept) and monoclonal antibodies (infliximab and adalimumab). There is 
high variability in PsA patient response to these biologics, with up to 40% of patients 
showing minimal-to-no disease remission. Due its low overall incidence, few 
pharmacogenetics studies have been done on PsA patients; however, many studies have 
been done on patients with PS. Often pharmacogenetic studies on biologics are often under-
powered so it is common for research to group patients being treated with different TNFα 
inhibitors so that statistical significance can be achieved (Sutherland et al., 2016).  
Studies on TNFα inhibitor-treated PS patients found variants in TNFα, TNFRSF1A, 
TNFRSF1, and TNFRSF10A lead to positive response to treatment (Vasilopoulos et al., 
2012;Tejasvi et al., 2012;Gallo et al., 2013;Tong et al., 2013;Murdaca et al., 2014;Morales-
Lara et al., 2012).   Together these studies indicate the crucial role of genetic variation in 
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TNFα signalling-associated genes and response to TNFα inhibitors. In addition to these 
TNFα signalling-associated genetic variants, response to TNFα inhibitors is also affected 
by variants in genes associated with Th-17 signalling, such as IL-23 and IL-17. Studies 
have found associations between positive response to treatment and variants in IL-23R and 
IL-17F (Gallo et al., 2013; Prieto-Perez et al., 2015).  
Fc gamma receptors (FCGRs) are expressed on most immune cells and regulate 
functions such as cytokine release, apoptosis, and cytotoxicity. Associations have been 
found between the genes that code for these receptors and positive response to anti-TNFα 
therapy. Variants in genes such as FCGR2A, FCGR3A, SLCO1C1 were found to be 
associated with a greater clearance of PS symptoms when treated with TNFα inhibitors (M. 
Julia et al., 2013; A. Julia et al., 2015; Ramirez et al., 2012). 
 
1.5.3.2.4.2 IL-12/IL-23 inhibitors 
Studies examining the pharmacogenetics of IL-12/23 inhibitors have primarily 
shown associations to HLA genes or genes in the IL-12/23 pathway. Numerous studies that 
have investigated the response to ustekinumab found the efficacy to be more frequent and 
more rapid in HLA-Cw6-positive patients (Chiu et al., 2014; Talamonti et al., 2013). A 
multi-parameter logistical regression analysis identified HLA-Cw6 to be a more accurate 
indicator of positive response to ustekinumab if a variant in IL-12B was also present. 
Furthermore, HLA-Cw6 proved to be a more accurate indicator of positive response to 
ustekinumab in the absence of variants in IL12B and/or the IL-6 (Galluzzo et al., 2015). 
Prieto Perez et al. identified an association between a variant in IL-17F and patients who 
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did not respond to ustekinumab treatment (Prieto-Perez et al., 2015). This is in keeping 
with the established relationship between the IL-12/IL-23 signalling cascade and IL-17 
genes.  
 
1.5.3.2.4.3 IL-17 inhibitors 
 Thus far no published studies have investigated the pharmacogenetics of IL-17 
inhibitors. 
 
1.5.3.3 RNA Variations in Precision Medicine  
1.5.3.3.1 messenger RNA 
 messenger RNAs (mRNAs) are genetic transcripts that code for proteins and are 
the mechanism by which genes are expressed. mRNA is transcribed from DNA by RNA 
polymerase II within the nucleus. After transcription is complete a 5’ methyl-guanine cap 
and a 3’ polyadenyline tail are added. Once processed the mRNA transcript is packaged 
with mRNA-binding proteins and exported into the cytoplasm. Once in the cytoplasm the 
mRNA transcripts are bound by either a ribosomal complex for translation or a microRNA 
(miRNA) complex for translational inhibition (Cole, 2001).   
Pharmacogenetic and pharmacogenomic investigations of RNA variants are 
primarily done by microarray or sequencing. Targeted pharmacogenetics approaches 
involve panels of selected genes with known or suspected associations with treatment 
response, which are examined with DNA microarrays composed of probes that are 
complementary to mRNA transcripts (Katagiri & Glazebrook, 2009). 
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Transcriptomics is the comprehensive analysis of the all RNA transcripts in a 
sample. This type of investigations uses microarray or sequencing methods to identify 
associations with treatment response. These investigations examine all known mRNA 
transcripts to identify differential expression and attempt to determine causation. 
1.5.3.3.2 microRNA 
microRNAs (miRNAs) are 17-22nt sequences which act as a regulators of gene 
expression by binding mRNA transcripts and either suppressing or inhibiting their 
translation (Mi, Zhang, Zhang, & Huang, 2013). miRNA biogenesis begins when RNA 
polymerase II transcribes the miRNA-containing loci. This transcript forms one or more 
hairpin structures which are referred to as primary miRNA (pri-miRNA). The stem of the 
primary miRNA is then bound by DGCR8, which is then bound by DROSHA, thus making 
the microprocessor complex. This complex trims the transcript into a ~60-70nt precursor 
miRNA (pre-miRNA). EXPORTIN5 then exports the precursor miRNA into the cytoplasm 
and releases it. The precursor miRNA is then recognized by DICER. DICER binds TRBP2 
and cleaves the stem loops of the hairpin, making a short double-stranded miRNA. The 
Argonaute 2 (AGO2) interacts with DICER causing it to release the bound miRNA. AGO2 
then binds the double-stranded miRNA and releases one strand of the miRNA. The strand 
of miRNA that remains bound to AGO2 is referred to as the guide strand. When one 
miRNA strand is selected to be the guide strand more frequently than the other it is 
considered the “major product” of that precursor miRNA and is often (but not always) 
denoted by the absence of a star or the suffix -5p. The “minor product” is often denoted by 
a star or the suffix -3p (Bartel, 2004).  
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The guide miRNA strand interacts with AGO2 and other proteins to form RISC 
(RNA-Induced Silencing Complex), which is responsible for miRNA-induced gene 
silencing through RNAi (RNA Inactivation). RISC guides the miRNA to a target mRNA 
based on complete (or nearly complete) complementarity to the mRNA transcript (Bartel, 
2004). miRNA binding of mRNA is dependent on the seed region of the miRNA, which 
binds the 3’ untranslated region. The seed region is a conserved seven base pair sequence, 
commonly positioned from nucleotide 2 – 7 from the 5’end of the miRNA transcript, where 
initial binding of an mRNA occurs (Grimson et al., 2007).  
When RISC binds to an mRNA transcript it leads to translational 
repression/silencing or mRNA cleavage (Grimson et al., 2007). If there is imperfect binding 
of the miRNA to the mRNA transcript, translational repression/silencing is more likely to 
occur. Imperfect binding causes RISC to remain bound to the mRNA transcript making it 
impossible for translational machinery to bind and for translation to begin. Immediate post-
binding mRNA cleavage is most likely to occur with increased pairing between the miRNA 
and mRNA transcripts (Bartel, 2004). This occurs more frequently with mRNA binding of 
siRNAs (often an exogenous small RNA transcript, which has a similar function to 
miRNAs) (Grimson et al., 2007). After mRNA cleavage, the miRNA remains intact and 
can continue binding and cleaving additional mRNA transcripts (Bartel, 2004).  
 
1.5.3.3.2.1 Circulating miRNAs 
miRNAs primarily function in the cytoplasm but are known to be excised by a cell 
and invaginated by a neighboring cell, leading to intercellular communication via 
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regulation of gene expression. The exact mechanism of release from the cell is currently 
unknown but is hypothesized to occur during a loss of integrity in the plasma membrane 
and/or during cell death. These extracellular pre-miRNAs and mature miRNAs are bound 
to either high-density lipoproteins or the AGO2 protein, or they are encapsulated in 
microvesicles or exosomes which in turn inhibits RNase digestion in the plasma (Mi et al., 
2013). Once released from a cell into the plasma, these microparticles can be absorbed by 
the blood stream; they are then referred to as ‘circulating miRNAs’ (Figure 1.2). 
Circulating miRNAs are a major form of intercellular communication (Creemers, Tijsen, 
& Pinto, 2012).  
miRNAs are frequently investigated as potential biomarkers in many conditions 
because of their potential to non-invasively aid in diagnostics, prognostics, or therapeutic 
response prediction. Circulating miRNA biomarkers were initially investigated in cancer 
research. For example, when compared to levels in healthy controls, miR-141 was 
significantly increased in individuals who had metastatic prostate cancer. Similarly, a 
miRNA profile of increased miR-486 and miR-30 and decreased miR-1 and miR-499 levels 
was found in patients with non-small-cell lung cancer. These and many other studies have 
shown the predictive potential of circulating miRNAs that could one day have clinical 
utility (Mi et al., 2013). 
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Figure 1.2 - Schematic of miRNAs being excised from a cell, where they are referred to as 
‘circulating miRNA’. This figure was used with permissions from Wolters Kluwer 
Publishing Company; (Creemers, Tijsen, & Pinto, 2012). Appendix E contains copyright 
permissions to use this figure. 
 
The use of circulating miRNAs as biomarkers is currently being examined in 
inflammatory disease. miRNAs are known to regulate immune response and the 
development of immune-related cells, both of which are factors that contribute to 
inflammatory disease pathogenesis (Mi et al., 2013). For instance, miR-150 expression is 
known to be critical to the development of mature T- and B-cells, but its over-expression 
severely decreases the formation of mature T-cells (Zhou, Wang, Mayr, Bartel, & Lodish, 
2007). Up-regulation of miR-151-5p and miR-28-5p was observed in two independent 
circulating miRNA studies on ulcerative colitis patients (Paraskevi et al., 2012).  
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 Pharmacogenetic and pharmacogenomic investigations of miRNA variants are 
primarily done by microarray or sequencing. Targeted pharmacogenetics approaches 
involve panels of selected miRNAs with known or suspected associations with treatment 
response, which are examined with DNA microarrays composed of probes that are 
complementary to miRNA transcripts (Katagiri & Glazebrook, 2009). Similar 
investigations can be done targeting differential miRNA expression potentially associated 
with treatment response, which are examined with microarrays composed of probes 
specially designed to bind miRNAs (Shingara et al., 2005).  
The comprehensive analyses of the miRNA transcripts has been given the name 
“miRomics”. This type of investigation uses microarray and sequencing methods to 
identify associations between differentially expressed miRNAs with treatment response. 
These investigations examine all known miRNA transcripts to identify differential 
expression and attempt to determine causation. 
 
 
1.5.3.4 mRNA Variations Causing Differential Drug Response in Psoriatic Disease 
 Transcriptomic investigations of drug response in patients undergoing treatment 
for PS and PsA have identified associations with differential mRNA profiles. These studies 
identified differential mRNA expression of genes that are primarily responsible for T-cell 
regulation and cytokine production. A few transcriptomic investigations into drug response 
in PsA and PS patients have been done that are primarily associated with pharmacokinetic 
and pharmacodynamic pathways. These genetic variations that impact response to PS/PsA 
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treatment are generally found in genes that code for drug-metabolizing enzymes, drug 
transportation proteins, and cell-surface receptors. These associations have predominantly 
been found in signalling pathways that these pharmaceuticals act on, such as TNFα, IL-
12/23, and IL-17 inhibitors (Sutherland et al., 2016).  
 
1.5.3.4.1 Methotrexate  
Pharmacogenomics investigations have been performed on PS and PsA patient 
cohorts treated with MTX.  In a microarray analysis of gene expression in PS patients, a 
significant down-regulation of the mRNAs involved with helper T-cells (i.e., Th-1, Th-17 
and Th-22) was observed (Goldminz et al., 2015). There has been only one comparative 
transcriptomic analysis done on PsA patients, comparing those being treated with MTX 
and those who were not undergoing treatment. Through microarray, responders to MTX 
were found to have an increased expression of 12 genes and a decreased expression of 33 
genes (Cuchacovich, Perez-Alamino, Zea, & Espinoza, 2014). Further comprehensive 
investigations are required to identify additional genetic variations associated with MTX 
response. 
 
1.5.3.4.2 TNFα Inhibitors 
Studies have used a targeted approach to examine the influence of etanercept on 
gene expression in PS patients. These studies have displayed a significant reduction in 
mRNA expression levels in TLR-2 and -9 and key notch signalling pathway genes 
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(NOTCH1, NOTCH2 and JAGGED1) when matched to untreated PS controls 
(Skarmoutsou et al., 2015; Vageli et al., 2015). Another study demonstrated an increase in 
mRNA levels of survivin and capase3 transcripts in lesional and non-lesional skin after 
etanercept treatment. These results suggest etanercept’s mechanism of action is correlated 
to a decrease of keratinocyte regulation and the subsequent increase in keratinocyte 
apoptosis (Lembo et al., 2016). A decreased in expression levels of 161 genes and increased 
expression levels of 27 genes was observed in patietns being treated with TNFα inhibitors 
when compared to an untreated control group (Cuchacovich et al., 2014). 
A study examining response to adalimumab found an overall suppression of genes 
involved in the Th-17 signalling pathway in the skin and PBMCs of PS patients. 
Specifically, this study found a down-regulation of Th-17 polarizing cytokines (IL-23A, 
TGF-β1, IL-1β), Th-17 cytokines (IL-17, IL-22), Th-1 polarizing cytokines (IFN-α, TNFα), 
chemokines (IL-8, CCL20), and antimicrobial peptides (HBD-2, S100A7) (Balato et al., 
2014). Another study identified a decrease in NOTCH1 mRNA levels in the skin of 
responders to adalimumab (Skarmoutsou et al., 2015).  
 
1.5.3.4.3 IL-12/23 Inhibitors  
Multiple studies have examined gene expression profiles of PS patients undergoing 
treatment with IL-12/23 inhibitors; however, no studies have been published that examine 
the effects of ustekinumab on PsA patients. Several genes known to be involved in the 
pathogenesis of PS have displayed a significant down-regulation in responders to 
ustekinumab treatment (Gudjonsson & Krueger, 2012). Another investigation identified a 
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significant reduction in NGF expression and an increase in GATA3 and IL-22RA1 
expression (Baerveldt et al., 2013). Responders to ustekinumab had an increase in IL-20, 
IL-21 and p40 expression in lesional skin in their pre-treatment transcriptomes (Gedebjerg, 
Johansen, Kragballe, & Iversen, 2013). Another study demonstrated the down-regulation 
of expression of genes crucial to the Notch signalling pathway, NOTCH1 and NOTCH2, in 
the skin biopsies of PS patients undergoing ustekinumab therapy (Skarmoutsou et al., 
2015). 
 
1.5.3.4.4 IL-17 Inhibitors 
PS patients treated with secukinumab exhibited down-regulation of genes coding 
for chemokines and cytokines. This change in transcriptomic profile showed a significant 
decrease in Th-17-associated genes (IL-17A, IL-17F, IL-21, IL-22, IL-8, DEFB4, CCL20), 
Th-1-associated genes (IFN-γ, IL-12B), proliferation marker (KRT16), and innate 
immunity-associated genes (TNFα, IL-6) (Hueber et al., 2010).  
 Pharmacogenomic investigations have been done on PS patients taking 
ixekizumab, which is currently in clinical trials (Boyd & Kavanaugh, 2015). mRNA 
expression levels in lesional skin from PS patients treated with ixekizumab showed a down-
regulation of IL-19, IL-8, CXCL1, CCL20, GZMB and LCN2 when compared to mRNA 
levels at baseline and after 6 weeks of therapy (Krueger et al., 2012). The suppression of 
these genes was more significant than in the transcriptomes of patients treated with 
etanercept. This indicates that ixekizumab has a larger impact on the PS transcriptome at 
baseline. Comparisons between psoriatic skin pre- and post treatment with ixekizumab also 
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revealed that of the 1200 genes that were differentially expressed, 643 genes became 
normalized after two weeks (Krueger et al., 2012). Wang and colleagues found similar 
results, noting the majority of genes that were up-regulated in PS patients were significantly 
suppressed in response to ixekizumab therapy (Wang et al., 2014). Intriguingly, there was 
a significant down-regulation of genes associated with cardiovascular disease and 
atherosclerosis – comorbidities commonly associated with PS (Ryan et al., 2011; Wang et 
al., 2014).  
1.5.3.5 miRNA Variations Causing Differential Drug Response in Psoriatic Disease 
Very few studies have investigated differential miRNA expression in response to 
treatment of PS, while none investigated differential miRNA expression in response to 
treatment of PsA. A study on PS patients undergoing treatment with MTX found that 
decreased levels of miR-223 and miR-143 in the PBMCs of these patients were directly 
correlated to disease severity (Lovendorf, Zibert, Gyldenlove, Ropke, & Skov, 2014). 
Investigations into miRNA expression demonstrated that miR106b, miR142-3p, miR-223, 
and miR-126 were significantly down-regulated in PS patients who responded to etanercept 
when compared with non-responders (Pivarcsi, Meisgen, Xu, Stahle, & Sonkoly, 2013). 
Thus far only a few studies have investigated the field of pharmacogenomics of PsA, and 
therefore further studies are required on the differential miRNA expression as a marker of 
response to treatment. 
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1.5.3.5.1 Methodologies of miRNA Extraction from Plasma 
 Since circulating miRNAs were identified as a potential source of stable and non-
invasive biomarkers, researchers have been optimizing miRNA extraction procedures from 
plasma to achieve high miRNA yields with minimal contamination. Proper plasma 
isolation, RNA extraction, RNA size separation, and miRNA quantification are all required 
to produce optimum results (McAlexander, Phillips, & Witwer, 2013; Moret et al., 2013).  
 To ensure highest possible yields, all miRNA extraction procedures must be 
performed in an RNase-free environment to minimize RNase degradation until the RNA 
has been reverse transcribed into cDNA. Plasma isolation should be performed as soon as 
possible after venipuncture to reduce contamination from hemolysis. Centrifugation of 
whole blood causes separates it into layers from which the plasma is transferred to a fresh 
tube. Often, a second centrifugation is performed to remove cellular contents from the 
plasma, which can bias results with an intracellular miRNA profile from platelets and white 
blood cells. If possible ultracentrifugation should be considered to ensure no contamination. 
miRNAs are well preserved in frozen plasma (-80°C) allowing for miRNA extractions to 
be performed at a later time (McAlexander et al., 2013; Moret et al., 2013). 
RNA extraction from plasma is normally performed by mixing the plasma with a 
phenol-chloroform solution that separates the RNA into an aqueous phase after 
centrifugation. The RNA is then precipitated out of the aqueous phase using ethanol; 
however, this process is less efficient with small RNAs than with larger species and can be 
optimized using differential concentrations of ethanol. Techniques for miRNA isolation 
from total RNA include size separation by filtered column or by magnetic beads. Column 
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separation is a more traditional approach that is low cost and effective in size separation 
but results in lower yield because some miRNAs remain in the filter after elution. Magnetic-
bead separation is a newer technique that is more costly but highly effective in size 
separation with minimal loss of miRNAs throughout the procedure (McAlexander et al., 
2013; Moret et al., 2013). 
After miRNA is properly extracted, samples can then be quantified and 
standardized either for differential expression analyses using microarray or for library 
preparation using NGS. Currently, quantification methods are far from optimal. Standard 
spectrophotometer quantification methods are not suitable for plasma-extracted RNA due 
to the paucity of miRNAs and carryover contaminants. The small size of miRNA limits the 
efficiency of most conventional biological amplification processes and adds bias to 
expression quantifications. It has also been reported that RNA extracted from plasma can 
be contaminated with inhibitors of quantitative polymerase chain reaction (qPCR). qPCR 
is inefficient at miRNA quantification on a genomic scale and is more suitable for 
validation purposes. Unlike qPCR, microarray technology labels each miRNA molecule 
and does not include any amplification step, thereby removing that source of potential bias. 
The optimization and standardization of methods for miRNA extraction from plasma will 
improve the clinical utility of circulating miRNA biomarkers with regards to diagnosis, 
prognosis, and predicting response to treatment (McAlexander et al., 2013; Moret et al., 
2013). 
There are well established protocols for sequencing intracellular miRNA, which is 
much more abundant than circulating miRNA. Using extracted miRNA from plasma for 
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genomic analysis using NGS technologies is difficult in nature due to small size of miRNA, 
low yields when extracted from plasma, and suboptimal quantification techniques. The 
small size of the miRNAs necessitates adaptors that increase fragment length and the low 
yield necessitates increasing amplification cycles. Library preparation procedures often 
require a known concentration of miRNA in a sample to reduce variability between the 
resultant concentrations of prepared libraries; however, the lack of appropriate 
quantification techniques limits this potential point of standardization. Limiting factors 
such as these were points of optimization during the development of library preparation 
methods for sequencing on Ion Torrent or Illumina platforms (Head et al., 2014). At the 
time of this investigation, a literature review failed to find publications on sequencing 
circulating miRNAs from human plasma using NGS technologies. Two papers had been 
published that sequenced the contents of exosomes excised by human cell lines and serum; 
however, these investigations involved procedural modifications and did not include other 
species of non-exosomal microRNAs (Schageman et al., 2013; Lunavat et al., 2015). The 
co-author of Lunavat et al. (2015), published the protocol used to successfully prepare 
libraries in this investigation. 
Overall, miRNA extraction and library preparation methods have improved; 
however further optimization is required to maximize this potential for biomarkers. Method 
selection varies depending on the laboratories capacity and should be employed and 
compatibility between reagent chemistry and sequencing platforms should always be 
considered. Once established, additional in-house modification may be required to optimize 
the sequencing of circulating miRNAs. 
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 Rationale  
PS prevalence in NF is double that of any other Caucasian population worldwide 
(Gulliver et al., 2011). This is due in part to genetic isolation of a small founding population 
and in part due to the low UV indexes per annum (Gulliver et al., 2011). Given that arthritis 
is developed by one third of PS patients it can be reasonably assumed that there is also an 
increased incidence of PsA in NF, although it has not been officially documented (Rahman 
& Elder, 2005).  
Biologics are the current gold standard for the treatment of moderate to severe PsA. 
Predicting response to biologics is important because between 35-50% of patients do not 
respond and continue to experience disease progression (Gladman & Ritchlin, 2016). This 
class of pharmaceuticals poses a large financial burden both on the individual and the health 
care system making response prediction of particular importance (Gladman & Ritchlin, 
2016). Despite research advances in the pharmacogenomics of PsA, few predictors of 
response have been discovered (Sutherland et al., 2016).  
Examining miRNA gives insight to the intracellular communication occurring at 
the level of the tissue (Kosaka et al., 2010). At the clinical level this is particularly important 
in PsA as an alternative to biopsies of deteriorating psoriatic joints, which may cause 
decreased mobility and increase complications. As seen in studies (Paraskevi et al., 2012; 
Wu et al., 2010), circulating miRNAs are highly stable, conveniently collectable, and non-
invasive sources of biomarkers (Mi et al., 2013). The scope of previous miRNA studies (in 
PS) were limited to microarray and qPCR of targeted miRNAs (Sutherland et al., 2016). 
Using the NGS platform for miRNA research is preferred over microarray and qPCR due 
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to its superior detection sensitivity, greater dynamic range of detection, higher accuracy of 
measuring differential expression levels, and does not require target selection (Tam, de 
Borja, Tsao, & McPherson, 2014).  
Given the high prevalence of psoriatic disease, the high interpatient variability and 
cost associated with biological therapy, the lack of access to tissue of primary pathology, 
and the advent of NGS to sequence circulating miRNA, the research objectives of this 
project are: 
 
1)  To develop and optimize a procedure for preparing circulating miRNA libraries 
for sequencing with Ion Torrent Technology; and 
 
2) To examine circulating miRNA library preparation, circulating miRNA          
sequencing, and circulating miRNA differential expression data analyses in a PGx-
PsA patient cohort as an exploratory investigation of these methodologies. 
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CHAPTER 2 
2 MATERIALS AND METHODS 
 Ethics approvals were obtained and patient recruitment began for the PsA 
pharmacogenomics project.  A cohort of PsA patients was treated with biologic agents and 
had blood samples taken pre-treatment, one-month post treatment, and three-months post 
treatment.  For this project, an optimized protocol for miRNA library preparation was 
needed.  After an optimal library preparation protocol was established, multiplexing 
capacity of chip loading for the Ion Torrent System was established. The 
pharmacogenomics (PGx) patient samples were then sequenced and the data underwent 
numerous analyses. Differential miRNA expression analyses, pathway analyses, network 
analyses, and an in silico functional analysis were performed to investigate miRNAs that 
could be contributing to differential response to PsA treatment. 
 
 Ethics approval 
 The "Pharmacogenomic Markers for Psoriatic Arthritis Treatment" study was 
approved by the Newfoundland and Labrador Health Research and Ethics Board; 
Researcher Portal File Number: 20170466, Reference Number: 2016.195. This study was 
also approved by the Eastern Health Research Proposals Approval Committee. The ethics 
approval granted states that the patients may be approached by rheumatologists for interest 
in study and their consent was obtained by a research nurse prior to taking part in the study. 
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 Sample Ascertainment for Optimization of Library Preparation 
 Three plasma samples, referred to as TF-Sample 1, TF-Sample 2, and TF-Sample 
3, were used to assess the quality and performance of the Thermo Fisher protocol; these 
samples were aliquots of the same pooled plasma that was extracted and de-identified from 
multiple individuals. Samples, referred to as CH-Sample 1, CH-Sample 2, and CH-Sample 
3, and CH-Sample 4 were used to test and optimize the Cheng et al. protocol and to test the 
chip loading capacity; these samples were aliquots of plasma that were extracted and de-
identified from a single individual. CH-Sample 5 and CH-Sample 6 were processed using 
the Cheng et al. protocol and were used to test chip loading capacity; these samples were 
aliquots of plasma that were extracted and de-identified from a single individual. (Cheng, 
Sharples, Scicluna, & Hill, 2014) 
 
 Sample Ascertainment for PGx Study Cohort  
 Nine participants were ascertained for this study during their routine appointments 
at Dr. Proton Rahman’s Rheumatology Clinic at St. Clare’s Mercy Hospital. To be eligible 
for the cohort patients must 1) satisfy CASPAR criteria for PsA, 2) be greater than 18 years 
of age, 3) be of non-aboriginal descent, 4) were about to begin treatment with a biologic 
(either secukinumab or ustekinumab), and 5) be naive to treatment with biologics or have 
been washed out from biologics treatment for more than three months. If the patient was 
eligible for the study they were then seen by the research nurse. The nurse would explain 
the study in detail, and if the patient was willing their consent would be obtained (see 
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Appendix C for consent form). Patients who agreed to participate in the research study had 
their blood drawn (up to 30mL), the biologic administered via sub-cutaneous injection, and 
were asked to return to the clinic to attain response status after one- and three-months post 
treatment (Figure 2.1). Patients’ blood was drawn between two weeks prior and one week 
after biologic was injected (Table 2.1). 
 
Figure 2.1 – Flow chart of study participant recruitment process.  
 
Table 2.1 - Sample ascertainment including biologic prescribed, date of blood drawn and 
date of bioligc administration.  
Patient # Biologic Pre-Date Blood Drawn Date Biologic Started 
02 Stelara 1-Nov-16 3-Nov-16 
06 Cosentyx 7-Dec-16 14-Dec-16 
07 Cosentyx 14-Dec-16 21-Dec-16 
08 Cosentyx 9-Jan-16 25-Jan-17 
10 Cosentyx 9-Feb-17 15-Feb-17 
11 Cosentyx 6-Mar-17 6-Mar-17 
12 Cosentyx 7-Mar-17 12-Mar-17 
13 Stelara 27-Mar-17 21-Mar-17 
14 Cosentyx 5-Apr-17 16-Apr-17 
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 Sample Processing 
 Whole blood samples were collected from PsA patients in 
Ethylenediaminetetraacetic acid tubes. The plasma was separated by the centrifugation at 
800 × g for 10 minutes at room temperature and then stored in aliquots of 1mL at -80°C. 
miRNAs were isolated from the plasma and treated with DNase. These samples then 
underwent library preparation and were quantified to ensure quality results. High quality 
prepared libraries were then loaded onto a chip and sequenced using the Ion Torrent 
System. The sequencing data generated from the Ion Torrent Server underwent numerous 
analyses (Figure 2.2). 
 
Figure 2.2 – Procedures involved in sample processing beginning with whole blood and 
ending with analysis of sequencing data.  
 
 Small RNA Extraction from Plasma 
 A mirVana™ PARIS™ Kit (Thermo Fisher Scienticific™ [herein referred to as 
TFS™], Catalogue#: AM1556. Waltham, MA., USA), following a modified mirVana™ 
PARIS™ RNA and Native Protein Purification Kit protocol (see Table 2.2; where inter-
60 
 
protocol discrepancies exist Table 2.2 can be referenced for exact numerical values), was 
used to extract small RNA species from plasma. (Invitrogen by Life Technologies, 2012)  
A total of 1mL of plasma was added to 1025µl of 2X Denaturing Solution (TFS™), mixed, 
and incubated on ice for 5 minutes. Following incubation, 2025µl of Acid-Phenol 
Chloroform (TFS™) was added, vortexed for 45 seconds, and centrifuged for 5 minutes at 
10,000 × g.  The interphase was visually inspected to ensure that it was sufficiently 
compact. The upper aqueous phase was transferred to a fresh tube and the volume recorded, 
ensuring that the lower phase was not disturbed. 
 To capture small species of RNA (<200 nt), a volume of 100% ethanol (Greenfield 
Speciality Alcohol Inc. ™, Catalogue#: P016EAAN. Toronto, ON., CA) equal to 1.25× the 
volume of the aqueous phase was added to the solution and vortexed for 30 seconds. An 
RNA capture filter was placed in a fresh collection tube and 700µl of aqueous phase-
ethanol solution was transferred onto the filter. Contents of the collection tube were then 
centrifuged for 15 seconds at 10,000 × g and the flow-through was discarded. This process 
was repeated until the entire aqueous phase-ethanol solution was filtered.  700µl of Wash 
1 Solution (TFS™) was added to the filter, centrifuged for 5-10 seconds at 10,000 × g, and 
the flow-through discarded. This was followed by 500µl of Wash 2/3 Solution (TFS™) and 
centrifuged through the filter for 5-10 seconds at 10,000 × g. The Wash 2/3 Solution process 
was then repeated. Contents of the collection tube were then centrifuged for 1 minute to 
remove any residual fluid from the filter. The filter was then transferred to a fresh collection 
tube. 40µl of 95°C nuclease-free water (H20 [TFS™]) was added to the middle of the filter 
to elute the small RNA species. The elution solution was incubated for 1 minute, and then 
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spun for 30 seconds at 10,000 × g. This step was then repeated with an additional 40µl of 
elution solution. The ~75µl of pooled eluate was stored at -80°C. 
 
Table 2.2 - Summary of variations and modifications between small RNA extraction 
protocols used during optimization 
Step in 
Procedure 
mirVana™ 
PARIS™ 
Kit 
Protocol 
mirVana™ PARIS™ 
RNA and Native 
Protein Purification 
Kit Protocol 
Additional Modifications 
to mirVana™ PARIS™ 
RNA and Native Protein 
Purification Kit Protocol 
Sample Input 625µl 200µl 1000µl 
2X Denaturing 
Solution 625µl 205µl 1025µl 
Acid-Phenol 
Chloroform 1250µl 410µl 2025µl 
Volume and 
Technique 
Used for 
Eluting Sample 
100µl 
 
(Dispensed 
on to filter 
at one time) 
100µl 
 
(50µl dispensed twice 
and combined through 
centrifugation) 
80µl 
 
(40µl dispensed twice and 
combined through 
centrifugation) 
 
 DNase Treatment 
 A TURBO DNA-free™ Kit (TFS™, Catalogue#: AM1907. Waltham, MA., USA) 
was used to guarantee all DNA contamination was removed from the extracted small RNA 
samples. The samples, which contained less than 200 µg of nucleic acid per mL, underwent 
a routine DNase treatment. A total of 0.1× the sample volume of 10X TURBO DNase 
buffer (TFS™) and 1µl TURBO DNase (TFS™) was added to ~75µl of the small RNA 
sample. The mixture was incubated at 37°C for 30 minutes. The total sample volume was 
then calculated and 0.1X sample volume of DNase Inactivation Reagent (TFS™) was 
added. The solution was then mixed well and incubated at room temperature for 5 minutes. 
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The tube was flicked 2-3 times during the incubation to ensure that the DNase Inactivation 
Reagent (TFS™) was re-dispersed. The mixture was then centrifuged at 10,000 × g for 1.5 
minutes to pellet the DNase Inactivation Reagent (TFS™). The DNA-free small RNA 
containing supernatant was then transferred into a fresh tube and stored at - 80°C. 
 Quality Assessment of Extracted RNA 
 Before going into library preparation, the presence of the small RNA samples was 
assessed. The small RNA samples were measured using a NanoDrop™ (TFS™, Waltham, 
MA., USA) to confirm the presence of miRNA in the sample, rather than measure the 
sample concentration. The NanoDrop™ 1000 instrument was tared using water, the RNA 
program was selected, and 1µl of the sample was added. All samples were tested in 
duplicate.  
 Library Preparation  
 Two different protocols were investigated in an attempt to optimize circulating 
miRNA library preparation (Table 2.3). First, a modified version of Thermo Fisher’s 
protocol for intracellular miRNA extraction and library preparation (Invitrogen by Life 
Technologies, 2012) was used to isolate and prepare libraries for extracellular or circulating 
miRNA. A second protocol entitled “Small RNA Library Construction for Exosomal RNA 
from Biological Samples for the Ion Torrent PGM™ and Ion S5™ System”, herein referred 
to as the “Cheng et al. protocol”, was subsequently modified and used. (Cheng, Sharples, 
Scicluna, & Hill, 2014) 
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Table 2.3 – Summary of variations and modifications between library preparation 
protocols used during optimization  
Step in 
Procedure 
Thermo Fisher Ion 
Total RNA-Seq v2  
Total Exosome 
RNA Protocol 
Cheng et al. 
Protocol 
Additional 
Modifications to 
Cheng et al. 
Protocol 
Magnetic Bead 
Clean up 
Module I 
 
On magnet 
incubation (x2): 5 
mins 
Elution volume: 
30µl 
On magnet 
incubation (x2): 5 
mins 
Elution volume: 
30µl 
On magnet 
incubation (x2): 7-9 
mins 
Elution volume: 
15µl 
Speed Vac N/A 30µl  3µl 15µl  3µl 
Hybridize and 
Ligate RNA 
R&D Systems 
Optimized adaptors Ion Adaptor Mix v2  
Reverse 
Transcription 
Reaction 
H20: 2µl 
10X RT Buffer: 4µl 
2.5 nM dNTP mix: 
2µl 
Ion RT Primer v2: 
8µl 
H20: 5µl 
10X RT Buffer: 4µl 
2.5 nM dNTP mix: 
2µl 
Ion RT Primer v2: 
5µl 
 
Magnetic Bead 
Cleanup 
Module II 
Beads: 5µl 
Binding Sol: 250µl 
H20: 60µl 
Ethanol: 275µl 
On magnet 
incubation: 2-5 mins 
No supernatant 
transfer 
Air dry time: 2-3 
mins 
 
 
 
 
 
 
Beads: 7µl 
Binding Sol: 140µl 
No H20 added 
Ethanol: 120µl 
On magnet 
incubation: 5 mins 
Supernatant 
transferred for 
second size selection 
H20: 72µl 
Ethanol: 78µl 
Beads: 7µl 
On magnet 
incubation: 5 mins 
Air dry time: 1-2 
mins 
 
 
 
 
On magnet 
incubation: 7-9 mins
 
 
 
 
 
 
On magnet 
incubation: 7-9 mins 
 
 
Amplification of 
cDNA 
16 cycles of 
94°C for 30 seconds, 
62°C for 30 seconds, 
68°C for 30 seconds 
14 cycles of 
94°C for 30 seconds, 
62°C for 30 seconds, 
68°C for 30 seconds 
 
Magnetic Bead 
Cleanup 
Module III 
Beads: 5µl 
Binding Sol: 280µl 
H20: 27µl 
Beads: 7µl 
Binding Sol: 140µl 
No H20 added 
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Step in 
Procedure 
Thermo Fisher Ion 
Total RNA-Seq v2  
Total Exosome 
RNA Protocol 
Cheng et al. 
Protocol 
Additional 
Modifications to 
Cheng et al. 
Protocol 
Magnetic Bead 
Cleanup 
Module III 
Ethanol: 230µl 
On magnet 
incubation: 2-5 mins 
Air dry time: 2-3 
mins 
 
 
 
 
 
 
Ethanol: 110µl 
On magnet 
incubation: 5 mins 
Supernatant 
transferred for 
second size selection 
H20: 35µl 
Ethanol: 35µl 
Beads: 7µl 
Air dry time: 1-2 
mins 
 
On magnet 
incubation: 7-9 mins 
 
 
 
 
 
 
 
 
 
2.4.4.1 Ion Total RNA-Seq v2 Kit  
2.4.4.1.1 Magnetic Bead Cleanup Module I 
 The process of enrichment was done twice to size select the desired small RNA 
species. Magnetic beads were used to capture and remove large RNA species (mRNA and 
rRNA) then, with increased ethanol concentrations, small-RNA species were selected for 
as follows: 
 Nucleic Acid Binding Beads (TFS™) were re-suspended and 7µl was added to a 
well of a 96-well plate (see Table 2.3) where inter-protocol discrepancies exist Table 2.3 
can be referenced for exact numerical values). Binding Solution Concentrate (TFS™) was 
added and mixed thoroughly. The small RNA sample (~75µl) was combined with beads 
and binding solution (Table 2.3). To bind any remaining large RNA species to the beads, 
105µl of 100% ethanol (Greenfield Speciality Alcohol Inc.™) was added and mixed 
thoroughly by pipetting the solution up and down 10 times. The plate was incubated for 5 
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minutes at room temperature, followed by incubation on the 96-well magnetic stand 
(Agencourt™) (see Table 2.3). Once the solution was clear, the supernatant was transferred 
to a fresh well.  
 To bind small RNA species, the plate was removed from the magnetic stand and 
30µl of H20, 570µl of 100% ethanol, and 7µl of beads were added to the sample and mixed 
thoroughly. The mixture was incubated for 5 minutes at room temperature off the magnetic 
stand. The sample was incubated (see Table 2.3) on a magnetic stand . After the solution 
had cleared, the supernatant was discarded. Then, 150µl of Wash Solution Concentrate 
(TFS™) was added to the sample and incubated for 30 seconds. While the plate was on the 
magnetic stand, the supernatant was discarded. The beads were left to air dry for 1-2 
minutes to remove all traces of ethanol solution.  
 The plate was then removed from the magnetic stand and the small RNAs were 
eluted from the beads using (see Table 2.3) 15µl of 80°C H20 (TFS™). The plate was 
incubated for 1 minute off the magnetic rack and then placed back on the magnetic rack for 
1 minute. Once the solution was clear, the eluate was transferred into a fresh tube (see 
Table 2.3).  
 The eluted sample was concentrated by a speed vacuum centrifuge to a final 
volume of 3µl, allowing the entire sample to be used in the hybridization reaction (see 
Table 2.3). 
2.4.4.1.2 Hybridize and Ligate RNA 
 In order to reverse transcribe small RNA, adaptors must be hybridized and ligated 
to the small RNA species. A hybridization mastermix was prepared on ice with 3µl of 
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Hybridization Solution (TFS™) and 2µl of adaptors (see Table 2.3) in a 0.2ml PCR tube 
(TFS™, Catalogue#: AB0620. Waltham, MA., USA). The mastermix was then added to 
the 3µl of enriched small RNA sample. The solution was mixed well and centrifuged briefly 
before being loaded into the SimpliAmp Thermal Cycler (TFS™, Catalogue#: A24811. 
Waltham, MA., USA) for 10 minutes at 65C, followed by 16C for 5 minutes. The sample 
was immediately placed on ice.  
 The 2X Ligation Buffer was heated to 37C, to ensure no white precipitate was 
present. A ligation master mix was prepared by combining 10µl of the 2X Ligation Buffer 
(TFS™) and 2µl of Ligation Enzyme Mix (TFS™). The 12µl ligation mastermix was 
vortexed, centrifuged briefly, and added to the 8µl of hybridization mastermix. The solution 
was mixed thoroughly and spun down before being loaded into the SimpliAmp Thermal 
Cycler for 16 hours at 16°C with the lid of the thermal cycler open.  
2.4.4.1.3 Reverse Transcription of RNA 
 In order to amplify the adaptor-bound small RNA species, the fragments were 
reverse transcribed into cDNA. A reverse transcription mastermix (see Table 2.3) was 
prepared on ice with the following components: H20, 10X Reverse Transcription Buffer 
(TFS™), 2.5nM dNTP Mix (TFS™), and Ion Reverse Transcription Primer v2 (TFS™). 
The 16µl reverse transcription mastermix was then combined with the 20µl ligation 
reaction, centrifuged, incubated at 70°C for 10 minutes, and snap-cooled on ice. Then 4µl 
of 10X SuperScript III Enzyme Mix (TFS™) was added to the sample. The sample was 
vortexed gently, spun down, and incubated at 42°C for 30 minutes. This was a possible 
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stopping point where the sample was either stored at -20°C overnight or was purified and 
size-selected immediately.  
2.4.4.1.4 Magnetic Bead Cleanup Module II - Purify and Size-Select cDNA 
 As was done in Magnetic Bead Cleanup Module I, the process of enrichment 
through magnetism is done twice on the same sample to size select the desired small cDNA 
product. The magnetic beads were used to capture and remove larger cDNA transcripts 
(>200bp) and with increased ethanol concentrations select for small cDNA transcripts 
(<200bp).  
 Nucleic Acid Binding Beads were completely re-suspended and added to a well 
on a 96-well plate (see Table 2.3). Binding Solution Concentrate (TFS™) was added (see 
Table 2.3) to the magnetic beads and mixed thoroughly. The 40µl reverse-transcription 
reaction was added to the well.  To bind larger cDNA, 100% ethanol was added (see Table 
2.3) to each sample, mixed thoroughly, and incubated for 5 minutes at room temperature. 
The plate was then incubated (see Table 2.3) on the magnetic stand. Once the solution was 
clear, the supernatant was transferred to a fresh well (see Table 2.3).  
 To bind the smaller cDNA transcripts, the plate was removed from the magnetic 
stand and 72µl of H20, 78µl of 100% ethanol, and 7µl of re-suspended beads were added 
and mixed thoroughly (see Table 2.3). The mixture was incubated for 5 minutes at room 
temperature off the magnetic stand. The sample was then placed on a magnetic stand to 
incubate (see Table 2.3). After the solution had cleared, the supernatant was discarded (see 
Table 2.3).  
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 While the processing plate remained on the magnetic stand, 150µl of Wash Buffer 
Concentrate (TFS™) was added and incubated for 30 seconds. The supernatant was then 
discarded and the beads were air dried (see Table 2.3). The sample was then removed from 
the magnetic plate and 12µl of 37°C H20 was added and mixed thoroughly. The sample 
was incubated at room temperature for 1 minute off of the magnetic stand. The processing 
plate was placed back on the magnetic stand and incubated for 1 minute. The 12µl eluate 
was then collected and transferred to a fresh tube and stored at -80C. 
2.4.4.1.5 Amplify cDNA 
 To enable multiplexing, the adaptor-bound small cDNA transcripts were labelled 
by a distinct barcode for down-stream identification. The barcoded, adaptor bound small 
cDNA transcripts were then amplified to increase the number of transcripts in the sample. 
A PCR and barcode mastermix was prepared by combining 45µl of Platinum PCR 
SuperMix High Fidelity (TFS™), 1µl of Ion Xpress RNA 3’ Barcode Primer (TFS™), and 
1µl of selected Ion Xpress RNA Barcode (TFS™). One half of the cDNA sample (6µl) was 
then added to the PCR mastermix, mixed, centrifuged, and loaded into the SimpliAmp 
Thermal Cycler under the following conditions: 94C for 2 minutes, 2 cycles of 94C for 
30 seconds, 50C for 30 seconds, 68C for 30 seconds; followed by 14 or 16 cycles (see 
Table 2.3)  of 94C for 30 seconds, 62C for 30 seconds, 68C for 30 seconds, and 68C 
for 5 minutes. 
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2.4.4.1.6 Magnetic Bead Cleanup Module III - Purify the Amplified DNA 
 Nucleic Acid Binding Beads were completely re-suspended, and added to a well 
on a 96-well plate (see Table 2.3). Binding Solution Concentrate (TFS™) was added (see 
Table 2.3) to the magnetic beads and mixed thoroughly. 53µl of amplified cDNA sample 
was added to the well.  To bind larger cDNA, 100% ethanol was added (see Table 2.3) to 
each sample and was mixed thoroughly. The sample was incubated for 5 minutes at room 
temperature and then incubated (see Table 2.3) on a magnetic stand. Once the solution was 
clear, the supernatant was transferred to a fresh well (see Table 2.3).  
 To bind smaller cDNA transcripts the sample was removed from the magnetic 
stand and 35µl of H20, 35µl of 100% ethanol, and 7µl of beads were added and mixed 
thoroughly (see Table 2.3). The mixture was incubated for 5 minutes at room temperature, 
and then placed on a magnetic stand to incubate (see Table 2.3). Once the solution was 
clear, the supernatant was discarded (see Table 2.3). 
 While the processing plate remained on the magnetic rack, 150µl of Wash Buffer 
Concentrate was added and incubated for 30 seconds. The supernatant was then discarded 
and the beads were air-dried (see Table 2.3). The sample was then removed from the 
magnetic stand and 37°C H20 was added (see Table 2.3) and mixed thoroughly. The sample 
was incubated at room temperature for 1 minute, and then placed on the magnetic stand to 
incubate for 1 minute. The eluate containing the prepared small RNA library was then 
collected (see Table 2.3), transferred to a fresh tube, and stored at -80C. 
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2.4.4.1.7 Assess the Yield and Size Distribution of the Amplified DNA 
 The yield and size distribution of the small cDNA transcripts was assessed using 
the Agilent 2200 TapeStation and D1000 Screen Tape System (Agilent™, Catalogue#: 
5067-5582. Santa Clara, CA., USA). All reagents were brought to room temperature, and 
3µl of buffer (Agilent™) was added to each well of the Tapestation strip (Agilent™). In 
the first well of the strip1µl of ladder (Agilent™) was added. In subsequent wells 1µl of 
sample was loaded. The strip was then loaded into an IKA vortexer (IKA® Works, Inc., 
Catalogue#: 0004049600, Wilmington, NC., USA), vortexed for 1 minute at 2000rpm, and 
centrifuged briefly. After being spun down, the tube strip was then loaded into the 2200 
Tapestation (Agilent™, Catalogue#: G2965AA. Santa Clara, CA., USA) and the 
concentration of the sample was measured.  
 The targeted size of the barcoded cDNA fragment falls between 94 base pair (bps) 
and 114 bps. Applying size regions of interest to the plot allows measurement of molarity 
of the barcoded cDNA (94-114 bps, referred to as “regional molarity”) to the total library 
(50-300 bps, referred to as “total molarity”) and the resulting ratio to be determined. To 
ensure quality sequencing results a Field Application Scientist (FAS) from TFS™ 
recommended that the regional molarity percentage of the samples be greater than 50%. 
 The electropherograms produced during library quantification represent the size 
distributions of the reads in a given library. The y-axis is the measure of fluorescence units, 
representing the sample concentration, and the x-axis is a measure of read length in base 
pairs, beginning at the 25 bps marker and ending at the 1500 bps marker (Figure 2.3). The 
red lines on the electropherogram indicate the read lengths spanning from 50-300 bps. 
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Because of the numerous size selection processes the protocol the reads in a prepared 
library should all fall within these lines. The green lines on the electropherogram indicate 
the read lengths spanning the desired fragment size lengths of 94-114 bps. There are four 
distinctive “peaks” that can be observed in prepared libraries. The peak composed of 
fragments approximately 85 bps in length represents an adaptor dimer, which occurs when 
two adaptors bind (2 × ~30 bps) without a miRNA inserted between them and are barcoded 
(20 bps) (Figure 2.4). The peak composed of fragments approximately 104 bps long 
represents cDNA fragments that have miRNA inserted between the adaptors, and are 
barcoded (Figure 2.5). 
 
Figure 2.3 – An electropherogram of a barcoded small RNA library (~104 bps) that has an 
adaptor dimer (~85 bps) and some large RNA species present (~150-240 bps). The red lines 
indicate the Total Molarity (50-300 bps) and the green lines indicate the Regional Molarity 
(94-114 bps).  
72 
 
 
Figure 2.4 - Schematic of cDNA fragments that do not have a miRNA inserted, which 
make up the ~85 bps adaptor dimer peak on the library-quantification electropherogram. 
 
 
 
Figure 2.5 - Schematic of cDNA fragments that have a miRNA inserted, which make up 
the ~100 bps sample peak on the library-quantification electropherogram.  
 
 When samples do not undergo proper size selection, the library would often 
contain large RNA species including transfer RNAs (tRNAs) and ribosomal RNAs 
(rRNAs). tRNAs are typically 76-90 nts in length, whereas rRNA species most likely to be 
present in the prepared libraries were the 5S subunit (~121 nts) and the 5.8S subunit (156 
nts) (Figure 2.3). 
2.4.4.1.8 Pool and Dilute Small RNA Libraries for Template Preparation 
 Once the molarity of each barcoded cDNA library (50-300 bps size range used) 
was determined, all libraries were diluted to 100pM. An equal amount of each library was 
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pooled for templating onto Ion Sphere particles™ (ISPs). All sequencing for this project 
was performed by a laboratory assistant in the Rahman-O’Rielly lab. 
2.4.4.2 Prepare Template for Sequencing 
 The Ion Torrent sequencing system has limited sensitivity and therefore cDNA 
libraries must undergo amplification prior to sequencing. This amplification is done by 
emulsifying PCR using ISPs (TFS™). During this procedure one cDNA fragment is bound 
to an ISP, which then undergoes oil emulsification to ensure no other fragments are bound. 
These ISPs bound with cDNA templates (T+ISPs) then undergo amplification in the 
OneTouch System where the cDNA is used as a template and the fragment is replicated 
exponentially.  
To quantify the T+ISP, the T+ISPs are fluorescently labelled, with one fluorophore 
bound to the Ion Sphere particles and one fluorophore bound the cDNA template that is 
bound to the ISP. The quantity of these fluorophores is measured and a ratio is generated 
that represents the proportion of template-positive ISPs in a sample. Inter-run variability in 
the proportion of T+ISPs in a sample is expected and is removed during normalization. The 
higher the proportion of T+ISPs in a sample the higher the quality of sequencing results 
can be anticipated.  
2.4.4.3 Hi-Q OneTouch2 200 Kit  
2.4.4.3.1 Prepare Template-positive ISPs  
 Samples were templated onto ISP’s and amplified on the Ion OneTouch™ 2 
System (OT2) (TFS™, Catalogue#:4474779. Waltham, MA., USA) by emulsion PCR. The 
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ION PI Master Mix (TFS™)  and ISP’s were brought to room temperature. The enzyme 
mix and pooled library were kept on ice. The input concentration of the pooled libraries 
was between 6-8pM in a volume of 100µl. ISPs and Master Mix were vortexed at maximum 
speed for one minute to re-suspend particles then briefly spun down. The following 
components were added to 2mL of ION PI Master Mix: 80µl of H20, 120µl of Ion PI 
Enzyme Mix (TFS™), 100µl of ISPs, and 100µl of diluted libraries. The amplification 
solution was vortexed, spun briefly, and added through the sample port of the Reaction 
Filter 800µl at a time. 200µl of Ion OT Reaction Oil (TFS™) was added through the sample 
port. The reaction filter was then inverted ensuring the sample port was rotated clockwise 
over the other two ports and loaded onto the OneTouch2 instrument (TFS™) within 15 
minutes of preparation.  
 Breaking solution was added to the Recovery Tubes (TFS™) in the OT2 
instrument and the run was started. A final spin was done at the end of the run to pellet the 
template-positive ISPs. The recovery tubes were removed and all but approximately 100µl 
of recovery solution was removed from each tube and discarded. The remaining 100µl was 
used to re-suspend the template-positive ISPs by pipetting. The suspensions were then 
combined in a fresh LoBind tube (Eppendorf™, Catalogue#: 022431005, Hamburg, DE.). 
To recover any remaining sample from the tubes, 100µl of H20 was used to rinse the 
recovery tubes and then added to the LoBind tube (Eppendorf™). The combined 
suspensions were brought up to 1mL with H20 and vortexed for 30 seconds. The template-
positive ISP suspensions were then centrifuged at 15,500 × g for 8 minutes. All but 
approximately 20µl of the supernatant was discarded. The remaining 20µl was diluted up 
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to 100µl with ISP Resuspension Solution. The solution was then vortexed for 30 seconds 
and spun briefly.  
2.4.4.3.2 Assess Quality of Unenriched, Template-positive ISPs 
 A Qubit® 2.0 Fluorometer (TFS™, Catalogue#: Q32866. Waltham, MA., USA) 
and the ION Sphere Quality Control Kit (TFS™, Catalogue#: 4468656. Waltham, MA., 
USA) were used to assess the quality of the unenriched, template-positive ISPs. Two 
fluorescent labels were used to determine what percentage of the ISP were bound with 
templates. One label (Alexa Fluor 488 [TFS™]) was bound to the ISP itself and another 
(Alexa Fluor 647 [TFS™]) was bound to the template-bound ISP. The ratio of bound ISPs 
over total ISPs is depicted by the 647:488 fluorescence ratio.  
 Each emulsified sample was run separately on the Qubit® by loading 2µl of the 
unenriched ISPs into a 0.2 mL PCR tube, 19µl of Annealing Buffer (TFS™), and 1µl of 
probes. The solution was mixed well, and the samples were loaded into the SimpliAmp 
Thermal Cycler and run at 95°C for 2 minutes followed by 37°C for 2 minutes. Then 200µl 
of Quality Control Wash Buffer (TFS™) was used to wash off the unbound probes. Once 
added, the solution was vortexed properly and centrifuged at maximum speed for 3 minutes. 
Ensuring not to disrupt the ISP pellets, all but 10µl of supernatant was discarded. The wash 
step was repeated twice more for a total of three washes. After the final wash, 190µl of 
Quality Control Wash Buffer was added and mixed well for a total volume of 200 µl. The 
sample was then loaded into a Qubit™ Assay Tube (TFS™,  Catalogue#: Q32856. 
Waltham, MA., USA), the Qubit Instrument (TFS™) and the percentage of bound ISPs 
was calculated.  
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2.4.4.3.3 Enrich the Template-positive ISPs  
 The sample was then enriched for template-positive ISPs using the Ion PI™ Hi-Q 
Template OT2 200 Kit (TFS™,  Catalogue#: A26434. Waltham, MA., USA). Melt-off 
Solution (TFS™) was prepared fresh using 280µl of Tween Solution (TFS™) and 40µl of 
NaOH (TFS™). MyOne C1 Beads (TFS™) were vortexed and 100µl was transferred into 
a fresh 1.5mL LoBind tube. The tube was then placed on a magnetic rack for 2 minutes. 
The supernatant was removed and discarded without disturbing the pelleted beads. Then, 
1mL of One Touch Wash Solution (TFS™) was added and the tube was removed from the 
magnetic rack. After being vortexed for 30 seconds and briefly centrifuged the tube was 
placed back on the rack for 2 minutes. The supernatant was once again removed and 
discarded. A total of 130µl of MyOne Bead Capture Solution (TFS™) was added to the 
tube which was removed from the rack, vortexed, and spun briefly.  
 An 8-well strip was prepared for loading into the OneTouch Enrichment System 
(ION One Touch ES; TFS™). Ensuring that all reagents and solutions were mixed well 
before transferring the following was added to the strip: well 1, template-positive ISPs 
(TFS™) (100 µl); well 2, MyOne C1 resuspended beads (TFS™) (130 µl); wells 3-5, One 
Touch ES Wash Solution (TFS™) (300µl each); well 6 & 8, empty; well 7, Melt-Off 
Solution (TFS™) (300 µl). Once loaded with the other components the OT ES was run. 
After the run was complete, the 0.2mL tube containing the enriched ISPs was centrifuged 
for 5 minutes at 15,500 × g. All but 10µl of the supernatant was then removed, and 200µl 
of H20 was added and mixed well. The solution was then re-centrifuged at 15,500 × g for 
5 minutes. The tube was visually inspected for a brown pellet.  
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 If the pellet is present, then the solution was pipetted up and down to re-suspend 
the pellet. The tube was then placed on a magnetic rack for 4 minutes. The supernatant was 
transferred into a new 0.2mL tube without disturbing the pellet, then centrifuged at 15,500 
× g for 5 minutes. All but 10µl of the supernatant was removed and H20 was then mixed 
well into the solution for a final volume of 100 µl. If the pellet was not present, all but 10µl 
of the supernatant was removed and discarded. The solution was brought to 100µl with H20 
and the pellet was re-suspended. The re-suspended solution continued on to sequencing.  
2.4.4.4 Ion PI Hi-Q Sequencing 200 Kit 
 Once the Ion Proton System for Next-Generation Sequencing System (TFS™, 
Catalogue#: 4476610. Waltham, MA., USA) was properly initialized and the planned run 
created, the enriched template-positive ISPs were prepared and the chip was loaded for 
sequencing using the Ion PI Hi-Q Sequencing 200 Kit (TFS™,  Catalogue#: A26433. 
Waltham, MA., USA).   
2.4.4.4.1 Prepare the Enriched Template-positive ISPs for Sequencing 
 The Control ISPs (TFS™) were re-suspended and 5µl was mixed well with the 
enriched, template-positive ISPs. The solution was then centrifuged for 5 minutes at 15,500 
× g. Without disturbing the pellet, all but 10µl of supernatant was discarded. 15µl of 
Annealing Buffer (TFS™) and 20µl Sequencing Primer (TFS™) were added to the solution 
which was briefly vortexed and spun. The reaction was then loaded into the SimpliAmp 
Thermal Cycler (95° for 2 minutes, 37° for 2 minutes). Then 10µl of Loading Buffer 
(TFS™) was added and the solution was vortexed and spun.  
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2.4.4.4.2 Load the ION PI Chip v3 
 The entire prepared sample (55µl) was dispensed into the Ion P1 Chip v3 (TFS™) 
loading well. The chip was then spun in the minifuge for 10 minutes. Foaming solution was 
created by adding 49µl of 50% Annealing Buffer (TFS™) with 1µl of ION PI Foaming 
Solution (TFS™) and injecting 100µl of air with a p200 pipette and tip into the mixture 
and mixing well. An additional 100µl of air was injected into the mixture and mixed again. 
Excess reagents were washed from the chip by adding 100µl of foam into the chip loading 
port. The liquid expelled from the exit well was removed. 55µl of 50% Annealing buffer 
was dispensed into the chip loading well, and the chip was spun in the minifuge for 30 
seconds. Liquid was removed from the exit well. 100µl of foam was injected into chip 
loading port. 55µl of 50% Annealing Buffer was dispensed into chip loading well, and the 
chip was spun in the minifuge for 30 seconds. Excess liquid was removed from the exit 
well. 100µl of Flushing Solution (TFS™) was injected into the chip loading port three 
times, while avoiding transferring bubbles from the pipette tip. The expelled liquid was 
removed from the exit well after each injection. Then 6µl of Hi-Q Sequencing Polymerase 
(TFS™) was then combined with 60µl of 50% Annealing Buffer and mixed. 65µl of the 
Polymerase Solution (TFS™) was then injected into the chip loading port, and the expelled 
liquid was remove from the exit well. The chip was left to incubate for 5 minutes at room 
temperature before being loaded into the Ion Proton System for Next-Generation 
Sequencing System (TFS™) and initiating the sequencing run. 
 The patient samples loaded onto PI chips were barcoded such that the three time 
points for each patient could be loaded onto the same chip. Because of the barcoding system 
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that was established to accommodate the larger project, the pre-treatment samples could 
not all be loaded onto the same chip and were therefore loaded on two separate chips (see 
Future Directions – Section 4.8). 
 
 Grouping Patients by Clinical Response  
The primary endpoint indicated by the rheumatologist was ACR50 responders, as 
this was deemed a more meaningful outcome than ACR20. A patient is deemed an ACR50 
responder when a 50% improvement in tender or swollen joint counts is achieved and there 
is a 50% improvement in at least three of the other five criteria outlined in the introduction 
(PhUSE Wiki contributors, 2012). Clinical parameters used in this categorization included 
CDAI, PRO’s, HASQ-DI, and an acute phase reactant (ESR). 
 
 PGx Patient Data Analyses  
 The comprehensive miRNA analyses were performed with patients categorized as 
ACR50 responders (patient 2, 10, 13, and 14) and ACR50 non-responders (patient 6, 7, 8, 
11, and 12), as indicated by the rheumatologist.  Data collected from the sequencing of 
these samples was processed with the comprehensive miRNA analyses pipeline and used 
for subsequent analyses. 
 Comprehensive miRNA Analyses Pipeline 
The sequencing results from the Ion Proton System for Next-Generation 
Sequencing were exported out as a FASTQ file, which contains the raw sequencing reads 
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of each sample and provides a numeric quality score for each nucleotide in the raw 
sequencing reads (Cock, Fields, Goto, Heuer, & Rice, 2010). In order to analyze the 
sequencing results, the FASTQ files were loaded into a miRNA-Seq pipeline (Figure 2.6) 
designed by the Rahman-O’Rielly Data Analyst.  
2.6.1.1 Read Pre-Processing  
The Ion Torrent FASTQ raw read files were submitted for pre-trim quality 
assessment by the FastQC software. This software reports on the quality of the reads and 
enables the user to customize the trimming of adapters and nucleotides from the 3’ and 5’ 
ends that have low-quality read depth. The adaptors were then trimmed off of the raw reads 
using the Cutadapt (Marcel Martin, MIT-licensed) software and the file was then submitted 
for post-trim quality assessment by the FastQC software (Babraham Bioinformatics) 
(Martin, 2011).  
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Figure 2.6 – Flow chart of comprehensive miRNA analyses pipeline. See Figure 3.16 for 
in-depth analyses of differentially expressed miRNAs. 
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2.6.1.2 miRNA Variant Detection 
For each sample the Bowtie alignment software (John Hopkins University) is used 
to align the adaptor-trimmed reads in a FASTQ file and generates the Binary Alignment 
Map (BAM) file to the human reference genome (hg19), which contains the genomic 
positions of the short reads in a binary and compressed format (H. Li et al., 2009). The 
aligned BAM file was then submitted to Genome Analysis ToolKit (GATK) software 
(Broad Institute) which called the detected miRNA variants.  
2.6.1.3 Known and Novel miRNA Detection  
 The aligned reads in BAM file format were then submitted for mapping using 
miRDeep2 mapper software (Max Delbrück Center) (Friedlander, Mackowiak, Li, Chen, 
& Rajewsky, 2012). The miRDeep2 module was used to detect the reads that mapped to 
miRNA loci and compared them to the miRBase database, which is curated with known, 
annotated miRNAs. A summary report file and a file that quantifies known and novel 
miRNAs from that sample were then generated for differential miRNA expression analysis. 
2.6.1.4 Differential miRNA Expression Analyses of ACR50 Response Groupings and 
Clinical Data Sets  
The known and novel miRNAs’ expression was then analyzed using the edgeR 
software (Bioconductor) to detect differentially expressed miRNAs between response 
groupings and on clinical datasets. The read counts were normalized before comparison to 
decrease the potential for read biases. The edgeR software normalizes the read data by 
dividing the read count by the total number of reads; this value is then rescaled to counts 
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per million (I. Gonzalez, 2014). Boxplots and multi-dimensional scaling (MDS) plots were 
generated to visualize the read distribution and clustering of the samples. The data was 
separated by the dichotomous response groupings, ACR50 responders vs. non-responders, 
and the expression level of a miRNA in responders was compared to the average expression 
level of that miRNA in the non-responders.  
 Increased and decreased expression is indicated by the fold change value (logFC), 
when this value is greater than zero there is increased miRNA expression and when this 
value is less than zero there is decreased miRNA expression. In the analysis, the logFC of 
miRNA ‘x’ was calculated as log(expression of miRNA x in responders) minus the 
log(expression of miRNA x in non-responders). Thus, a logFC value greater than zero 
indicates higher expression of the corresponding miRNA in responder, while a logFC value 
less than zero indicates higher expression of the corresponding miRNA in non-responders.  
Linear regression was performed to determine if there was an association between 
differentially expressed miRNAs and ACR50 response groups or clinical datasets (HAQ-
DI, CDAI, and ESR). These findings were deemed statistically significant at a False 
Discovery Rate (FDR) <0.05, corrected using the Benjamini–Hochberg procedure. Given 
that this is an exploratory study, findings with 0.05>FDR<0.2 (selected by the Rahman-
O’Rielly bioinformatician based on previous experience and literature assessment) were 
deemed suggestively significant (Motta et al., 2013; Weilner et al., 2015).  Increasing the 
cut off will detect more lenient associations, because these analyses were exploratory in 
nature this was done to test the methodology.  
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When no suggestive significance was reached, the top 100 differentially expressed 
miRNAs were prioritized for investigations of collectively targeted genes to attempt to 
identify significant associations. This analysis was performed to determine the probability 
of miRNA-mRNA binding. This was done by examining the structure and accessibility of 
the site of potential binding, otherwise known as miRNA-recognition elements (Reyes-
Herrera, Ficarra, Acquaviva, & Macii, 2011). The target gene prediction was based on the 
dataset from microrna.org, which is a well-curated database with conserved miRNAs and 
accurate mirSVR scores (Betel, Koppal, Agius, Sander, & Leslie, 2010). mirSVR scores 
are generated based on contextual features of binding and target site information using a 
single integrated model trained with support vector regression (a supervised, machine 
learning algorithm) (Betel et al., 2010). The mirSVR scores are interpreted as a likelihood 
of target downregulation, as the mirSVR approaches zero the meaningfulness of the 
potential downregulation drops as the number of target prediction quickly rises. The 
predicted binding score for these analyses was set at a cut off of mirSVR >0.3, resulting in 
a lower number of predictions that have a higher probability of occurring. 
 Review of the literature published on the identified differentially expressed 
miRNAs (from both response groupings and clinical datasets) was performed using 
miRBase and PubMed. miRBase was used to establish if the identified miRNA was the 
major or minor product was done in order to determine potential variation in nomenclature 
for searching on PubMed. Each miRNA was searched using the hsa- prefix, the simple miR 
nomenclature, as well as the * or -3p/-5p suffixes. The search results were reported on if 
the study pertained treatment response or pathogenesis of related disorders.  
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2.6.1.4.1 Gene Pathway Analyses Using Top-100 Differentially Expressed miRNAs  
A gene pathway analysis was done using the Fisher’s-exact-T test the findings were 
adjusted by FDR. The database used for this pathway analysis was the Kyoto Encyclopedia 
of Genes and Genomes (KEGG) (Kanehisa Laboratories). The miRNA pathway analysis 
was performed using the top 100 differentially expressed miRNAs (~5% of total known 
miRNA) to determine which pathways are common to these miRNAs and response 
groupings or clinical datasets (data not shown).  
2.6.1.4.2 miRNA-mRNA Network Analyses and in silico Functional Analysis of Top 
100 Differentially Expressed miRNAs  
The top 100 differentially expressed miRNAs and the collectively targeted genes 
for response groupings or clinical dataset underwent a network analysis where the miRNA-
mRNA interactions were visualized by Cytoscape software (Cytoscape Consortium); 
similarly, the data underwent an in silico functional enrichment analysis and functional 
module interactions were also visualized by Cytospace software. The GO (Gene Ontology) 
Consortium project is a database of standardized nomenclature for genes and gene products 
relevant to molecular functions, biological processes, or cellular locations. Using this 
controlled vocabulary, genes and gene products are grouped into bins (otherwise known as 
gene sets of functional groupings) based on their relatedness.  In the context of this project, 
genes collectively targeted by differentially expressed miRNAs were entered into the GO 
software and associations were identified to significantly enriched gene sets based on 
biological processes.  
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These associations are indicated with lines of varying thicknesses, which are 
representative of Kappa scores. A Kappa score is a measure of correlation between two 
terms. In the context of this data a thicker line indicates a stronger interaction, between 
miRNA and mRNA or between miRNA-mRNA predicted binding and a biological process, 
and a higher probability that the correlation has been experimentally validated (either in 
vitro or in silico). Therefore, there is a positive correlation between the line thickness and 
predicted miRNA-mRNA binding. The network analysis visualized the miRNA that 
collectively target the same mRNA, and the in silico functional analysis visualized the 
biological processes that are collectively associated with the miRNA-mRNA interactions.  
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CHAPTER 3 
3 RESULTS  
 Optimization of Circulating miRNA Library Preparations  
The first objective of this project was to develop and optimize a procedure for 
preparing successful circulating miRNA libraries for sequencing with Ion Torrent 
Technology. Two different protocols were investigated in an attempt to optimize 
circulating miRNA library preparation. Briefly, the modified Thermo Fisher protocol 
yielded low-quality results and therefore additional modifications were made in an attempt 
to improve library quantification and sequencing quality. After many unsuccessful library 
preparations using various modifications to the original Thermo Fisher protocol, a second 
protocol entitled “Small RNA Library Construction for Exosomal RNA from Biological 
Samples for the Ion Torrent PGM™ and Ion S5™ System” called the Cheng et al. protocol, 
modifications of which successfully sequenced samples.  
This section provides the results of the investigations that contributed to the 
optimization of library preparation for circulating miRNA. This procedure is technically 
challenging, labour intensive, and with minimal quality analysis steps; therefore, it was 
common to have uninformative results. The results that did not contribute to the 
optimization of the procedure were not included (n=8, see Appendix A for examples).  
The procedures utilized to optimize miRNA libraries and the samples used to 
achieve this (Figure 3.1) as well as the library preparation and sequencing metrics (Table 
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3.1) are provided. The successful libraries were then used to test the chip loading capacity 
using a varying number of samples at varying molarities (Figure 3.1). 
 
 
Figure 3.1 – Overview of the modification performed for the optimization of the library 
preparation protocol. The Thermo Fisher (TF) and Cheng et al. (CH) protocols underwent 
various modifications to determine the optimal procedure for miRNA library preparation. 
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Table 3.1 - Library preparation and sequencing metrics with descriptions and desired 
range. 
Library & 
Sequencing 
Metrics 
Description 
Total 
Molarity 
 
This value indicates total concentration of the prepared library that falls 
within the anticipated read lengths of a miRNA sample library (50-300 
bps– indicated by the red lines on the electropherogram). The highest 
possible regional molarity is optimal when considering the 
electropherogram profile, which should have a sample peak within the 
desired read length (94-114 bps). The total molarity of libraries quantified 
over the course of this project range between 47.1- 362nmol/l. 
Regional 
Molarity 
 
This value indicates the concentration of the prepared library that falls 
within the desired read length (94-114 bps– indicated by the green lines on 
the electropherogram), and therefore is likely to contain miRNA. The 
highest possible regional molarity is optimal while considering the 
electropherogram profile, which should have a sample peak within the 
desired read length. The regional molarity of libraries quantified over the 
course of this project range between 5.32-165nmol/l.   
Percent 
Regional 
Molarity 
The percent region molarity is calculated by the regional molarity divided 
by the total molarity. This value indicates the percentage of the prepared 
library that falls within the desired read length. A percent regional 
molarity of ~50% is likely to produce quality sequencing results; however, 
the electropherogram profile should be taken into consideration when 
determining if the library is of adequate quality to sequence. 
Mean Read 
Length 
The average size of cDNA fragments, with an optimal length of 15-35 
bps. 
Total Reads The number of cDNA fragments in the library, with the highest possible 
quantity being optimal. 
Reads Passing 
Filter 
The number of cDNA fragments that are of sufficient quality, with the 
highest possible quantity of total reads being optimal 
Aligned 
Reads 
The number of cDNA fragments that mapped to the hg19 reference 
genome, with the highest possible quantity of aligned reads being optimal. 
Percent 
Mapped 
Reads 
The proportion of reads passing filter that aligned to the hg19 reference 
genome, with the highest percentage possible. 
miRNA 
Reads 
The number of reads that map to an annotated/known miRNA regions of 
the genome, optimally exceeding 1 million. 
Percent 
miRNA 
Reads 
The percentage of reads passing filter that mapped to a known miRNA 
region of the genome, optimally exceeding 10%. 
Number Of 
miRNA 
Detected 
The number of different miRNA detected in each library, with an optimal 
total number of 400-800. 
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 miRNA Library Preparation and Sequencing using the Thermo 
Fisher Protocol Modifications 
3.1.1.1 Modified Thermo Fisher Protocol #1 (TF-Sample 1)  
 TF-Sample 1 was the first sample processed through the circulating miRNA 
sequencing pipeline using the modified Thermo Fisher protocol for intracellular miRNA 
extraction and library preparation (Figure 3.2).  
 
 
Figure 3.2 – Flow chart depicting protocol modifications and subsequent results in TF-
Sample 1. 
   
 The library of TF-Sample 1 was quantified as having a total molarity of 47.1nmol/l 
and a regional molarity of 5.32 nmol/l, resulting in an inadequate regional molarity 
percentage of 11.3% (Table 3.2). Quality assessment revealed a large adaptor dimer peak 
at 85 bps with an insufficient sample peak corresponding to miRNA at 102 bps (Figure 
3.3). The library of TF-Sample 1 sequenced 59,075 miRNA reads that passed quality filters, 
63.85% of which mapped to known miRNAs, detecting a total of 33 different miRNAs. 
However, most metrics failed to meet the minimum requirements of a successfully prepared 
library (Table 3.3). 
 
 
 91 
 
Table 3.2 – Results of the library quantification of TF-Sample 1. 
Library Quantification 
Metrics Desired Thresholds TF-Sample 1 
Total Molarity High 47.1 nmol /l 
Regional Molarity High 5.32 nmol /l 
Percent Regional Molarity ~50% 11.3%. 
 
 
 
Figure 3.3 - Electropherogram depicting the size distribution and concentration of small 
RNA in the TF-Sample 1 library. The y-axis is the measure of fluorescence units, 
representing the sample concentration, and the x-axis is a measure of base pairs, 
representing the length of the cDNA fragment. The first and third peak indicate the lower 
and upper marker, known to be 25 and 1500 base pairs long. The peak in the middle is 
representative of TF-Sample 1 library, where the * indicates the adaptor dimer and the + 
indicates the sample. The red lines on the electropherogram indicate the read lengths 
spanning from 50-300 bps, indicating the total molarity. The green lines on the 
electropherogram indicate the read lengths spanning 94-114 bps, indicating the regional 
molarity. 
 
 
 
 
*   
     + 
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Table 3.3 – Results of circulating miRNA sequencing of TF-Sample 1.  
Sequencing Metrics Desired Thresholds TF-Sample 1 
Mean Read Length 15-35 bps 17 bps 
Total Reads 10M 133,744 
Reads Passing Filters Highest % of total 59,075 
Aligned Reads Highest % of total 46,247 
Percent Mapped Reads High 78.29% 
miRNA Reads >1M 37,718 
Percent miRNA Reads >10% 63.85% 
miRNA Detected 400-800 33 
3.1.1.2 Modified Thermo Fisher Protocol #2 (TF-Sample 2) 
 In an attempt to reduce the adaptor dimer, half of the indicated adaptor and primer 
input was added during library preparation and the plasma input was increased to 625µl on 
the recommendation of the FAS (Figure 3.4). 
 
 
Figure 3.4 - Flow chart depicting protocol modifications and subsequent results in TF-
Sample 2A and TF-Sample 2B. 
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  When the input volume of plasma was increased (TF-Sample 2A), all metrics 
relating to molarity were increased compared with TF-Sample 1 (Table 3.4). Similarly, all 
sequencing metrics were also increased relative to TF-Sample 1 except percent miRNA 
reads. TF-Sample 2A was quantified as having a total molarity of 263 nmol/l and a regional 
molarity of 45.3 nmol/l, resulting in a regional molarity percentage of 17.2% (Table 3.4). 
The electropherogram showed a very large adaptor dimer peak at 89 bps, a small peak in 
the shoulder at approximately 102 bps, and another small peak at 148 bps (Figure 3.5). All 
sequencing metrics for TF-Sample 2A failed to meet criteria except mean read length and 
percent miRNA reads. Library sequencing generated 165,079 miRNA reads that passed 
quality filters, 43.74% of which mapped to known miRNAs, detecting a total of 185 
different miRNAs.  
 When the adapter and primer inputs were decreased by half, there was a 
corresponding decrease in total and regional molarity, while the percent regional molarity 
remained virtually unchanged. Likewise, the majority of sequencing metrics also increased 
compared with TF-Sample 2A. TF-Sample 2B was quantified as having a total molarity of 
134 nmol/l and a regional molarity of 17.6 nmol/l, resulting in a regional molarity 
percentage of 17.6% (Table 3.4). The electropherogram showed a very large adaptor dimer 
peak at 89 bps, a small peak in the shoulder representing the sample at ~101 bps, and 
another small peak at ~146 bps (Figure 3.6). All sequencing metrics for TF-Sample 2B 
failed to meet criteria except mean read length and percent miRNA reads. Library 
sequencing generated 82,569 miRNA reads that passed quality filters, 30.64% of which 
mapped to known miRNAs, detecting a total of 152 different miRNAs (Table 3.5).    
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Table 3.4 - Results of the library quantification of TF-Sample 2A and TF-Sample 2B.  
Library Quantification 
Metrics 
Desired 
Thresholds TF-Sample 2A TF-Sample 2B 
Total Molarity High 263 nmol/l 134 nmol/l 
Regional Molarity High 45.3 nmol/l 17.6 nmol/l 
Percent Regional Molarity ~50% 17.2%. 17.6%. 
 
 
Figure 3.5 - Electropherogram depicting the size distribution and concentration of small 
RNA in the TF-Sample 2A library. 
 
 
Figure 3.6 - Electropherogram depicting the size distribution and concentration of small 
RNA in the TF-Sample 2B library.  
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Table 3.5 – Results of sequencing TF-Sample 2A and TF-Sample 2B.  
Sequencing Metrics Desired Thresholds TF-Sample 2A TF-Sample 2B
Mean Read Length 15-35 bp 22 bp 28 bp 
Total Reads 10M 793,158 473,909 
Reads Passing Filters Highest % of total 377,393 269,470 
Aligned Reads Highest % of total 334,319 238,980 
Percent Mapped Reads High 88.59% 88.69% 
miRNA Reads >1M 165,079 82,569 
Percent miRNA Reads >10% 43.74% 30.64% 
miRNA Detected 400-800 185 152 
 
3.1.1.3 Modified Thermo Fisher Protocol #3 (TF-Sample 3) 
In an attempt to decrease the adaptor dimer, the adaptor input was reduced by half 
and a comparison was done between half the primer/barcode input and the full 
primer/barcode input using TF-Sample 3 (Figure 3.7). 
 TF-Sample 3A (half volume of primer and barcode) was quantified as having a 
total molarity of 133 nmol/l and a regional molarity of 21.7 nmol/l, resulting in a regional 
molarity percentage of 16.3% (Table 3.6). The electropherogram showed a very large 
adaptor dimer peak at 86 bps, a small sample peak at approximately 102 bps, and a small 
tRNA peak at 117 bps (Figure 3.8). TF-Sample 3A* (i.e., TF-Sample 3 that went through 
an additional cleanup process) was quantified as having a total molarity of 63.7 nmol/l and 
a regional molarity of 10.6 nmol/l, resulting in a regional molarity percentage of 16.6% 
(Table 3.6). The electropherogram showed a large adaptor dimer peak at 85 bps, a small 
sample peak at 104 bps, and a small tRNA peak at 116 bps (Figure 3.9). Library sequencing 
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generated 1,191,795 miRNA reads that passed quality filters, 31.47% of which mapped to 
known miRNAs, detecting a total of 307 different miRNAs (Table 3.7). 
 
 
Figure 3.7 - Flow chart depicting protocol modifications and subsequent results in TF-
Sample 3A, TF-Sample 3A*, and TF-Sample 3B. 
 
 TF-Sample 3B (full volume of primer and barcode) was quantified as having a 
total molarity of 72.6 nmol/l and a regional molarity of 5.69 nmol/l, resulting in a regional 
molarity percentage of 7.8% (Table 3.6). The electropherogram showed a large adaptor 
dimer peak at 84 bps as well as an extended shoulder of the slope which spanned the sample 
peak region (Figure 3.10). Library sequencing generated 128,149 miRNA reads that passed 
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quality filters, 42.75% of which mapped to known miRNAs, detecting a total of 160 
different miRNAs (Table 3.7). 
 
Table 3.6 - Results of the library quantification of TF-Sample 3A, TF-Sample 3A*, and 
TF-Sample 3B.  
 
 
 
Figure 3.8 - Electropherogram depicting the size distribution and concentration of small 
RNA in the TF-Sample 3A library.  
 
Library 
Quantification 
Metrics 
Desired 
Thresholds 
TF-Sample 
3A 
TF-Sample 
3A* 
TF-Sample 
3B 
Total Molarity High 133 nmol/l 63.7 nmol/l 72.6 nmol/l 
Regional Molarity High 21.7 nmol/l 10.6 nmol/l 5.69 nmol/l 
Percent Regional 
Molarity 
~50% 16.3% 16.6% 7.8% 
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Figure 3.9 - Electropherogram depicting the size distribution and concentration of small 
RNA in the TF-Sample 3A* library.  
 
 
 
Figure 3.10 - Electropherogram depicting the size distribution and concentration of small 
RNA in the TF-Sample 3B library.  
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Table 3.7 – Results of sequencing TF-Sample 3A* and 3B.  
 
3.1.1.4 Small RNA Control Sample  
 At this point in the investigation, given the suboptimal results, assurance was 
needed that the procedure was being adhered to and proper laboratory techniques were 
being used. In order to control for human error, a Small RNA Control reagent included in 
the Ion RNA-Seq kit served as a standardized sample concentration used for library 
preparation (Figure 3.11).  
 
 
Figure 3.11 - Flow chart depicting protocol modifications and subsequent results in Sample 
SmRNACon. 
 
 “Sample SmRNACon” was quantified as having a total molarity of 292 nmol/l 
and a regional molarity of 114 nmol/l, resulting in a regional molarity percentage of 39% 
Sequencing Metrics Desired Thresholds TF-Sample 3A* TF-Sample 3B
Mean Read Length 15-35bp 32 bp 21 bp 
Total Reads 10M 1,566,703 254,889 
Reads Passing Filters Highest % of total 1,191,795 128,149 
Aligned Reads Highest % of total 1,121,911 119,705 
Percent Mapped Reads High 94.14% 93.41% 
miRNA Reads >1M 375,001 54,783 
Percent miRNA Reads >10% 31.47% 42.75% 
miRNA Detected 400-800 307 160 
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(Table 3.8). The electropherogram showed a very large sample peak at 108 bps, a smaller 
peak at 164 bps and another large peak at 248 bps (Figure 3.12). 
 
Table 3.8 - Results of the library quantification of Sample SmRNACon.  
Library Quantification Metrics Desired Thresholds Sample SmRNACon 
Total Molarity High 292 nmol /l 
Regional Molarity High 114 nmol /l 
Percent Regional Molarity ~50% 39%. 
 
 
 
Figure 3.12 - Electropherogram depicting the size distribution and concentration of small 
RNA in the Small RNA Control library.  
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 miRNA Library Preparation and Sequencing using the Cheng et 
al. Protocol Modifications  
3.1.2.1 Modified Cheng et al. Protocol #1 (CH-Sample 1)  
After establishing that the FAS-recommended protocol was inadequate for 
producing the desired library quality, a new protocol for library preparation published by 
Cheng et al. was attempted using CH-Sample 1. (Cheng et al., 2014) 
 
 
Figure 3.13 - Flow chart depicting protocol modifications and subsequent results in CH-
Sample 1. 
   
 CH-Sample 1A was quantified as having a total molarity of 159 nmol/l and a 
regional molarity of 60.2 nmol/l, resulting in a regional molarity percentage of 37.9% 
(Table 3.9). The electropherogram showed a very small adaptor dimer peak at 87 bps, a 
very large miRNA sample peak at 117 bps, a small tRNA peak at 165 bps, and two small 
rRNA peaks at 186 bps and 246 bps (Figure 3.14). The library sequenced 10,395,297 reads 
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that passed quality filters, 24.56% of which mapped to known miRNAs, detecting a total 
of 588 different miRNAs.  
 The library generated using CH-Sample 1 was of acceptable quality; however, it 
contained undesired larger species of RNA. To reduce the quantity of larger RNA species, 
CH-Sample 1B was processed with additional on-magnet wait times (2 extra minutes) to 
increase the precision of the size selection process. CH-Sample 1B was quantified as having 
a total molarity of 205 nmol/l and a regional molarity of 84 nmol/l, resulting in a regional 
molarity percentage of 40.9% (Table 3.9). The electropherogram of showed a small adaptor 
dimer peak at 86 bps, a very large sample miRNA peak at 117 bps, a very small tRNA at 
approximately 166 bps, and a very small rRNA peak at 242 bps (Figure 3.15). The library 
generated 10,765,595 reads that passed quality filters, 30.20% of which mapped to known 
miRNAs, detecting a total of 656 different miRNAs (Table 3.10).   
 
Table 3.9 – Results of the library quantification of CH-Sample 1A and CH-Sample 1B.  
Library Quantification 
Metrics 
Desired 
Thresholds CH-Sample 1A CH-Sample 1B 
Total Molarity High 159 nmol/l 205 nmol/l 
Regional Molarity High 60.2 nmol/l 84 nmol/l 
Percent Regional 
Molarity 
~50% 37.9% 40.9% 
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Figure 3.14 - Electropherogram depicting the size distribution and concentration of small 
RNA in the CH-Sample 1A library.  
 
 
 
Figure 3.15 - Electropherogram depicting the size distribution and concentration of small 
RNA in the CH-Sample 1B library.  
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Table 3.10 – Results of sequencing CH-Sample 1A and CH-Sample 1B.  
Sequencing Metrics Desired Thresholds CH-Sample 1A CH-Sample 1B 
Mean Read Length 15-35bp 37 bp 28 bp 
Total Reads 10M 10,724,283 11,295,958 
Reads Passing Filters Highest % of total 10,395,297 10,765,595 
Aligned Reads Highest % of total 9,970,735 10,262,687 
Percent Mapped Reads High 95.92% 95.33% 
miRNA Reads >1M 2,553,114 3,251,662 
Percent miRNA Reads >10% 24.56% 30.20% 
miRNA Detected 400-800 588 656 
 
 Optimizing Chip Loading Capacity 
Once an optimized library preparation protocol was established, the optimization of 
chip loading began. In order to maximize the number of libraries that could be sequenced 
on one chip without decreasing the quality of sequencing metrics, 4 separate chip runs were 
performed. The first run, 6@8pM, had 6 libraries (regional morality percentage of >35%) 
loaded on the chip at 8 pM each. The second run, 7@6pM, had 7 successful libraries loaded 
on the chip at 6 pM each. The third run, 6@6pM, had 6 successful libraries loaded on the 
chip at 6 pM each. The forth run, 9@6pM, had 9 successful libraries loaded on the chip at 
6 pM each. Each sample that was loaded onto the chips during these runs is outlined below 
with its associated quality metrics. 
 CH-Sample 1B 
 The library of CH-Sample 1B sequenced at 6@8pM had 2,681,996 miRNA reads 
and detected 606 miRNAs. The library sequenced at 7@8pM had 3,251,662 miRNA reads 
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and detected 656 miRNAs. The library of sequenced at 6@6pM had 2,655,820 miRNA 
reads and detected 612 miRNAs. The library of sequenced at 9@6pM had 1,207,334 
miRNA reads and detected 492 miRNAs (Table 3.11). 
 
Table 3.11 - Results of multiple sequencing runs of CH-Sample 1B, loaded at different 
molarities and/or loaded with different number of samples on the sequencing chip.  
CH-Sample 1B 
Total Molarity 205 nmol/l 
Regional Molarity 84 nmol/l 
Percent Regional Molarity 40.9% 
Chip Loading Conditions 
Desired 
Thresholds 6@8pM 7@8pM 6@6pM 9@6pM 
Mean Read Length 15-35bp 27 bp 28 bp 27 bp 27 bp 
Total Reads 10M 9,120,699 11,295,958 8,904,659 4,168,540
Reads Passing Filters 
Highest % of 
total 
8,605,744 10,765,595 8,417,074 3,915,399
Aligned Reads 
Highest % of 
total 
8,170,418 10,262,687 8,005,450 3,714,112
Percent Mapped Reads High 94.94% 95.33% 95.11% 94.86% 
miRNA Reads >1M 2,681,996 3,251,662 2,655,820 1,207,334
Percent miRNA Reads >10% 31.17% 30.20% 31.55% 30.84% 
miRNA Detected 400-800 606 656 612 492 
 
 CH-Sample 2A 
 The library of CH-Sample 2A sequenced at 6@8pM had 3,849,111 miRNA reads 
and detected 719 miRNAs. The library sequenced at 7@8pM had 3,506,927 miRNA reads 
and detected 719 miRNAs. The library sequenced at 6@6pM had 4,492,068 miRNA reads 
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and detected 775 miRNAs. The library sequenced at 9@6pM had 2,982,039 miRNA reads 
and detected 686 miRNAs (Table 3.12). 
 
Table 3.12 - Results of multiple sequencing run of CH-Sample 2A, loaded at different 
molarities and/or loaded with different number of samples on the sequencing chip. 
CH-Sample 2A 
Total Molarity 69.5 nmol/l 
Regional Molarity 37.1 nmol/l 
Percent Regional 
Molarity 
53.4% 
Chip Loading 
Conditions 
Desired 
Thresholds 
6@8pM 7@8pM 6@6pM 9@6pM 
Mean Read Length 15-35bp 23 bp 23 bp 23 bp 23 bp 
Total Reads 10M 11,898,004 10,892,710 13,844,706 9,325,402 
Reads Passing Filters 
Highest % of 
total 
9,336,216 8,636,110 10,819,580 7,247,430 
Aligned Reads 
Highest % of 
total 
8,697,941 8,076,508 10,102,958 6,761,555 
Percent Mapped 
Reads 
High 93.16% 93.52% 93.38% 93.30% 
miRNA Reads >1M 3,849,111 3,506,927 4,492,068 2,982,039 
Percent miRNA 
Reads 
>10% 41.23% 40.61% 41.52% 41.15% 
miRNA Detected 400-800 719 719 775 686 
 
 
 CH-Sample 2B 
 The library of CH-Sample 2B sequenced at 6@8pM had 3,548,187 miRNA reads 
and detected 713 miRNAs. The library sequenced at 7@8pM had 3,326,817 miRNA reads 
and detected 697 miRNAs. The library sequenced at 6@6pM had 4,186,769 miRNA reads 
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and detected 753 miRNAs. The library sequenced at 9@6pM had 2,277,177 miRNA reads 
and detected 632 miRNAs (Table 3.13).  
 
Table 3.13 - Results of multiple sequencing run of CH-Sample 2B, loaded at different 
molarities and/or loaded with different number of samples on the sequencing chip.  
CH-Sample 2B 
Total Molarity 93.9 nmol/l 
Regional Molarity 44.4 nmol/l 
Percent Regional 
Molarity 
47.3% 
Chip Loading 
Conditions 
Desired 
Thresholds 
6@8pM 7@8pM 6@6pM 9@6pM 
Mean Read Length 15-35bp 22 bp 22 bp 22 bp 22 bp 
Total Reads 10M 10,870,402 10,210,875 13,080,873 7,283,505
Reads Passing Filters 
Highest % of 
total 
8,011,803 7,660,753 9,656,956 5,332,995
Aligned Reads 
Highest % of 
total 
7,488,973 7,185,659 9,054,920 4,982,695
Percent Mapped Reads High 93.47% 93.80% 93.77% 93.43% 
miRNA Reads >1M 3,548,187 3,326,817 4,186,769 2,277,177
Percent miRNA Reads >10% 44.29% 43.43% 43.35% 42.70% 
miRNA Detected 400-800 713 697 753 632 
 
 CH-Sample 3A 
 The library of CH-Sample 3A sequenced at 6@8pM had 6,765,690 miRNA reads 
and detected 766 miRNAs. The library sequenced at 7@8pM had 7,381,776 miRNA reads 
and detected 802 miRNAs.  The library sequenced at 6@6pM had 7,715,774 miRNA reads 
and detected 791 miRNAs. The library sequenced at 9@6pM had 3,749,194 miRNA reads 
and detected 657 miRNAs (Table 3.14). 
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Table 3.14 - Results of multiple sequencing run of CH-Sample 3A, loaded at different 
molarities and/or loaded with different number of samples on the sequencing chip.  
CH-Sample 3A 
Total Molarity 250 nmol/l 
Regional Molarity 153 nmol/l 
Percent Regional 
Molarity 
61.2% 
Chip Loading 
Conditions 
Desired 
Thresholds 6@8pM 7@8pM 6@6pM 9@6pM 
Mean Read Length 15-35bp 24 bp 24 bp 24 bp 24 bp 
Total Reads 10M 15,077,181 16,660,648 17,307,747 8,517,446 
Reads Passing Filters 
Highest % 
of total 
13,474,507 15,026,824 15,472,821 7,578,241 
Aligned Reads 
Highest % 
of total 
12,736,343 14,242,989 14,640,686 7,150,327 
Percent Mapped 
Reads 
High 94.52% 94.78% 94.62% 94.35% 
miRNA Reads >1M 6,765,690 7,381,776 7,715,774 3,749,194 
Percent miRNA 
Reads 
>10% 50.21% 49.12% 49.87% 49.47% 
miRNA Detected 400-800 766 802 791 657 
 
 CH-Sample 3B  
 The library of CH-Sample 3B sequenced at 6@8pM had 4,629,033 miRNA reads 
and detected 694 miRNAs. The library sequenced at 7@8pM had 6,722,682 miRNA reads 
and detected 767 miRNAs.  The library sequenced at 6@6pM had 4,442,858 miRNA reads 
and detected 678 miRNAs. The library sequenced at 9@6pM had 2,241,975 miRNA reads 
and detected 573 miRNAs (Table 3.15). 
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Table 3.15 - Results of multiple sequencing run of CH-Sample 3B, loaded at different 
molarities and/or loaded with different number of samples on the sequencing chip.  
CH-Sample 3B 
Total Molarity 331 nmol/l 
Regional Molarity 208 nmol/l 
Percent Regional Molarity 62.8% 
Chip Loading Conditions 
Desired 
Thresholds 6@8pM 7@8pM 6@6pM 9@6pM 
Mean Read Length 15-35bp 23 bp 24 bp 23 bp 23 bp 
Total Reads 10M 10,406,120 15,181,195 9,943,531 5,101,471
Reads Passing Filters 
Highest % 
of total 
9,047,819 13,417,347 8,666,200 4,404,131
Aligned Reads 
Highest % 
of total 
8,480,245 12,656,294 8,147,169 4,116,465
Percent Mapped Reads High 93.73% 94.33% 94.01% 93.47% 
miRNA Reads >1M 4,629,033 6,722,682 4,442,858 2,241,975
Percent miRNA Reads >10% 51.16% 50.10% 51.27% 50.91% 
miRNA Detected 400-800 694 767 678 573 
 
 
 CH-Sample 4 
 The library of CH-Sample 4 sequenced at 6@8pM had 3,865,195 miRNA reads 
and detected 634 miRNAs. The library sequenced at 7@8pM had 3,659,867 miRNA reads 
and detected 631 miRNAs.  The library sequenced at 6@6pM had 4,556,733 miRNA reads 
and detected 658 miRNAs. The library sequenced at 9@6pM had 2,501,037 miRNA reads 
and detected 568 miRNAs (Table 3.16). 
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Table 3.16 - Results of multiple sequencing run of CH-Sample 4, loaded at different 
molarities and/or loaded with different number of samples on the sequencing chip.  
CH-Sample 4 
Total Molarity 79.9 nmol/l 
Regional Molarity 30.6 nmol/l 
Percent Regional Molarity 38.3% 
Chip Loading Conditions 
Desired 
Thresholds 6@8pM 7@8pM 6@6pM 9@6pM 
Mean Read Length 15-35bp 21 bp 22 bp 21 bp 21 bp 
Total Reads 10M 7,425,193 7,031,336 8,741,415 4,873,923
Reads Passing Filters 
Highest % of 
total 
6,061,797 5,808,195 7,141,614 3,940,071
Aligned Reads 
Highest % of 
total 
5,733,980 5,508,149 6,775,428 3,721,042
Percent Mapped Reads High 94.59% 94.83% 94.87% 94.44% 
miRNA Reads >1M 3,865,195 3,659,867 4,556,733 2,501,037
Percent miRNA Reads >10% 63.76% 63.01% 63.81% 63.48% 
miRNA Detected 400-800 634 631 658 568 
 
 Chip Run Comparison  
 
 Run 1 had 6 samples loaded at 8 pM and sequenced a total of 64,797,599 reads; 
25,339,212 of those were miRNA reads and a total of 4132 miRNAs were detected. Run 2 
had 7 samples loaded at 8 pM and sequenced a total of 81,997,005 reads; 30,402,845 of 
those were miRNA reads and a total of 4860 miRNAs were detected. Run 3 had 6 samples 
loaded at 6 pM and sequenced 71,822,931 reads; 28,050,022 of those were miRNA reads 
and detected a total of 4267 miRNAs. Run 4 had 9 samples loaded at 6 pM and sequenced 
65,402,227; 19,771,108 of those were miRNA reads and detected a total of 5147 miRNAs 
(Table 3.17). 
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Table 3.17 - Results of multiple sequencing runs with chips loaded at different molarities 
and/or loaded with different number of samples on the sequencing chip.  
 
Chip Run 
Comparison 
Run 1 Run 2 Run 3 Run 4 
6@8pM 7@8pM 6@6pM 9@6pM 
% T-ISP’s 7% 9% 6.4% 6.5% 
Total reads 64,797,599 81,997,005 71,822,931 65,402,227 
Total aligned reads 51,307,900 67,903,021 56,726,611 49,450,376 
Total miRNA reads 25,339,212 30,402,845 28,050,022 19,771,108 
Total miRNA detected 4132 4860 4267 5147 
 
 
 PGx PsA Cohort Library Preparation and Sequencing Results 
 A summary of library preparation results for the nine PsA patients is indicated in 
Table 3.18. PsA patient libraries were quantified as having total morlarities ranging from 
111-275 nmol/l, regional molarities ranging from 49.4-165 nmol/l, and percent regional 
molarities rangning from 44.5-66.1%. For the electropherograms of the PsA patient 
libraries see Appendix B. A summary of sequencing results for the nine PsA patient 
samples, generated by the Ion Torrent System, are indicated in Table 3.18. Raw data 
collected from sequencing these samples was used for subsequent analyses perfomed 
through the comprehensive miRNA analyses pipeline.  
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Table 3.18 – Summary of library preparation and sequencing results of the PGx patient samples. Bolded values are important 
library metrics for assessing quality of the prepared libraries.  
Library Metrics 
Desired 
Thresholds Patient 2 Patient 6 Patient 7 Patient 8 Patient 10 Patient 12 Patient 13 Patient 14 
Total Molarity High 142 nmol /l 111 nmol/l 130 nmol/l 190 nmol/l 162 nmol/l 234 nmol/l 180 nmol/l 275 nmol/l
Regional 
Molarity High 83.5 nmol /l 49.4 nmol/l 69.2 nmol/l 115 nmol/l 98.7 nmol/l 135 nmol/l 119 nmol/l 165 nmol/l
Percent 
Regional 
Molarity 
~50% 58.8% 44.5% 53.2% 60.5% 60.9% 57.7% 66.1% 60.0% 
Mean Read 
Length 15-35bp 24 bp 27 bp 23 bp 25 bp 24 bp 27 bp 25 bp 26 bp 
Total Reads 10M 12,285,203 15,257,693 13,805,888 11,407,235 13,777,447 19,618,782 18,011,848 19,430,276
Reads Passing 
Filters 
Highest % 
of total 10,553,278 14,363,192 11,643,534 10,521,082 12,617,228 18,556,802 16,387,945 18,408,616
Aligned Reads Highest % of total 9,901,417 13,659,253 11,004,407 9,958,734 11,903,955 17,683,645 15,528,710 17,509,053
Percent 
Mapped Reads High 93.82% 95.10% 94.51% 94.66% 94.35% 95.29% 94.76% 95.11% 
miRNA Reads >1M 4,671,889 4,355,535 4,715,021 4,165,755 5,538,278 6,619,036 6,695,083 9,061,954
Percent miRNA 
Reads >10% 44.27% 30.32% 40.49% 39.59% 43.89% 35.67% 40.85% 49.23% 
miRNA 
Detected 400-800 741 686 731 683 725 776 794 810 
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 Clinical Results and Response Groupings 
 Patients ranged from 37 to 64 years of age, with a mean age of 53.8 and a standard 
deviation of 7.0. There were 4 males (44.4%) and 5 females (55.6%) recruited for this study 
(Table 3.19). Two patients (22.2%) were prescribed the IL-12/23 inhibitor, ustekinumab 
(Stelera®), and seven patients (77.8%) were prescribed the IL-17 inhibitor, secukinumab 
(Consentyx®) (Table 3.19).  
 Monitoring disease progression and determining treatment response was done 
using the recorded values for each criterion (Table 3.20), resulting in the categorization of 
patients into clinical response grouping (Table 3.21). 
 
Table 3.19 – Patient information including patient ID, the biologic the patient was 
prescribed, the patient’s age, and the patient’s sex.  
Patient ID Drug Age Sex 
2 Stelara 49 Male 
6 Cosentyx 56 Female 
7 Cosentyx 56 Female 
8 Cosentyx 58 Male 
10 Cosentyx 64 Female 
11 Cosentyx 55 Female 
12 Cosentyx 55 Male 
13 Stelara 55 Female 
14 Cosentyx 37 Male 
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Table 3.20 - Clinical values of HAQ-DI, CDAI, and ESR that were used to monitoring 
disease progression and treatment response. 
 
Patient ID HAQ-DI CDAI ESR (mm/hr) 
Pre 1m 3m Pre 1m 3 m Pre 1 m 3m 
2 0.22 0.11 0 29 2 0 13 4 2 
6 1.25 0.8 1.2 28 23 41 5 0 6 
7 1.05 1.2 0.7 22 20 31 40 50 38 
8 0.85 0.85 0.75 53 22 18 29 14 19 
10 1.35 1.55 1.85 47 47 16 24 15 24 
11 1.25 1.25 1.1 39 26 22 34 26 26 
12 2 1.85 1.7 51 48 49 27 40 25 
13 0.95 1 0.7 30 18 3 10 10 8 
14 0.7 0.5 0.5 21 4 1 2 2 2 
 
Table 3.21  - Clinical groupings of responders and non-responders to biologics treatment. 
Response groupings Patient 
ACR50 Non- Responders 
6 
7 
8 
11 
12 
ACR50 Responders 
2 
10 
13 
14 
 
 Analyses of PGx Samples Using the Comprehensive miRNA Pipeline 
Data generated by the comprehensive miRNA pipeline used for analyses (Figure 
3.16) is outlined in Table 3.22. Three major datasets were generated from the 
comprehensive miRNA analyses pipeline: identified novel miRNAs, identified miRNA 
variants, and differential miRNA expression. 
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Table 3.22 - Summary of sequencing results used for the comprehensive miRNA pipeline. 
Response 
groupings Patient 
Total 
Reads 
Trimmed
Reads 
Aligned 
Reads 
Precursor 
miRNA 
Reads 
Mature 
miRNA 
Reads 
Known 
miRNA 
with 5x 
coverage 
Non- 
Responders 
6 15,193,152 407,758 10,073,266 3,480 4,228,455 747 
7 13,748,316 276,721 7,579,642 3,294 4,556,267 792 
8 11,357,574 263,873 7,253,612 3,290 4,001,759 743 
11 15,093,112 236,845 10,810,641 4,208 5,801,842 795 
12 19,277,033 310,222 12,452,582 5,016 6,456,913 855 
Responders 
2 12,239,356 430,052 7,587,572 4,145 4,515,962 805 
10 13,710,176 341,803 8,440,832 3,622 5,338,171 796 
13 17,713,699 336,244 11,830,895 3,628 6,524,251 862 
14 19,100,094 210,621 13,966,733 10,939 8,743,105 874 
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Figure 3.16 – Flow chart depicting the analyses performed using the comprehensive miRNA analyses pipeline (Section 3.5), including miRNA variant and 
novel miRNA analyses (Section 3.5.1), differential expression (DE) analysis between ACR50 responders and non-responders  (Section 3.5.2), differential 
expression analyses relative to clinical datasets (Section 3.5.3), pathway analyses (Section 3.5.4), network analyses (Section 3.5.5), and a function enrichment 
analysis (Section 3.6.6). The tables corresponding to analyses only display the suggestively significant results. 
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 Identified miRNA Variants and Identified Known and Novel 
miRNAs 
In the 2822 detected miRNAs, there were 1936 variants identified (data not shown). 
In the nine PGx samples, a total of 2822 miRNAs were detected (data not shown). Of the 
2822 miRNAs detected, 1902 have previously been identified. Therefore, the analysis 
detected 920 novel miRNAs that had not yet been annotated by miRDeep2/ miRBase (data 
not shown). Of the 920 novel miRNAs, nine miRNAs were found exclusively in the 
responder group and eight novel miRNAs were found exclusively in the non-responder 
group (Table 3.23).  
 
Table 3.23 – Novel miRNAs identified in responders or non-responders. Where (+) 
indicates that patients possess that novel miRNA and (–) indicates that patient does not 
possess that novel miRNA. 
 Responders Non-Responders 
chr 02 10 13 14 06 07 08 11 12 
chr2:88355218-88355276 + + + - - - - - - 
chr3:185279931-185279996 + - + + - - - - - 
chr5:32431097-32431160 + + + - - - - - - 
chr5:171831837-171831897 + + + - - - - - - 
chr6:28726146-28726212 + + + - - - - - - 
chr7:77005493-77005573 + + + - - - - - - 
chr9:95500873-95500934 + - + + - - - - - 
chr13:43323439-43323498 + + - + - - - - - 
chr2:27304884-27304952 - - - - - + - + + 
chr2:96656064-96656124 - - - - - + - + + 
chr3:41563653-41563715 - - - - - - + + + 
chr4:81946113-81946170 - - - - - - + + + 
chr6:8086643-8086702 - - - - + - + - + 
chr6:137113031-137113087 - - - - - + + - + 
chr17:7210149-7210207 - - - - - + - + + 
chr19:1253356-1253424 - - - - - + - + + 
chrX:153593853-153593910 - - - - + + - - + 
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 Differential miRNA Expression between ACR50 Response 
Groupings 
The read counts underwent normalization, and the distribution of the counts was 
visualized (Figure 3.17). A differential miRNA expression analysis was then performed 
under the hypothesis that differential miRNA expression levels exist between responders 
and non-responders.  
 
Figure 3.17 – Boxplot visualization of the distribution of normalized reads sequenced from 
each sample. 
 
 As shown on the MDS plot of fold change (Figure 3.18), the responder and non-
responder groups did not cluster well in the differential expression analysis. The differential 
expression analyses metrics are outline and described in Table 3.24. The p-values for the 
differential miRNA expression associations between responders and non-responders were 
not significant after correcting for multiple testing (Table 3.25). Because no significant 
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associations were found, the top 100 differentially expressed miRNAs were prioritized for 
examination to identify mutually targeted genes (Table 3.26). 
 
Figure 3.18 - MDS plot of Fold change of miRNA expression between responders 
(indicated in green) and non-responders (indicated in red). 
 
Table 3.24 - Differential expression analyses metric and descriptions. 
Differential Expression 
Analyses Metric  
Description  
LogFC (Log Fold 
Change) 
Log of the fold change, of the differential expression, 
between groups 
LogCPM (Log Counts 
Per Million) 
Measure of expression level similar to fragments per 
kilobase of transcript per million mapped reads 
LR (Logarithm Ratio)  Ratio between a change in two values 
p-value Measure of significance of the identified association 
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Table 3.25 – Top seven differentially expressed miRNAs between ACR50 response 
grouping, where no significance was reached after correcting for multiple testing. 
Mature ID 
Non-responders  
Read Counts 
Responders  
Read Counts Analysis Metrics 
6 7 8 11 12 2 10 13 14 logFC logCPM LR p-value FDR
miR-106a-3p 4 3 5 5 5 7 8 15 7 -1.12 2.78 6.57 0.01 0.998
miR-96-5p 11 19 21 41 17 39 25 55 76 -1.15 5.10 6.17 0.01 0.998
miR-296-5p 15 13 24 24 9 55 32 31 21 -1.04 4.65 5.57 0.02 0.998
miR-3194-5p 14 2 6 3 9 6 25 7 32 -1.39 3.58 5.44 0.02 0.998
miR-150-5p 608 1565 489 436 743 2439 444 565 3842 -1.25 10.27 4.51 0.03 0.998
miR-183-5p 4 9 11 16 7 20 11 15 25 -0.91 3.77 4.17 0.04 0.998
miR-193a-5p 6 30 12 10 24 41 13 38 42 -1.02 4.62 4.16 0.04 0.998
 
Table 3.26 – mRNA targets common to all of the top 100 differentially expressed miRNAs 
between ACR50 response grouping. 
Target Gene Gene Description 
HTR1B 5-hydroxytryptamine (serotonin) receptor 1B, G protein-coupled 
SSSCA1 Sjogren syndrome/scleroderma autoantigen 1 
AQP5 aquaporin 5 
KRTAP3-2 keratin associated protein 3-2 
HGS hepatocyte growth factor-regulated tyrosine kinase substrate 
BAX BCL2-associated X protein 
CCNE1 cyclin E1 
RYK receptor-like tyrosine kinase 
IRS1 insulin receptor substrate 1 
FOXO1 forkhead box O1 
EZR ezrin 
TBC1D9 TBC1 domain family, member 9 (with GRAM domain) 
EGR2 early growth response 2 
P2RX7 purinergic receptor P2X, ligand-gated ion channel, 7 
RUNX1T1 runt-related transcription factor 1; translocated to, 1 (cyclin D-related) 
ODF2 outer dense fiber of sperm tails 2 
CELSR2 cadherin, EGF LAG seven-pass G-type receptor 2 
MYRIP myosin VIIA and Rab interacting protein 
CCND1 cyclin D1 
ADCY6 adenylate cyclase 6 
MYB v-myb avian myeloblastosis viral oncogene homolog 
MITF microphthalmia-associated transcription factor 
BTRC beta-transducin repeat containing E3 ubiquitin protein ligase 
BCL2 B-cell CLL/lymphoma 2 
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 Differential miRNA Expression Incorporating Clinical Data 
The differentially expressed miRNAs that reached suggestive significance for each 
set of clinical data (CDAI, HAQ-DI, and ESR) are outlined below; only miRNAs reaching 
a significance cut-off FDR of <0.05 (stastically significant) and <0.2 (suggestively 
significant) are displayed.  
Differentially expressed miRNAs, reaching suggestive and statistical significance, 
associated with CDAI values at one-month and three-months post treatment are displayed 
in Table 3.27 and Table 3.28, respectively. Differentially expressed miRNAs, reaching 
suggestive and statistical significance, associated with HAQ-DI values at one-month and 
three-months post treatment are displayed in Table 3.29 and Table 3.30, respectively. No 
differentially expressed miRNAs reached suggestive significance for the ESR values at 
one-month post treatment. Statistically significant differentially expressed miRNAs 
associated with ESR values at three-months post treatment are displayed in Table 3.31. A 
summary of differentially expressed miRNAs that are associated with multiple datasets is 
displayed in Table 3.32. 
 
Table 3.27 – Suggestively significant differentially expressed miRNAs associated with 
CDAI values at one-month post treatment with the statistically significant differentially 
expressed miRNAs incidated in the bordered cells. 
CDAI 1 month 
Mature ID Patient Read Counts Analysis Metrics 6 7 8 11 12 2 10 13 14 logFC logCPM LR p-value FDR 
miR-124-3p 4 1 1 0 1 4 0 4 43 -0.13 2.86 22.32 2.31E-06 1.3E-03
miR-1275 0 4 2 1 0 6 1 1 6 -0.09 1.49 18.12 2.08E-05 6.0E-03
miR-582-5p 2 7 7 5 4 19 5 5 49 -0.07 3.60 15.27 9.34E-05 1.8E-02
miR-150-5p 611 1535 460 453 768 2403 450 540 4042 -0.05 10.29 10.82 1.00E-03 0.15 
miR-31-5p 3 8 3 2 5 24 3 1 19 -0.05 3.03 10.09 1.49E-03 0.17 
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Table 3.28 - Statistically significant differentially expressed miRNAs associated with 
CDAI values at three-months post treatment. 
CDAI 3 months 
Mature ID 
Patient Read Counts Analysis Metrics 
6 7 8 11 12 2 10 13 14 logFC logCPM LR p-value FDR
miR-582-5p 2 7 7 5 4 19 5 5 49 -0.06 3.60 13.72 2.13E-04 0.12
 
Table 3.29 - Statistically significant differentially expressed miRNAs associated with 
HAQ-DI values at one-month post treatment. 
HAQ-DI 1 month 
Mature.ID 
Patient Read Counts Analysis Metrics 
6 7 8 11 12 2 10 13 14 logFC logCPM LR p-value FDR 
miR-124-3p 4 1 1 0 1 4 0 4 43 -3.88 2.86 14.61 1.32E-04 0.08 
miR-582-5p 2 7 7 5 4 19 5 5 49 -1.99 3.60 12.14 4.93E-04 0.14 
 
Table 3.30 - Suggestively significant differentially expressed miRNAs associated with 
HAQ-DI values at three-months post treatment with the statistically significant 
differentially expressed miRNA incidated in the bordered cell. 
HAQ-DI 3 months 
Mature 
ID 
Patient Read Counts Analysis Metrics 
6 7 8 11 12 2 10 13 14 logFC logCPM LR p-value FDR 
miR-1275 0 4 2 1 0 6 1 1 6 -2.60 1.49 21.61 3.34E-06 1.94E-03 
miR-27a-5p 2 7 2 1 3 13 1 3 6 -1.57 2.17 12.26 4.64E-04 0.13 
miR-582-5p 2 7 7 5 4 19 5 5 49 -1.78 3.60 10.87 9.80E-04 0.13 
miR-124-3p 4 1 1 0 1 4 0 4 43 -3.72 2.86 10.74 1.05E-03 0.13 
miR-31-5p 3 8 3 2 5 24 3 1 19 -1.57 3.03 10.66 1.10E-03 0.13 
miR-4433b-
3p 24 69 16 88 28 184 24 64 40 -1.31 5.91 9.23 2.38E-03 0.20 
miR-150-5p 611 1535 460 453 768 2403 450 540 4042 -1.43 10.29 9.20 2.42E-03 0.20 
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Table 3.31 – Suggestively significant differentially expressed miRNAs associated with 
ESR values at three-months post treatment with the statistically significant differentially 
expressed miRNAs incidated in the bordered cells. 
ESR 3 months 
Mature.ID 
Patient Read Counts Analysis Metrics 
6 7 8 11 12 2 10 13 14 logFC logCPM LR p-value FDR 
miR-124-3p 4 1 1 0 1 4 0 4 43 -0.14 2.86 15.93 6.59E-053.83E-02
miR-146a-3p 122 31 86 47 31 129 35 166 103 -0.07 6.39 14.47 1.42E-044.14E-02
 
Table 3.32 - Differentially expressed miRNAs found to be associated with more than one 
analysis. 
Differentially Expressed miRNAs Analyses 
miR-150-5p 
Responders vs. Non-responders 
CDAI 1 month 
HAQ-DI 3 months 
miR-124-3p 
CDAI 1 month 
HAQ-DI 1 month 
HAQ-DI 3 months 
ESR 3 months 
miR-1275 CDAI 1 month HAQ-DI 3 months 
miR-582-5p 
CDAI 1 month 
CDAI 3 months 
HAQ-DI 1 month 
HAQ-DI 3 months 
miR-31-5p CDAI 1 month HAQ-DI 3 months 
 
 Pathway Analysis Using Top 100 Differentially Expressed 
miRNAs  
The pathway analysis metrics and their descriptions are outline in Table 3.33. The 
top five pathways significantly associated with the differentially expressed miRNAs 
between responders and non-responders are outlined in Table 3.34. The top five pathways 
significantly associated with the differentially expressed miRNAs and HAQ-DI values at 
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one-month and three-months post treatment are outlined in Table 3.35 and Table 3.36, 
respectively. The top five pathways significantly associated with the differentially 
expressed miRNAs and CDAI values at one-month and three-months post treatment are 
outlined in Table 3.37 and Table 3.38, respectively. The top five pathways significantly 
associated with the differentially expressed miRNAs and ESR values at one-month and 
three-months post treatment are outlined in Table 3.39 and Table 3.40, respectively.  
 
Table 3.33 – Pathway analysis metrics and descriptions. 
Pathway Analysis 
Metric  
Description  
KEGG pathway Pathway found to be associated with differentially express miRNA 
and the collectively targeted genes 
KEGG pathway ID KEGG ID associated with pathway identified 
p-value Measure of significance of the identified association  
#genes Number of genes associated with that pathway 
#miRNA Number of miRNAs associated with that pathway  
 
Table 3.34 – Top five pathways associated with differentially expressed miRNAs between 
clinical response groupings. 
Pathways Associated Clinical Response Groupings  
# KEGG pathway KEGG 
pathway ID 
p-value #genes #miRNAs
1 Proteoglycans in cancer  hsa05205 4.33E-19 138 72 
2 Axon guidance  hsa04360 7.41E-12 92 68 
3 TGF-beta signalling pathway  hsa04350 1.61E-10 59 57 
4 Signalling pathways regulating 
pluripotency of stem cells  hsa04550 
6.99E-08 93 60 
5 Hippo signalling pathway  hsa04390 6.99E-08 97 69 
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Table 3.35 - Top five pathways associated with differentially expressed miRNAs relative 
to the CDAI1 dataset. 
Pathways Associated with CDAI1  
 
# 
KEGG pathway KEGG 
pathway ID 
p-value #genes #miRNAs
1 Proteoglycans in cancer hsa05205 2.54E-08 126 68 
2 TGF-beta signalling pathway  hsa04350 7.37E-08 58 59 
3 ECM-receptor interaction  hsa04512 2.22E-07 52 55 
4 Morphine addiction  hsa05032 4.15E-07 59 57 
5 Lysine degradation  hsa00310 6.87E-07 35 48 
 
Table 3.36 - Top five pathways associated with differentially expressed miRNAs relative 
to the CDAI3 dataset.  
Pathways Associated with CDAI3  
 
# 
KEGG pathway KEGG 
pathway ID 
p-value #genes #miRNAs
1 Proteoglycans in cancer  hsa05205 1.30E-09 120 66 
2 Hippo signalling pathway  hsa04390 1.92E-09 94 64 
3 Fatty acid biosynthesis  hsa00061 1.16E-08 7 11 
4 TGF-beta signalling pathway  hsa04350 1.81E-07 52 49 
5 Axon guidance  hsa04360 9.43E-07 77 61 
 
Table 3.37  - Top five pathways associated with differentially expressed miRNAs relative 
to the HAQ-DI1 dataset. 
Pathways Associated with HAQ-DI1  
 
# 
KEGG pathway KEGG 
pathway ID 
p-value #genes #miRNAs
1 Morphine addiction  hsa05032 5.98E-08 58 55 
2 Axon guidance  hsa04360 5.98E-08 91 59 
3 Proteoglycans in cancer  hsa05205 2.31E-07 120 68 
4 Circadian entrainment  hsa04713 2.58E-05 64 59 
5 Hippo signalling pathway  hsa04390 2.58E-05 91 67 
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Table 3.38 - Top five pathways associated with differentially expressed miRNAs relative 
to the HAQ-DI3 dataset. 
Pathways Associated with HAQ-DI3  
 
# 
KEGG pathway KEGG 
pathway ID 
p-value #genes #miRNAs
1 TGF-beta signalling pathway  hsa04350 1.53E-07 56 55 
2 Proteoglycans in cancer  hsa05205 2.15E-06 122 68 
3 Hippo signalling pathway  hsa04390 6.59E-06 92 67 
4 Lysine degradation  hsa00310 1.45E-05 33 48 
5 ECM-receptor interaction  hsa04512 1.45E-05 45 53 
 
Table 3.39 - Top five pathways associated with differentially expressed miRNAs relative 
to the ESR1 dataset. 
Pathways Associated with ESR1  
 
# 
KEGG pathway KEGG 
pathway ID 
p-value #genes #miRNAs
1 TGF-beta signalling pathway  hsa04350 2.09E-09 59 63 
2 Proteoglycans in cancer  hsa05205 3.14E-09 130 70 
3 Pathways in cancer  hsa05200 3.38E-07 236 76 
4 ECM-receptor interaction  hsa04512 2.60E-06 51 57 
5 Axon guidance  hsa04360 2.63E-06 83 67 
 
Table 3.40 - Top five pathways associated with differentially expressed miRNAs relative 
to the ESR3 dataset. 
Pathways Associated with ESR3 
 
# 
KEGG pathway KEGG 
pathway ID 
p-value #genes #miRNAs
1 Axon guidance  hsa04360 1.11E-07 88 67 
2 Proteoglycans in cancer  hsa05205 1.11E-07 120 67 
3 TGF-beta signalling pathway  hsa04350 1.13E-06 57 55 
4 N-Glycan biosynthesis  hsa00510 2.58E-05 31 35 
5 Pathways in cancer  hsa05200 1.49E-04 225 77 
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 Network Analysis/Predictive Binding of Top 100 Differentially 
Expressed miRNAs  
A network analysis performed on the top 100 differentially expressed miRNAs 
between responders and non-responders is visualized in Figure 3.19. A network analysis 
performed on the top 100 differentially expressed miRNAs and CDAI values at one-month 
and three-months post treatment are visualized in Figure 3.20 and Figure 3.21, 
respectively. A network analysis performed on the top 100 differentially expressed 
miRNAs and HAQ-DI values at one-month and three-months post treatment are visualized 
in Figure 3.22 and Figure 3.23, respectively. A network analysis performed on the top 100 
differentially expressed miRNAs and ESR values at one-month and three-months post 
treatment are visualized in Figure 3.24 and Figure 3.25, respectively. 
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Figure 3.19 – Network analysis of top 100 differentially expressed miRNAs (red text), between responders and non-responders 
(black text), and the collectively targeted genes. All miRNA-mRNA interactions in this network, as depicted by all lines being of 
equal thickness, have an equal likelihood of occurrence. 
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Figure 3.20 - Network analysis of top 100 differentially expressed miRNAs (red text), 
relative to CDAI values at 1 month, and the collectively targeted genes (black text). A 
miRNA-mRNA interaction has a higher likelihood of occurrence when indicated by thicker 
lines in the network. 
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Figure 3.21 - Network analysis of top 100 differentially expressed miRNAs (red text), 
relative to CDAI values at 3 months, and the collectively targeted genes (black text). A 
miRNA-mRNA interaction has a higher likelihood of occurrence when indicated by thicker 
lines in the network. 
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Figure 3.22 - Network analysis of top 100 differentially expressed miRNAs (red text), 
relative to HAQ-DI values at 1 month, and the collectively targeted genes (black text). All 
miRNA-mRNA interactions in this network, as depicted by all lines being of equal 
thickness, have an equal likelihood of occurrence. A miRNA-mRNA interaction has a 
higher likelihood of occurrence when indicated by thicker lines in the network. 
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Figure 3.23 - Network analysis of top 100 differentially expressed miRNAs (red text), 
relative to HAQ-DI values at 3 months, and the collectively targeted genes (black text).  A 
miRNA-mRNA interaction has a higher likelihood of occurrence when indicated by thicker 
lines in the network. 
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Figure 3.24 - Network analysis of top 100 differentially expressed miRNAs (red text), 
relative to ESR values at 1 month, and the collectively targeted genes (black text). A 
miRNA-mRNA interaction has a higher likelihood of occurrence when indicated by thicker 
lines in the network. 
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Figure 3.25 - Network analysis of top 100 differentially expressed miRNAs (red text), 
relative to ESR values at 3 months, and the collectively targeted genes (black text). A 
miRNA-mRNA interaction has a higher likelihood of occurrence when indicated by thicker 
lines in the network. 
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 In silico Functional Analysis of Top Differentially Expressed 
miRNAs and Top Mutually Targeted Genes  
 The in silico functional analysis was performed with the top 100 differentially 
expressed miRNAs between responders and non-responders and the results are visualized 
in Figure 3.26. Within this in silico functional analysis three main functional modules were 
identified: a) skeletal muscle satellite cell maintenance involved in skeletal muscle 
regeneration, b) purine nucleoside biosynthetic process, and c) cytoplasmic mRNA 
processing body assembly.  
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Figure 3.26 – An example of an in silico functional enrichment analysis of genes collectively targeted by the top differentially 
expressed miRNAs in responders.  
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CHAPTER 4 
4 DISCUSSION 
 The optimization for circulating miRNA library preparations was first performed 
during this project in order to process patient samples effectively. After an optimal library 
preparation protocol was established, chip loading capacity was tested to create a reference 
for multiplexing patient samples efficiently. A cohort of PsA patients was treated with 
biologic agents and their blood samples were drawn pre-treatment, one-month post 
treatment, and three-month post treatment. The PGx patient samples were run on the Ion 
Torrent System and the resultant sequencing data underwent numerous analyses. 
Differential miRNA expression analyses were performed both between ACR50 response 
groupings and on clinical datasets. A comprehensive literature review was conducted on 
the identified differentially expressed miRNAs for potential implications in treatment 
response or disease pathogenesis. Subsequently, pathway and network analyses were 
performed on these results, which examined the miRNA profiles for associated signalling 
cascades and collectively targeted genes. Finally, an in silico functional analysis was 
performed using differentially expressed miRNA datasets generated between ACR50 
response groupings to determine biological functions associated with the identified 
miRNA-mRNA network.   
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 Optimization of Circulating miRNA Library Preparations  
 As stated in the introduction, the first objective of this project was to develop and 
optimize a procedure for preparing successful circulating miRNA libraries for sequencing 
using Ion Torrent Technology. With respect to miRNA sequencing using NGS technology, 
there are a number of quality measures that need to be met during library preparation and 
sequencing to ensure high-quality, accurate results (Table 3.1).  
 Thermo Fisher Protocol Modifications 
 It was quite evident that the TF protocol failed to meet the minimum criteria with 
respect to quality of the miRNA library preparation and downstream miRNA sequencing. 
In the electropherogram of TF-Sample 1, there was an excessive adaptor dimer peak at 85 
bps, indicating heightened background noise, and there was an insufficient sample peak 
corresponding to miRNA at 102 bps, indicating that minimal fragments fell within the 
targeted size range. The mean read length was on the lower end of the desired metric due 
to the large adaptor dimer lowering the average length of reads in the sample. The total read 
count was predictably low given the low total sample concentration. The large adaptor 
dimer was composed of reads that were ~85 bps and as such were removed during filtering, 
resulting in a low percentage of total reads that passed filtering. A moderate amount of 
reads that passed filtering did align to the reference genome (alignment involves 
determining the position of a read relative to a reference genome). Similarly, a moderate 
percentage of those aligned reads mapped to miRNAs (mapping refers to the allocating 
aligned reads to miRNA loci). This suboptimal miRNA sequencing result was expected 
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due to the insufficiently small but appropriately sized (i.e., 94-144 bps) sample peak 
corresponding to miRNA. The suboptimal results for TF-Sample 1 library quantification 
were likely due to either the excessive adaptor dimers present and/or to the insufficient size 
of the sample peak corresponding to miRNA. The large adaptor dimer seen in the 
electropherogram could have been due to adaptor input excess or an inadequately 
proportioned adaptor-primer ratio, whereas the small sample peak observed in the 
electropherogram could have been due to human error or to the modified protocol being 
flawed.  
Although the classic scientific method suggests that only one variable should be 
addressed at a time to determine why a procedure fails, the extremely low-quality results 
of the TF-prepared libraries necessitated multiple modifications to be implemented 
simultaneously. The excessive adaptor dimer present in each TF-prepared library, occupied 
unnecessary space on the chip and caused increased background noise thus reducing the 
quality of sequencing results. This was addressed by modifying both the adaptor volumes 
and adaptor-primer ratios. The insufficient sample peak corresponding to miRNA, which 
indicated that the input volume of the sample was too low or that the sample was being lost 
at during the procedure, was addressed by increasing the sample input consistently until the 
results improved.  
 After the suboptimal results of the TF-Sample 1 library, the first step was to 
optimize the input of these adaptors as well as increase the input volume of plasma. The 
majority of the metrics for molarity and sequencing quality were improved by increasing 
the input volume of plasma. Larger species of RNA in TF-Sample 2A (and 2B) also 
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contributed to the increased the total sample molarity. However, the lower-percent miRNA 
reads actually decreased as the content of the regional molarity was not miRNA species, 
but rather the shoulder of the adapter dimer that fell in the regional molarity range of 94-
104 bps on the electropheogram. The corresponding decrease in total and regional molarity 
when the adaptor and primer input was halved failed to affect percent regional molarity 
because the adapter dimer shoulder area was decreased proportionally.  
 The majority of sequencing metrics were also decreased in TF-Sample 2B when 
compared with TF-Sample 2A, which is consistent with a decreased input of adapters. 
Although the mean read length in TF-Sample 2A and 2B fell within the desired metric, it 
was towards the upper range for TF-Sample 2B likely due to larger species of RNA in the 
sample which can increase the mean read length. The total read counts for both TF-Sample 
2A and TF-Sample 2B were both much lower than the desired metric. This was likely due 
to the reads that made up the large adaptor dimer that were removed during filtering, 
resulting in a low percentage of total reads passing filtering in both samples. Consequently, 
the majority of reads had been filtered out of both samples due to size such that only a 
moderate percentage of total reads mapped to the reference genome. A moderate amount 
of the reads that passed filtering aligned to the reference genome; this was expected due to 
the small but appropriate length sample peak. The number of miRNA reads fell well below 
the desired metric, although there was double the amount of miRNA reads in TF-Sample 
2A than in TF-Sample 2B. This low number of miRNA reads resulted in a very low number 
of miRNAs detected, which was very similar in both TF-Sample 2A and TF-Sample 2B. 
These results show that decreasing the adaptor/primer input by half does not affect the 
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number of miRNAs detected but does affect the depth of coverage of those miRNA species 
(number of miRNA reads).  
 After addressing the adaptor input volume, the large adaptor dimers observed in 
the electropherogram of TF-Sample 2A and 2B could have been due to an inadequately 
proportioned adaptor-primer ratio. The small sample peak seen in the electropherogram of 
TF-Sample 2A and 2B could still have been due to human error or the modified protocol 
being flawed. After the suboptimal results of the TF-Sample 2A and 2B libraries, the 
second point of investigation was to optimize the adaptor-primer ratio. 
 The large adaptor dimer in the library of TF-Sample 3A, in addition to the 
presence of some larger species of RNA in the sample, resulted in increased total molarity. 
Given the persistent large adapter dimer still present in the library, an additional Magnetic 
Bead Cleanup Module was recommended to be performed by the FAS from TF in order to 
remove the adaptor dimer through the process of size selection. After the additional 
cleanup, the total molarity of TF-Sample 3A* had decreased by more than half, resulting 
in a substantial loss in library quality. Although the adaptor dimer peak, sample peak, and 
most of the larger species of RNA in the sample were low or removed during the additional 
clean up, all indices of molarity were also low, well below the desired thresholds. The mean 
read length fell within the upper range of the desired metric. The total read count for TF-
Sample 3A* was higher than any other sample previously processed but was still well 
below the desired metric. Consequently, this additional procedure did not have the desired 
results and was not used going forward. 
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 The total molarity of TF-Sample 3B was moderately high, the regional molarity 
was very low, and the percent regional molarity was very low. There was no visible sample 
peak within the desired range, suggesting that the sample might have been lost during 
processing. Because of this possibility, it was difficult to draw conclusions about the 
importance of barcode and primer volumes from this run. Assuming TF-Sample 3B was 
not lost in processing, the library quantification results indicate that decreasing the adaptor 
input by half (but not the primer inputs) resulted in a decrease of regional molarity by more 
than half. While the mean read length in TF-Sample 3B was in the acceptable range, the 
total read count for TF-Sample 3B was much lower than TF-Sample 3A* and was well 
below the desired metric. Because the majority of reads had been filtered out of both 
samples due to size, only a moderate percentage of total reads mapped to the reference 
genome. The number of miRNA reads fell well below the desired metric in both samples, 
with almost seven times the number of miRNA reads present in TF-Sample 3A* than in 
TF-Sample 3B. The low number of miRNA reads resulted in a low number of miRNAs 
detected. However, despite the greater number of miRNA reads in TF-Sample 3A*, the 
number of detected miRNAs was only double that of TF-Sample 3B. This demonstrated 
that, not only does TF-Sample 3A* have a larger number of detected miRNAs, but that 
there was greater coverage of these miRNAs. These results showed that decreasing the 
adaptor but not the primer or barcode inputs resulted in better sequencing quality from the 
samples; however, further improvements were required.  
 When compared with previous samples, the electropherogram profiles of TF-
Samples 3A, 3A*, and 3B did not suggest that modifying the adaptor-primer ratio increases 
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the quality of the library produced. After addressing the adaptor input volume and the 
adaptor-primer ratio, the excessive adaptor dimers and insufficiently small but 
appropriately sized (i.e., 94-144 bp) sample peak corresponding to miRNA observed in the 
electropherogram of TF-Samples 3A, 3A*, and 3B could have been due to human error or 
to the modified protocol being flawed. Consequently, the third point of investigation was 
the possibility that human error was causing these suboptimal results. 
 To investigate if the source of suboptimal library preparations and sequencing 
results was attributable to human error, a standardized sample (with known concentration) 
was used for library preparation. With respect to small RNA, an optimal library result was 
produced using the Sample SmRNACon. The electropherogram profile of this sample 
differed greatly from the previous experiments because the Sample SmRNACon did not 
undergo size-selection processes (e.g., mirVana PARIS Kit or Magnetic Bead Cleanup 
Modules) to remove larger RNA species. As a result, there was a very large sample peak, 
a smaller peak that indicated the presence of tRNA species, and another large peak that 
indicated the presence of rRNA species. Consequently, the library result was slightly below 
the desired threshold for percent regional molarity with respect to miRNA. Noteworthy, 
the Ion Adaptor v2 reagent (part of the Ion Total RNA-Seq Kit v2) was used instead of the 
‘R&D Systems Optimized’ adaptor reagent, suggesting that the previous suboptimal result 
could have been due to the adaptor reagent. This result proved that the protocol was being 
adhered to properly and that human error was not primarily responsible for the previous 
suboptimal results, and therefore this sample was not sequenced. After addressing the 
adaptor input volume, the adaptor-primer ratio, and the possible human error, the 
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previously observed suboptimal results could have been due to the modified protocol being 
flawed. After the successful results of the Sample SmRNACon library, the fourth point of 
investigation was to attempt a library preparation using a different published protocol. 
 Cheng et al. Protocol Modifications  
 The superiority of the CH protocol became evident with the library quantification 
of CH-Sample 1A. The total molarity and regional molarity were high and the percent 
regional molarity was slightly below the desired threshold. When compared with libraries 
prepared using the TF protocol, the electropherogram profile of this sample indicated that 
the CH protocol was superior and was therefore used for all library preparations from this 
point forward. The mean read length in CH-Sample 1A was longer than the desired metric, 
likely due to the presence of large RNA species. The total read counts exceed the desired 
threshold, which was expected based on the electropherogram profile. Likewise, very large 
proportion of the total read count that passed filtering and aligned to the reference genome, 
a large percentage of which mapped to known miRNAs, resulted in a miRNA read count 
that well exceeded the desired threshold. This was responsible for the detection of a large 
number of miRNAs. This sample generated optimal results in both library quantification 
and sequencing quality.    
 Despite the library preparation of CH-Sample 1A being successful, a small 
adaptor dimer was present as well as larger species of RNAs. To further refine the quality 
of libraries prepared, additional on-magnet incubation times were used in an attempt to 
remove the larger species of RNA. The total and regional molarity of CH-Sample 1B were 
very high and the percent regional molarity increased slightly compared with CH-Sample 
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1A and was marginally below the desired threshold. Although the peak for the adaptor 
dimer was increased compared with CH-Sample 1A, this was expected due to the overall 
higher library concentration. In contrast to CH-Sample 1A, the result with CH-Sample 1B 
indicated that the additional on-magnet wait times reduced the amount of large RNA 
species present and increased the sample concentration by ensuring that all fragments were 
bound and released from the magnetic beads at the right times. Therefore, additional on-
magnet incubation times were used going forward. The mean read length in CH-Sample 
1B was on the upper range of the desired metric but did not exceed its upper limit because 
the larger RNA species had been size selected out through increased on-magnet incubation 
times. The total read counts exceed the desired threshold which was expected based on the 
electropherogram profile. Likewise, a very large proportion of the total read count passed 
filtering and aligned to the reference genome – a large percentage of which mapped to 
known miRNAs and had a miRNA read count that well exceeded the desired threshold. 
This was responsible for the detection of a large number of miRNAs. This sample generated 
optimal results in both library quantification and sequencing quality. 
 
 Preparing for Optimal Sequencing   
 Chip Loading Properties  
 With regards to RNA-Seq, the P1 chip can be loaded with 60-80 million cDNA 
transcripts. When the number of samples loaded on the P1 chip is increased, the number of 
possible reads loaded from each sample is decreased. This is to say that the more samples 
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loaded the less information will be available from each of those samples. Each sample was 
loaded onto the chip at a molarity anticipated by the total number of samples loaded on that 
same chip. One variable that is affected by multiplexing/differential chip loading is average 
read depth, with the average read depth of each sample loaded onto a chip decreasing with 
a higher number of samples per chip or with an increase in the molarity of each sample. 
(Campbell et al., 2015) In general, the higher the proportion of T+ISPs in a sample, the 
higher the quality of sequencing results produced. Inter-run variability in the proportion of 
T+ISPs in a sample is expected and is removed during normalization. 
Because of the variability between the chip loading capacity and the quality of 
sequencing results generated, the chip loading capacity for the RNA-Seq samples was 
evaluated before the PGx samples were loaded for sequencing. The purpose of this 
evaluation was to ensure that three time points (i.e., pre-treatment, post-treatment one 
month, and post-treatment three months) from the same individual could be loaded on to 
the same chip to eliminate inter-run variability (see Future Directions – Section 4.8). In the 
context of this project, the pre-treatment samples were loaded and sequenced at similar 
molarities to the chips that will be loaded with three time points in the broader project.  
 Sequencing Quality of Samples under Different Loading 
Conditions 
 Samples loaded under different conditions (different molarities and multiplexing 
with different number of samples) produced sequencing results that varied in quality. Two 
metrics, miRNA reads and miRNAs detected, were used to assess sequencing quality and 
a noticeable trend appeared whereby all of the samples assessed generated the highest 
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sequencing quality under two sequencing conditions (i.e., 7@8pM and 6@6pM) (Table 
4.1). 
 
Table 4.1 – Trend in library concentration and chip loading capacity. 
4.2.2.1 Samples that Sequenced Best at 7@8pM 
 Three of the tested samples, CH-Sample 1B, CH-Sample 3A, and CH-Sample 3B, 
produced the best sequencing quality under the 7@8pM run condition. When the samples 
were sequenced with either 6@8pM or 6@6pM there was a midrange number of miRNA 
reads and a midrange number of miRNAs detected. This indicates that the differential 
molarities of these samples did not affect the number of miRNA reads or number of 
miRNAs detected. When sequenced with 9@6pM, the samples had the lowest number of 
miRNA reads and lowest number of miRNAs detected. This was the least informative 
sequencing run for these samples, demonstrating that increasing the number of samples to 
9 per chip at 6pM considerably decreased the quality of sequencing results. Increasing the 
number of samples to 7 per chip at 8pM increased the quality of sequencing results. On the 
periphery, this finding is somewhat in contrast with next generation sequencing (exome or 
targeted panels) trends. However, the relatively low number of reads that comprise a 
Sample number Best Chip Run 
CH-Sample 1B 7@8pM 
CH-Sample 2A 6@6pM 
CH-Sample 2B 6@6pM 
CH-Sample 3A 7@8pM 
CH-Sample 3B 7@8pM 
CH-Sample 4 6@6pM 
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miRNA library (compared with exome sequencing) combined with the 6@8pM run not 
saturating the capacity of the P1 chip, allowed for the higher multiplexing capacity 
achieved with the 7@8pM run. In contrast, when the samples were sequenced with 
7@8pM, they had the highest number of miRNA reads and miRNAs detected of all the 
sequencing runs performed. The 7@8pM sequencing run was the most informative for 
these samples, enabling quality differential expression analyses, miRNA variant detection, 
and novel miRNA discovery.  
4.2.2.2 Samples that Sequenced Best at 6@6pM 
 Three of the tested samples, CH-Sample 2A, CH-Sample 2B, and CH-Sample 4, 
produced the best sequencing quality under the 6@6pM run condition. When the samples 
were sequenced with either 6@8pM or 7@8pM there was a midrange number of miRNA 
reads and a midrange number of miRNAs detected. This indicates that for these samples 
the number of samples loaded onto the chip at 8pM did not affect the number of miRNA 
reads or number of miRNAs detected. When sequenced with 9@6pM, the samples had the 
lowest number of miRNA reads and lowest number of miRNAs detected. This was the least 
informative sequencing run for these samples, demonstrating that increasing the number of 
samples to 9 per chip at 6pM considerably decreased the quality of sequencing results. 
Decreasing the number of samples to 6 per chip at 6pM increased the quality of sequencing 
results, suggests that decreasing the number of samples increases the number of sequenced 
reads and miRNA detected. The 6@6pM sequencing run was the most informative for these 
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samples, enabling quality differential expression analyses, miRNA variant detection, and 
novel miRNA discovery.  
4.2.2.3 Trend Between Library Quality and Chip Loading Conditions 
 The dichotomous trend in sequencing results under differential loading conditions 
could be explained by the composition of the sample libraries.  CH-Sample 1B, CH-Sample 
3A, and CH-Sample 3B all had the best sequencing quality results when a moderate number 
of samples per chip were loaded at an increased molarity (7@8pM). The electropherograms 
of the sample libraries that sequenced best at 7@8pM all displayed a very large peak 
between 105-117 bps and had minimal adapter dimers and minimal large RNA species 
present, indicating quality library preparation. These results indicate that if the prepared 
library is of good quality then chip loading conditions should be 7@8pM. In contrast, CH-
Sample 2A, CH-Sample 2B, and CH-Sample 4 all had the best sequencing quality results 
when there was a lower number of samples per chip at a decreased molarity (6@6pM). The 
electropherograms of the sample libraries that sequence best at 6@6pM all displayed 
adaptor dimers that were proportional in concentrations to the sample libraries. These 
results indicate that if adapter dimers are present, especially those that are of proportional 
concentration to the sample, then chip loading conditions should be 6@6pM.  
 
 Clinical Information and Response Grouping 
 While optimization for library preparation and chip loading capacities was 
underway, clinical assessment and blood sampling of PsA patients was underway. Blood 
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was drawn from PsA patients before they began treatment with biologic agents, one month 
after treatment began, and three-months after treatment began. The pre-treatment sample 
was used to establish a baseline miRNA profile. This baseline profile would then be 
compared to miRNA profile after one- and three-months of treatment. This approach would 
allow for an intra-individual differential miRNA expression analysis which is much more 
informative than inter-individual comparisons. The method of drawing blood pre-treatment 
was performed consistently across patients other than Patient 13. Patient 13 blood was 
drawn one week after the biologic had been administered. This was due to unforeseen 
clinical circumstances, as patient self-injected prior to having their blood drawn. Due to the 
exploratory nature of this project, Patient 13 was included as a baseline sample to increase 
the cohort size and subsequent data set. However, this is not a true baseline sample, as 
miRNA expression profiles would likely change one week after treatment began, and 
therefore Patient 13 will not be included in the analyses of the broader project.  
 PsA patients were either prescribed secukinumab (an IL-17 inhibitor) or 
ustekinumab (an IL-12/23 inhibitor). These treatment groups were collectively examined 
because of similar molecular and clinical results. Molecularly, the pharmaceuticals both 
target the same effector molecule, where secukinumab acts directly by inhibiting the IL-17 
pathway and ustekinumab acts indirectly by inhibiting the IL-17 pathway. Clinically, there 
are very subtle differences in ACR50 response rates between these pharmaceuticals, with 
ustekinumab having a slightly higher incidence of mucocutaneous infections that are seen 
less commonly with secukinumab. These pharmaceuticals are often collectively examined 
and compared to treatment response to TNFα inhibitors, which targets a separate signalling 
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pathway and has a very different response profile to IL-12/23 or IL-17 inhibitors. An 
eventual goal of the broader PGx project is to better understand when to prescribe TNFα 
pathway inhibitors versus IL-17 pathway inhibitors (see Future Directions – Section 4.8). 
This project was focused on examining the IL-17 axis, which is inhibited by IL-17A and 
IL-12/23; TNFα inhibitors could be compared at a later date. It was with this rationale that 
patients treated with ustekinumab and secukinumab were grouped together for analyses. 
 The assessments performed to determine response status included the ACR50 
(primary endpoint) and CDAI as global measurements of disease activity, disability as 
measured by HAQ-DI, and acute phase reactants as measured by ESR. The results of these 
assessments were collectively examined to determine each patient’s response status. 
ACR50 and CDAI are very similar indicators of disease progression or clinical response. 
These two criteria normally result in the same response groupings. CDAI differs from 
ACR50 in that is does not require an acute phase reactant and is therefore more easily used 
in clinic. Because acute phase reactant results were available, the ACR50 was used to assess 
treatment response in the PGx cohort. Under these parameters, just under one half of the 
PsA patients who were included in this study met the ACR50 response criteria. 
 
 Data Analyses 
 The FASTQC software was originally developed for Illumina sequencing results 
and therefore is not optimized to analyze Ion Torrent data. The comprehensive miRNA 
analysis pipeline, developed by the Rahman-O’Rielly bioinformatician, was more tailored 
for Ion Torrent data analysis and therefore produced different values for the sequencing 
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summary (Table 3.18 vs. Table 3.22). The raw data from the Ion Torrent System used for 
the comprehensive miRNA analyses generated different results because of the differential 
pipeline parameters such as datasets and cut-offs used. Read-depth filtering was set at 5x 
coverage for known miRNAs as this coverage level is standard in the field. (Conesa et al., 
2016) These analyses were performed using a relatively small dataset, (n=9) therefore 
attaining suggestive significance, and to a greater extent statistical significance, for the 
identified associations was difficult. As the cohort size increases or other datasets 
contribute to the analyses, a greater number of significant findings are more probable (see 
Future Directions – Section 4.8).  
 miRNA Variant and Novel miRNAs Analyses 
 miRNA variant analyses are used to determine associations between variants 
within the precursor or mature miRNAs and clinical phenotypes. Variants in precursor 
miRNAs can affect the binding affinity of the RISC complex thereby influencing the 
mRNA-inhibition capacity of that miRNA. Variants in the mature miRNA can affect 
miRNA-mRNA binding which could influence the expression level of that mRNA 
transcript. To investigate these findings further predictive binding analyses would have to 
be performed by incorporating the miRNA variant into the algorithm. miRNA variant 
analyses were performed as part of the comprehensive analysis; however, they were not 
investigated fully given they were not the main focus of this project.  
  Novel miRNA analyses are discovery-based and are used to identify unannotated 
miRNAs that could be responsible for a clinical phenotype. Identification of novel miRNAs 
is one of the strengths of using NGS technologies when investigating miRNAs. Other 
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miRNA investigation techniques, such as qPCR or microarrays, are targeted approaches 
and therefore only examine the targeted transcripts. To investigate these findings further, 
predictive binding analyses of the novel transcript would have to be performed. Novel 
miRNA analyses were performed as part of the comprehensive analysis; however, they 
were not investigated fully given they were not the main focus of this project. 
 Differential miRNA Expression Analyses 
Normalization is a technique used to remove potential biases that are produced by 
technical differences that occur during sample processing (Gonzalez, 2014). These 
technical differences can occur at various stages during sample processing: differential 
concentrations of prepared libraries, differential proportion of libraries that are miRNA 
reads, differential molarities and/or number of libraries loaded into the OneTouch, 
differential percentages of template positive ISPs loaded onto the P1 chip, and differential 
number of reads in samples loaded onto the P1 chip – all of which can impact the total 
number of aligned reads. The pharmacogenomics dataset was normalized using edgeR 
software. Because read counts are considered proportional to miRNA expression, inter-
sample normalization is required. In order to normalize the data, an appropriate baseline 
must be established and the read counts for each sample must be measured relative to this 
baseline (Gonzalez, 2014). Normalization of read counts was done using edgeR software 
for more accurate differential expression analyses.  
There are some limitations associated with normalization. These limitations pertain 
to miRNAs that are unique to a sample or to miRNAs that are highly expressed in a sample 
contributing to a decrease in available space for remaining miRNAs (Gonzalez, 2014). If 
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the data does not undergo normalization, then sampling limitations such as this can 
compromise the integrity of miRNA differential expression analyses (Gonzalez, 2014).   
 Once normalized, read depths across the same sample (which is sequenced under 
different multiplexing conditions) should result in the same level of coverage of a miRNA. 
If normalization is executed correctly, the within-replicate correlation will be very high. 
Standards for depth of coverage differ depending on the chip loading conditions. For the 
purpose of this project, the read-depth cut off was set at 5x coverage. Coverage for miRNA-
Seq investigations can range from 5-20 distinct mapping per genome. Because this project 
was exploratory in nature, a low depth of coverage was applied during filtering to increase 
the size of available datasets (Conesa et al., 2016).  
4.4.2.1 Differential miRNA Expression Analyses of ACR50 Response Groupings 
 Identifying differential miRNA expression and its associations with treatment 
response in a PsA cohort was used to explore the capabilities of the comprehensive miRNA 
analyses pipeline. Differential expression is often measure by an intra-individual 
comparison between two time points; however, for the purpose of this study the expression 
level of a particular miRNA in a responder was compared to the mean expression level of 
that miRNA in the non-responder group. 
 Seven differentially expressed miRNA were associated with response groupings; 
however, this association was lost after correcting for multiple testing. The limited 
associations found were in keeping with the poor clustering results observed on the MDS 
plot. The published literature on the differentially expressed miRNAs identified between 
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ACR50 responders and non-responders pertaining to drug response or related disease 
pathogenesis are provided in Table 4.2 and Table 4.3, respectively. Of the seven 
differentially expressed miRNA, only miR-150-5p has been reported to be involved in 
response to biologics in patients with PS (TNFα–inhibitors). miR-96-5p has been 
investigated for possible involvement in differential response to other monoclonal 
antibodies. Increased expression of miR-150-5p was found to be associated with the 
pathogenesis of myasthenia gravis, autoimmune pancreatitis, and other autoimmune 
diseases.  
 Because no significance was found after correcting for multiple testing, the top 
100 differentially expressed miRNAs were prioritized for investigations into collectively 
targeted genes. No functional annotation was performed on the 24 collectively targeted 
genes; this was because the top 100 differentially expressed miRNAs (and corresponding 
targeted genes) were analyzed using pathway enrichment and network analyses to better 
define biological function.  
 156 
 
Table 4.2 – The published literature related to drug response in identified differentially expressed miRNAs between ACR50 
response groupings and in clinical datasets. 
Mature 
miRNA ID Clinical Dataset(s) 
Publications Related Differential miRNA Expression leading to Differential Drug Response 
Differential 
Expression
Related Disease 
or Model Used Treatment Response Reference 
miR-106a-3p Responders vs. Non-responders N/A N/A N/A N/A 
miR-96-5p Responders vs. Non-responders Decrease CRC cell lines response to cetuximab and panitumumab (Ress et al., 2015) 
miR-296-5p Responders vs. Non-responders 
Increase 
early stage 
laryngeal 
carcinoma 
resistance to radiotherapy (Maia et al., 2015) 
Decrease general carcinogenesis 
resistance to ionizing radiation (IR), alkylating 
agents, anthracyclines, and platinum-containing 
compounds 
(van Jaarsveld et al., 
2014) 
miR-3194-5p Responders vs. Non-responders N/A N/A N/A N/A 
miR-150-5p 
Responders vs. Non-
responders, CDAI 1 
month, HAQ-DI 3 months
Increase PS Response to TNFα inhibitors (Torri et al., 2017) 
Decrease non-small cell lung cancer respond well to radiation (Menon et al., 2016) 
Decrease murine model adverse reaction to radiation (Dinh et al., 2016) 
miR-183-5p Responders vs. Non-responders Increase 
triple-negative 
breast cancer 
sensitivity to anthracyclines or taxanes-based 
adjuvant chemotherapy (Ouyang et al., 2014) 
 
 
miR-193a-5p 
 
 
 
Responders vs. Non-
responders 
Increase 
Human and 
murine squamous 
cell carcinoma cell 
lines 
Treatment with cisplatin (Ory et al., 2011) 
Decrease Wilms' tumor blastema 
resistance to neoadjuvant chemotherapy followed 
by nephrectomy (Watson et al., 2013) 
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Mature 
miRNA ID Clinical Dataset(s) 
Publications Related Differential miRNA Expression leading to Differential Drug Response 
Differential 
Expression
Related Disease 
or Model Used Treatment Response Reference 
 
 
miR-193a-5p 
Increase osteosarcoma response to ifosfamide (Gougelet et al., 2011) 
Decrease ovarian cancer response to decitabine followed by carboplatin (Benson, Skaar, Liu, Nephew, & Matei, 2015)
Decrease bladder cancer cells lines cisplatin sensitivity (J. Zhou et al., 2016) 
miR-124-3p 
CDAI 1 month, HAQ-DI 
month, HAQ-DI 3 months, 
ESR 3 months 
Decrease Crohn’s Disease response to exclusive enteral nutrition therapy (Guo et al., 2016) 
Decrease Type 2 Diabetes post-gastric bypass surgery (Zhu, Yin, Li, & Mao, 2017) 
miR-1275 CDAI 1 month, HAQ-DI 3 months Increase 
endothelial cells 
lines post-curcumin treatment 
(Bai, Wang, Sun, Zhang, 
& Dong, 2016) 
miR-582-5p 
CDAI 1 month, CDAI 3 
months, HAQ-DI 1 month, 
HAQ-DI 3 months 
Decrease Chronic morphine or heroin users opioid-induced immunosuppression (Long et al., 2016) 
miR-31-5p CDAI 1 month, HAQ-DI 3 months 
Increase colorectal cancer shorter progression-free survival after treament with anti-EGFR therapeutics (Igarashi et al., 2015) 
Increase colorectal cancer progression-free survival after treatment with cetuximab (Kiss et al., 2016) 
Increase metastatic CRC response to cetuximab (Mlcochova et al., 2015)
Decrease human colonic epithelial cells Protected against radiation induced apoptosis 
(Kim, Zhang, Barron, & 
Shay, 2014) 
Decrease human keratinocytes response to protein kinase C inhibitors (Liu et al., 2017) 
miR-27a-5p HAQ-DI 3 months N/A N/A N/A N/A 
miR-4433b-
3p HAQ-DI 3 months N/A N/A N/A N/A 
miR-146a-3p ESR 3 months N/A N/A N/A N/A 
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Table 4.3 - The published literature pertaining to related disease pathogenesis in identified differentially expressed miRNAs 
identified between ACR50 response groupings and in clinical datasets. 
Mature 
miRNA ID 
Clinical 
Dataset(s) 
Publications Related to Differential miRNA Expression leading to Related Disease 
Pathogenesis 
Differential Expression Related Disease Reference 
miR-106a-3p Responders vs. Non-responders N/A N/A N/A 
miR-96-5p Responders vs. Non-responders N/A N/A N/A 
miR-296-5p Responders vs. Non-responders Decrease Asthma (Davis et al., 2017) 
miR-3194-5p Responders vs. Non-responders N/A N/A N/A 
miR-150-5p 
Responders vs. 
Non-responders, 
CDAI 1 month, 
HAQ-DI 3 
months 
Increased Myasthenia Gravis 
(Punga, Andersson, 
Alimohammadi, & Punga, 
2015) 
Increased Myasthenia Gravis (Punga et al., 2014) 
Increase Autoimmune Pancreatitis 
(Hamada, Masamune, 
Kanno, & Shimosegawa, 
2015) 
Decrease primary Sjögren's syndrome (Chen et al., 2017) 
Decrease type 1 diabetes mellitus 
(Assmann, Recamonde-
Mendoza, De Souza, & 
Crispim, 2017) 
miR-183-5p Responders vs. Non-responders 
 
Decrease Anterior Uveitis in Rat Model 
(Hsu, Chang, Lin, & Yang, 
2015) 
Increase 
Reduces Osteogenic 
Differentiation in Bone Marrow 
Stromal (Stem) Cells 
(Davis et al., 2017) 
miR-193a-5p Responders vs. Non-responders N/A N/A N/A 
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Mature 
miRNA ID 
Clinical 
Dataset(s) 
Publications Related to Differential miRNA Expression leading to Related Disease 
Pathogenesis 
Differential Expression Related Disease Reference 
miR-124-3p 
CDAI 1 month, 
HAQ-DI month, 
HAQ-DI 3 
months, ESR 3 
months 
N/A N/A N/A 
miR-1275 
CDAI 1 month, 
HAQ-DI 3 
months 
Decrease type 1 diabetes mellitus (Assmann et al., 2017) 
Increase immune thrombocytopenic purpura (Zuo et al., 2017) 
miR-582-5p 
CDAI 1 month, 
CDAI 3 months, 
HAQ-DI 1 
month, HAQ-DI 
3 months 
N/A N/A N/A 
miR-31-5p 
CDAI 1 month, 
HAQ-DI 3 
months 
Increase hypertrophic scar formation (Wang et al., 2017) 
Decrease cemento-ossifying fibroma (in silico prediction) (Pereira et al., 2017) 
Decrease Celiac Disease (Magni et al., 2014) 
Increase Crohn’s Disease (Peck et al., 2015) 
Decrease Celiac Disease (Vaira et al., 2014) 
Decrease Celiac Disease (Buoli Comani et al., 2015) 
Increase In Keloid Fibroblasts (Li et al., 2013) 
Decrease In osteoarthritic cartilage-derived mesenchymal stem cell (Xia et al., 2016) 
miR-27a-5p HAQ-DI 3 months N/A N/A N/A 
miR-4433b-
3p 
HAQ-DI 3 
months N/A N/A N/A 
miR-146a-3p ESR 3 months N/A N/A N/A 
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4.4.2.2 Differential miRNA Expression Analyses Incorporating Clinical Data 
When the associations between differential expression of miRNAs and ACR50 
response groupings were deemed insignificant, they did not qualify for further analysis. 
Instead the clinical datasets were investigated for clinical contributions that could be 
affecting differential expression. For example, the ESR is known to lower as PsA symptoms 
subside; a lower ESR may be associated with differential expression of a miRNA that may 
be implicated in inflammation.  
This method of data analysis was slightly more informative than the differential 
response grouping analysis, with some miRNAs approaching significance. The published 
literature on the differentially expressed miRNAs identified in clinical datasets that pertain 
to drug response or related disease pathogenesis are provided in Table 4.2 and Table 4.3. 
miR-31-5p was found to be correlated with involvement in differential response to other 
monoclonal antibodies; this is in keeping with improved CDAI at one month and HAQ-DI 
at three months. miR-31-5p has also been investigated in other autimmune diseases such as 
celiac and Crohn’s disease. Increased expression of miR-150-5p was found to be associated 
with the pathogenesis of myasthenia gravis, a chronic autoimmune disease involving 
dysregulation of T-cell differentiation. Upregulation of miR-31-5p was seen in fibrocytes 
during hypertrophic scar formation, showing a possible association to dermatological 
issues. 
 The published literature on the differentially expressed miRNAs associated with 
HAQ-DI values at one-month and three-months post treatment is displayed in Table 4.2 
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and Table 4.3. Similar results of differential miRNA expression were seen between CDAI 
and HAQ-DI over time. Associations to miR-150-5p, and miR-31-5p were found; these 
miRNAs are known to be implicated in the development of autoimmune diseases or 
response to treatment with monoclonal antibodies, as mentioned above.  
 No differentially expressed miRNAs reached suggestive significance for the ESR 
values at one-month post treatment. The published literature on the differentially expressed 
miRNAs associated with ESR values at three-months post treatment is displayed in Table 
4.2 and Table 4.3.  As in CDAI and HAQ-DI, differential expression of miR-124-3p was 
found in the development and treatment of Crohn’s disease, with a decrease in expression 
as symptoms subsided. 
4.4.2.3 Pathway Analysis Using Top 100 Differentially Expressed miRNAs  
 The pathway analysis was performed on the top 100 differentially expressed 
miRNAs to identify pathways that might be implicated in treatment response. 
Proteoglycans in Cancer was the pathway with the strongest association to the differentially 
expressed miRNAs identified between ACR50 response groupings and the differentially 
expressed miRNAs that was identified relative to CDAI values at one- and three-months 
post treatment. These proteoglycans are known to contribute to cancer development by 
affecting proliferation, adhesion, angiogenesis, and metastasis. Morphine Addiction was 
the pathway with the strongest association with differentially expressed miRNA relative to 
the HAQ-DI values at one-month post treatment. This pathway influences neuronal 
function, inter-neuronal communication, and the brain-reward circuit. TGF-beta Signalling 
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Pathways was the pathway with the strongest association to the differentially expressed 
miRNAs relative to HAQ-DI values at three-month post treatment and ESR values at one-
month post treatment. The TGF-beta protein family includes activins and bone 
morphogenetic protein (BMPs), which are both highly conserved cytokines. Axon 
Guidance is the pathway with the strongest association to the differentially expressed 
miRNAs relative to ESR values at three-months post treatment. The Axon Guidance 
pathway is critical for the development of the neuronal network. 
 The identified pathways associated with ACR50 response groupings and with 
clinical datasets did not suggest a biological consequence of the differentially expressed 
miRNAs. This lack of potential causative factors is likely to do with the increased amount 
of data generated from research in other fields, such as cancer, when compared to research 
into autoimmune disorders. These results are minimally informative due to the lack of 
significance in the data used for the analyses and due to the bias of accessible information 
in the disease category that is being investigated.   
4.4.2.4 miRNA-mRNA Network Analyses and an in silico Functional Analysis of Top 
100 Differentially Expressed miRNAs  
 The network analysis generated as a visualization of the miRNA-mRNA 
interactions contains ten collectively targeted mRNAs by 26 of the top 100 differentially 
expressed miRNAs between ACR50 responders and non-responders. Of the ten 
collectively targeted genes, CNOT6L, EZH2, NME7, ERGIC2, and PTHLH are amongst 
the most frequently targeted. All miRNA-mRNA interactions in this network, as depicted 
by all lines being of equal thickness, have an equal likelihood of occurrence. miRNAs not 
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included in the visualization did not have a predictive binding score of >0.3 for any of the 
ten collectively targeted genes.  
 The network analysis of the differentially expressed miRNAs relative to the CDAI 
values at one-month post treatment showed ten collectively targeted genes and 25 miRNAs. 
Of the ten collectively targeted genes, CNOT6L, BTG3, PTHLH, SPRY1, ERGIC2, and RB1 
are amongst the most frequently targeted. Not only are these the genes most likely to be 
targeted, the target prediction of these genes has a higher likelihood of occurrence indicated 
by the thicker lines on the network. The network analysis of the differentially expressed 
miRNAs relative to the CDAI values at three-months post treatment showed ten 
collectively targeted genes and 23 miRNAs. Of the ten collectively targeted genes, EPC2, 
TRAPPC8, ERGIC2, IRX5, and SPRY1 are amongst the most frequently targeted. The target 
prediction of these genes has a higher likelihood of occurrence indicated by the thicker 
lines in the network. 
 The network analysis of the differentially expressed miRNAs relative to the HAQ-
DI values at one-month post treatment showed ten collectively targeted genes and 20 
miRNAs. Of the ten collectively targeted genes, BTG3, ERGIC2, PTHLH, HSP90B1, and 
ANKHD1 are amongst the most frequently targeted. All miRNA-mRNA interactions in this 
network, as depicted by all lines being of equal thickness, have an equal likelihood of 
occurrence. The network analysis of the differentially expressed miRNAs relative to the 
HAQ-DI values at three-months post treatment showed ten collectively targeted genes and 
15 miRNAs. Of the ten collectively targeted genes, RB1, SPRY1, ERGIC2, TAF4B, and 
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CNOT6L are amongst the most frequently targeted. The target prediction of these genes has 
a higher likelihood of occurrence indicated by the thicker lines in the network. 
 The network analysis of the differentially expressed miRNAs relative to the ESR 
values at one-month post treatment showed ten collectively targeted genes and 20 miRNAs. 
Of the ten collectively targeted genes, PTHLH, BTG3, CNOT6L, and RB1 are amongst the 
most frequently targeted. The target prediction of these genes has a higher likelihood of 
occurrence indicated by the thicker lines in the network. The network analysis of the 
differentially expressed miRNAs relative to the ESR values at three-months post treatment 
showed ten collectively targeted genes and 22 miRNAs. Of the ten collectively targeted 
genes BTG3, ERGIC2, CNOT6L, and PTHLH are amongst the most frequently targeted. 
The target prediction of these genes has a higher likelihood of occurrence indicated by the 
thicker lines in the network. 
 These networks were generated as a preliminary analysis and were exploratory in 
nature. Genes common to multiple network analyses such as CNOT6L, ERGIC2, BTG3, 
and PTHLH would be investigated further if increased significance was found. As the 
cohort size of the PsA patients treated with IL-12/23 and IL-17 inhibitors increases, and 
the TNFα cohort (see Future Directions – Section 4.8) is included in these analyses, the 
networks will provide more accurate and informative predictive binding results.   
 An in silico functional enrichment analysis was done on the top 100 differentially 
expressed miRNAs between ACR50 responders and non-responders and the collectively 
targeted genes to examine biological function associated with the miRNA-mRNA 
interaction. At present, there appears to be no clear link between the three main functional 
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modules (skeletal muscle satellite cell maintenance involved in skeletal muscle 
regeneration, purine nucleoside biosynthetic process, and cytoplasmic mRNA processing 
body assembly) from miRNA studies and known pathogenesis of PsA or 
secukinumab/ustekinumab treatment. Increases in sample size and independent validation 
is required before the significance of these findings can be determined.  
 In the case of this exploratory project, some figures generated by software (such 
as Cytoscape) are difficult to read because of the larger number of data points and the lack 
of significant findings. As shown in Figure 3.26, the software depicted all possible 
interactions. In the broader project, which will have a larger dataset and the possibility of 
significant findings, these diagrams will become more refined and legible.  
 
 Clinical Relevance 
 Precision medicine is important in terms of the patient; at the moment, precision 
medicine is largely conducted on a trial-and-error basis, which is neither the safest nor the 
most cost-effective approach. Precision medicine initiatives are currently underway for 
diagnostic markers, prognostic markers, and predictive markers for response to treatment. 
With regards to response to treatment, the field of pharmacogenomics is currently oriented 
towards predicting response or non-response but also predicting the development of 
adverse events. Predicting response is of the greatest value for patients who do not respond 
to treatment as their disease progression would otherwise continue while the cost of 
treatment would constitute a large financial burden ($20,000 to $30,000 per year).  
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 Pharmacogenomics of PsA is focused primarily on treatment with TNFα 
inhibitors, which are a more traditionally used biologic, and on IL-17 pathway inhibitors, 
which are a newer type of biologic. Currently, clinicians have limited evidence as to which 
type of biologic to prescribe. This project, as well as the associated broader project, will 
help to indicate which patients should be prescribed which biologic. To determine which 
biologic is most appropriate, different pharmacogenomics approaches could be used 
including DNA profiles, epigenetics profiles, and RNA profiles. RNA profiles allow for 
the investigation of mRNAs, intracellular miRNAs, and circulating miRNAs. The most 
clinically relevant profile, without resorting to a tissue biopsy, would be circulating 
miRNAs as it lends insight to the inter-cellular communication occurring in the disease 
tissue.  
 Circulating miRNA pharmacogenomic profiling (as with all RNA 
pharmacogenomics profiling) is of particular clinical utility when a predictive marker is 
available at baseline, which may suggest an efficacious course of treatment for a patient. 
Intra-individual comparison of miRNA profiles can also be of clinical utility as they 
indicate up- and down-regulation of miRNAs, which could lend insight into the mechanism 
of action of the drug or the pathogenesis of disease.  
 The results generated from this project at this time are not clinically actionable. 
Given the sample size this is exploratory data for hypothesis genetration and must still be 
validated. This project’s aim was to develop and optimize a framework of assays and 
analyses that can be used to identify associations that may be clinically relevant once the 
cohort size is large enough to reach significance. The goal of the broader project is to 
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increase the patient cohort being prescribed IL-17 pathway inhibitors to 20 and to match 
that cohort with 20 patients being prescribed TNFα inhibitors. With an increased sample 
intake and dataset size, a multi time point comparison of response profiling between 
patients prescribed IL-17 pathway inhibitors and patients prescribed TNFα inhibitors will 
be performed. Findings from this investigation will then be validated by an independent 
cohort and prospectively tested in clinic to determine the relevance. Clinically predicting 
response to biologics in PsA patients would improve the current response rate (50% to 60% 
reaching ACR20 score). If a clinically relevant predictive marker or profile is found, 
response rates would ideally increase in a subset of patients, as 40% of non-responders will 
be removed.   
 
 Limitations 
 Although circulating miRNA profiles show great promise as a non-invasive 
biomarker for diagnosis, prognosis, and prediction of drug response, there are still some 
limitations to this type of investigation. Examining circulating miRNA profiles from 
plasma may not accurately represent was is occurring at the level of the involved tissue. 
This limitation can be addressed by increasing the cohort size or by the addition of other 
“–omics” datasets thereby increasing the likelihood of identifying accurate markers.  
Furthermore, future studies assessing the correlation between intracellar miRNA from 
serial synovial biopsies and circulating miRNA may also add further weight to the validity 
of assessing circulating miRNA as potential biomarkers.  
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 During the optimization portion of this project, limiting factors such as R&D 
Systems’ ‘Optimized’ adaptors and the flawed TF protocol were the cause of serious 
delays. The R&D Systems’ ‘Optimized’ adaptors were of unknown volume and 
concentration and therefore should not have been used in such a lengthy and costly 
protocol. The updated protocol which has since been published on the TF website for use 
with the Ion RNA-Seq, is reflective of the Cheng et al. protocol.  
 Numerous points during the library preparation procedure could have resulted in 
downstream inhibition if they were incorrectly performed. These potential points of 
contamination include: if phenol chloroform was transferred with the aqueous phase during 
RNA extraction, if DNase inactivation reagent was transferred with the sample-containing 
supernatant after DNase treatment, and if beads were incorrectly transferred at any point 
during the magnetic bead clean up modules (particularly in final transfer of each module).  
Another potential limitation in the library preparation procedure was the percentage of 
alcohol used. The TH and CH protocol both state that 100% ethanol must be used to ensure 
accurate size selection. Due to shipping restrictions, the highest percentage of alcohol that 
can be shipped to NF is 95%. To address each of these potential laboratory limitations, 
extra care was taken to ensure no contamination occurred and that fresh alcohol was used 
daily to maintain as high a percentage of alcohol as possible.  
 Ideally all the PGx samples would be loaded onto the same chip to ensure no inter-
run variability. This was not possible due to the barcoding system used to accommodate 
the broader project. The read bias that potentially occurred when the samples were run on 
different chips was addressed during normalization. As mentioned above there are many 
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points during sample processing, such as chip loading, which could bias the sequencing 
results. Normalization of the data using edgeR software should remedy these issues; 
however, these biases could still be possible.  
 The moderately low prevalence of PsA and the frequency of patients prescribed 
biologics made patient recruitment a limiting factor given the timeframe of this project. 
Due to the small sample size of this project, it was difficult to control for aspects such as 
co-medications, comorbidities, and sample ascertainment. The only co-medication 
controlled for in this project was concurrent treatment with other biologics; however, other 
medications such as steroids, NSAIDs, and methotrexate were not controlled for and could 
have therefore limited the quality of the results. Comorbidities such as other autoimmune 
diseases, which occur more frequently in patients already diagnosed with an autoimmune 
disease, can cause differential miRNA expression and confound the results generated. Co-
medications and comorbidities are only possible confounding factors in this project where 
the differential expression of miRNAs is compared between patients. However, in the 
broader project where differential expression of miRNAs is compared within an individual, 
it is less likely that these factors will confound the data. Data quality could have also been 
limited by the method of sample ascertainment and whether fresh samples are delivered to 
the lab in order to attain realistic inter-cellular communication. This can be difficult to do 
in practice and is dependent on a laboratory’s capacity.  
 Another limitation to the quality of results generated from this project is the 
response status of a patient. Response status is measured on a continuum. When a patient 
does not reach ACR50 and was therefore not deemed to be a responder, it does not 
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necessarily indicate that there was no response whatsoever (ie., they could have only 
reached ACR20 by the primary endpoint). Because half of the ACR50 criteria is reported 
by the patients, which is not always truly reflective of response status, miscategorization of 
responders is possible. This possibility of partial response (ACR20) or inappropriate self-
categorization will confound the data associated with response and limit the quality of 
results of the project. However, this type of bias will minimize any potential findings as the 
non-responder pool is being contaminated with partial responders, so the error will be 
towards the null. The ACR50 was selected as the response criteria as it represents a more 
meaningful clinical response. The ideal control group would be non-responders, as 
determined by patients not reaching ACR20. Given the magnitude of effect from the 
present biologics in standard clinical practice, our sample size was insufficient to retrieve 
a large group of non-responders that failed to reach ACR20. 
 Phase III registration studies for TNFα inhibitors and IL-17A monoclonal 
antibodies have reported slight differences in the incidence of opportunistic and serious 
infections. Although there is no head-to-head studies between these two classes of 
medications, numerically there appears to be a lower rate of infections among IL-17A 
blockade. Also, IL-17A monoclonoal antibodes are unlikely to aggravate diseases such as 
systemic lupus and multiple sclerosis. As patients for this study were selected from a real-
world setting, there would be a tendency to select patients with a slightly lower risk of 
infection. This may affect the generaliziability of our results. 
 Due to the small sample size, which limits the power of the study, an overall lack 
of significant findings was consistent across datasets, therefore the validation process and 
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subsequent functional studies were not possible. The furthest possible point of investigation 
for this project was network and the in silico functional analyses. These analyses are 
important because of how unlikely is it to find a single gene or miRNA dysregulation 
causing drug response or pathogenesis in a complex disease. It is more likely that a 
combination of dysregulated genes and miRNAs are responsible, which would necessitate 
a multi-omic approach to such research. As of yet, there are no FDA-approved clinical tests 
that are based on a pattern of dysregulation or are generated from multi-omic approaches; 
in the future, however, such steps will likely be necessary when treating complex diseases.  
 
 Summary and Conclusions  
 The development and optimization of a framework capable of preparing and 
sequencing circulating miRNA libraries was explored with a pharmacogenomic analyses 
of a PsA patient cohort.  miRNA library preparation was optimized through attempting two 
protocols and multiple modifications. After an optimal library preparation protocol was 
established, the loading capacity of the PI chip was tested to create a reference for an 
increase in multiplexing without a decrease in sequencing quality. This library preparation 
and sequencing framework was used to investigate the miRNA profiles of PsA patients 
being treated with biologics, a very expensive class of pharmaceutical with a ~50% 
response rate. Nine PsA patients treated with IL-17 pathway inhibitors consented to the 
study and their blood samples were drawn pre-treatment, one-month post treatment, and 
three-month post treatment. Patients who reached the primary endpoint (ACR50) were 
deemed responders and the other were deemed non-responders. The baseline patient 
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samples were sequenced by the Ion Torrent System, and the data underwent numerous 
analyses using a comprehensive miRNA pipeline. Differential miRNA expression analyses 
were performed both between ACR50 response groupings and on clinical datasets in 
attempt to identify a miRNA or a miRNA profile that could predict treatment outcome. 
Statistical significance was difficult to attain due to the small cohort size; however, the 
results of these analyses show the potential for identifying a predictive marker or profile. 
A comprehensive literature review was conducted to identify differentially expressed 
miRNAs for potential implications in treatment response of PsA pathogenesis, as would 
have been done if findings had been significant. The data was then analyzed using pathway 
analyses, network analyses, and functional enrichment analysis for associated signalling 
cascades, collectively targeted genes, and relevance to biological functions. These results 
demonstrated the complexity of miRNA and their mRNA regulatory capacity. Although 
this study found minimal statistically significant findings. However, statistically significant 
associations between differentially expressed miRNAs and clinical outcomes can be 
thoroughly investigated with these analyses to determine potential causative mechanisms 
for differential drug response or disease development.  
 In conclusion, the circulating miRNA sequencing framework developed for this 
project has proven capable of effectively extracting miRNA from plasma, preparing high-
quality libraries, sequence libraries in a high-throughput manner, and analyzing the 
sequencing data for potential associations. This project is part of a larger research agenda 
that could identify significant differential expression of cellular or circulating miRNAs that 
may have association with response to biologics in future PsA patient cohorts.  
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 Future Directions  
 An RNA sequencing framework was developed to investigate variants and 
differential expression of mRNA, intracellular miRNA, and circulating miRNA. This RNA 
sequencing framework (Figure 4.1) was designed and implemented by the author through 
a review of pertinent literature and by consulting the FAS from TF.  
Figure 4.1 – Summary of RNA sequencing framework for the broader project that enables 
mRNA and intercellular miRNA sequencing and collective data analysis. Highlighted is 
the focus of this project.  
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The mRNA sequencing branch of this framework now enables researchers in the 
Rahman/O’Rielly lab group to gain insight into gene expression, gene expression levels, 
alternative splicing, and variants in the transcripts of expressed genes. The intracellular 
miRNA sequencing branch of the framework enables the examination of intracellular 
regulation of gene expression. Understanding the source of intracellular miRNAs can also 
provide insight into cell types that are responsible for disease development. The peripheral 
blood mononucleocytes of the PsA patients will be sorted by cell types in order to perform 
more informative intracellular miRNA analyses. The circulating miRNA sequencing 
branch of the framework enables investigations on the intercellular regulation of gene 
expression. While this framework has the capacity to sequence mRNA, intracellular 
miRNA, and circulating miRNA, this project solely investigated circulating miRNAs. 
 Patients recruited for this study were prescribed either TNFα inhibitors, IL-17 
inhibitors, or IL-12/23 inhibitors. As the TNFα inhibitor cohort size increases, a collective 
comparative analysis of these biologics will be done in an attempt to identify therapeutic 
markers. 
Examining circulating miRNA profiles can indicate intracellular communication 
occurring at the level of the tissue, making these miRNAs particularly important in PsA as 
an alternative to biopsing deteriorating psoriatic joints. Research into circulating miRNAs 
as a non-invasive source of biomarkers is expanding. The majority of these studies are done 
using microarray and qPCR but are limited by their targeted approach. Sequencing miRNA 
using NGS is preferable due to the sensitivity of detection, dynamic range of detection, and 
accuracy of measuring differential expression levels. Given the high prevalence of psoriatic 
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disease in NF, interpatient variability and the high cost associated with biological therapy, 
the lack of access to tissue of primary pathology, and the advent of NGS to sequence 
circulating miRNA, a marker for response to treatment with biologics would have great 
clinically utility. This project has assembled a framework to enable the identification of 
circulating miRNAs or circulating miRNA profiles that may have clinical utility. The 
results generated from the broader project will represent the most comprehensive 
investigation of treatment response in PsA patients.  
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APPENDICES  
Appendix A – Procedures preformed that did not contribute to the optimization of 
miRNA library preparation 
 
 
Figure A1 – Result when incorrect concentration of ethanol was added in error during the 
last stages of library preparation causing the majority of the miRNAs to lose the adaptors 
resulting in an oversized lower marker.  
 
Figure A2 – Result when unknown error occurred at an unknown point during library 
preparation resulting in a sample concentration of zero
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Appendix B – Pharmacogenomics PsA Cohort Library Preparations 
 
Patient 2 
The miRNA library of this patient was quantified as having a total molarity of 142 
nmol/l and a regional molarity of 83.5 nmol/l, resulting in a regional molarity percentage 
of 58.8%. The electropherogram showed a slight adaptor dimer in the shoulder of the 
sample peak located at 106 bps and minimal large RNA species (Figure B1). The library 
sequenced 4,671,889 miRNA reads and detected a total of 741 different miRNAs  
 
 
Figure B1 - Electropherogram depicting the size distribution and concentration of small 
RNA in the library of Patient 2. 
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Patient 6 
The miRNA library of this patient was quantified as having a total molarity of 111 
nmol/l and a regional molarity of 49.4 nmol/l, resulting in a regional molarity percentage 
of 44.5%. The electropherogram showed a very small adaptor dimer peak at 86 bps, a 
sample peak at 117 bps (falling slightly outside of the desired size range), and some large 
RNA species (Figure B2). The library sequenced 4,355,535 miRNA reads and detected a 
total of 686 different miRNAs. 
  
 
Figure B2 - Electropherogram depicting the size distribution and concentration of small 
RNA in the library of Patient 6. 
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Patient 7 
The miRNA library of this patient was quantified as having a total molarity of 130 
nmol/l and a regional molarity of 69.2 nmol/l, resulting in a regional molarity percentage 
of 53.2%. The electropherogram showed a small adaptor dimer peak at 86 bps, a sample 
peak at 109 bps, and minimal large RNA species (Figure B3). The library sequenced 
4,715,021 miRNA reads and detected a total of 731 different miRNAs.    
 
 
Figure B3 - Electropherogram depicting the size distribution and concentration of small 
RNA in the library of Patient 7. 
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Patient 8 
The miRNA library of this patient was quantified as having a total molarity of 190 
nmol/l and a regional molarity of 115 nmol/l, resulting in a regional molarity percentage of 
60.5%. The electropherogram showed a small adaptor dimer peak at 85 bps, a sample peak 
at 111 bps, and minimal large RNA species (Figure B4). The library sequenced 4,165,755 
miRNA reads and detected a total of 683 different miRNAs. 
 
 
 
Figure B4 - Electropherogram depicting the size distribution and concentration of small 
RNA in the library of Patient 8. 
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Patient 10 
The miRNA library of this patient was quantified as having a total molarity of 162 
nmol/l and a regional molarity of 98.7 nmol/l, resulting in a regional molarity percentage 
of 60.9%. The electropherogram showed a slight adaptor dimer in the shoulder of the 
sample peak located at 109 bps and minimal large RNA species (Figure B5). The library 
sequenced 5,538,278 miRNA reads and detected a total of 725 different miRNAs. 
 
 
Figure B5 - Electropherogram depicting the size distribution and concentration of small 
RNA in the library of Patient 10. 
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Patient 11 
 The miRNA library of this patient was quantified as having a total molarity of 362 
nmol/l and a regional molarity of 157 nmol/l, resulting in a regional molarity percentage of 
43.4%. The electropherogram showed a large adaptor dimer peak at 86, a sample peak at 
107 bps, and some large RNA species peaks at 164 bps, 226 bps, and 277 bps (Figure B6). 
The library sequenced 5,968,026 miRNA reads and detected a total of 711 different 
miRNAs.  
 
 
Figure B6 - Electropherogram depicting the size distribution and concentration of small 
RNA in the library of Patient 11. 
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Patient 12 
 The miRNA library of this patient was quantified as having a total molarity of 234 
nmol/l and a regional molarity of 135 nmol/l, resulting in a regional molarity percentage of 
57.7%. The electropherogram showed a sample peak at 111 bps, and a large RNA species 
peak at 162 bps (Figure B7). The library sequenced 6,619,036 miRNA reads and detected 
a total of 776 different miRNAs. 
 
 
Figure B7 - Electropherogram depicting the size distribution and concentration of small 
RNA in the library of Patient 12. 
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Patient 13 
 The miRNA library of this patient was quantified as having a total molarity of 180 
nmol/l and a regional molarity of 119 nmol/l, resulting in a regional molarity percentage of 
66.1%. The electropherogram showed a small adaptor dimer in the shoulder of the sample 
peak located at 104 bps, and minimal large RNA species (Figure B8). The library 
sequenced 6,695,083 miRNA reads and detected a total of 794 different miRNAs. 
 
 
Figure B8 - Electropherogram depicting the size distribution and concentration of small 
RNA in the library of Patient 13. 
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Patient 14 
 The miRNA library of this patient was quantified as having a total molarity of 275 
nmol/l and a regional molarity of 165 nmol/l, resulting in a regional molarity percentage of 
60.0%. The electropherogram showed a sample peak located at 107 bps and minimal large 
RNA species (Figure B9). The library sequenced 9,061,954 miRNA reads and detected a 
total of 810 different miRNAs. 
 
 
Figure B9 – Electropherogram depicting the size distribution and concentration of small 
RNA in the library of Patient 14. 
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Appendix C – Consent form for patients taking part in the pharmacogenomics project  
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Appendix D – Copyright approval to use a figure from Suzuki et al., 2014 
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Appendix E - Copyright approval to use a figure from Creemers et al., 2012 
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Appendix E – The usage terms for draw.io, all flow charts created for this project were 
made using draw.io software.  
 
